#version: 0.2
t h
i n
t i
r e
a n
th e</w>
e r
e n
o n
o f</w>
a r
e d</w>
r o
o n</w>
o r
i n</w>
i t
o u
a t
i s</w>
s t
an d</w>
a l
t o</w>
o r</w>
a ti
in g</w>
a c
d i
e c
e s
e r</w>
a s
a l</w>
e s</w>
a t</w>
u s
i l
o m
e l
i c
i s
a s</w>
en t
l e
s u
e n</w>
n o
a n</w>
b e</w>
s i
p ro
o l
v e</w>
T h
o s
f or</w>
a b
c on
w h
w it
d u
wit h</w>
l y</w>
no t</w>
m e
d e
en t</w>
h a
ati on</w>
ar e</w>
th at</w>
i m
ti on</w>
l o
b e
a m
r i
v er
a d
Th e</w>
l e</w>
a g
s e
s h
e d
e m
ou l
u n
e x
v i
ti on
u l
c om
o p
a p
oul d</w>
u r
c h
er e</w>
o u</w>
s .</w>
s ,</w>
l i
f f
t s</w>
t a
i t</w>
m a
c e</w>
ent s</w>
s p
in g
p ati
n e
. .
ati on
ha ve</w>
t er
t r
f or
du c
i r
p re
u m
w e
p e
y ou</w>
q u
th e
sh ould</w>
o c
p er
th er</w>
p or
c l
b y</w>
th is</w>
at ed</w>
0 0
i d
us e</w>
e .</w>
h as</w>
ou r</w>
t re
p o
m ent</w>
di c
at e</w>
p l
i g
e ,</w>
be en</w>
e t
W h
il l</w>
re d</w>
t ed</w>
w as</w>
ou n
p h
in e</w>
as e</w>
w ill</w>
a f
os e</w>
y ,</w>
it y</w>
f ro
pati ents</w>
on e</w>
re n
h e
ic h</w>
re c
fro m</w>
p a
o t
y .</w>
ti c
u d
st r
a r</w>
u ro
s y
e v
wh ich</w>
pro duc
I f</w>
i c</w>
m on
p ar
c re
ta k
j ec
m in
an y</w>
ff ec
ma y</w>
ou t</w>
t e
y our</w>
c h</w>
d er
us t</w>
su l
u t
E uro
s o</w>
con t
in f
i v
en d
o d</w>
o ther</w>
al l</w>
an c
es .</w>
.. ..
ac c
ed .</w>
r a
an d
me dic
an t</w>
) .</w>
w ere</w>
di s
c an</w>
d a
tre at
ti m
tion s</w>
v el
e ffec
r is
u t</w>
y e
w or
ti ve</w>
st e
es s</w>
o g
ab le</w>
es ,</w>
for m
es e</w>
t er</w>
us ed</w>
c a
o d
an ce</w>
o v
or e</w>
su b
I n
d er</w>
s e</w>
ar y</w>
ou r
i f</w>
lo w
en c
al ly</w>
s er
a v
th er
e p
m ust</w>
es s
o b
ag e</w>
s ec
in cre
u re
an g
pre s
i on</w>
C om
Euro pe
m ent
si on</w>
ic al</w>
b er</w>
I n</w>
th ese</w>
ou s</w>
p os
th ere</w>
w a
al so</w>
com m
th an</w>
p le
s ol
su r
m ore</w>
g h
- -
ar m
ac t
f e
t ab
s t</w>
re por
i th
i r</w>
c o
0 0</w>
ig h
d o
ti v
i ti
h y
n o</w>
the y</w>
E U
t o
m is
I t</w>
Wh at</w>
a in
al l
c ar
ar k
i d</w>
t en
Europe an</w>
r u
ro u
treat ment</w>
re g
i f
v e
t ri
medic in
as t</w>
in jec
a ,</w>
h i
U n
h o
d .</w>
u m</w>
c i
d ose</w>
ver ,</w>
f o
e t</w>
it s</w>
el l
t h</w>
ed ,</w>
d e</w>
el y</w>
sp ec
ver y</w>
min i
d oc
en ce</w>
b ut</w>
w ith
w n</w>
ta in
ye ar
on ly</w>
wh o</w>
ation s</w>
for e</w>
u c
du r
m g</w>
m il
ff ic
a st
as s
2 00
as ed</w>
per i
Y ou</w>
er s</w>
su ch</w>
ad mini
se e</w>
an ti
m o
b lo
we ver,</w>
ch il
cl ud
al s</w>
i a</w>
the ir</w>
si b
re qu
ti c</w>
f ol
s om
) ,</w>
af ter</w>
t ,</w>
g n
f i
a il
A l
tab le
el l</w>
vi r
arm ac
p en
ur e</w>
u tion</w>
g o
tr an
d o</w>
it e</w>
u di
k e</w>
u b
in to</w>
g r
k no
k s</w>
' s</w>
wh en</w>
we e
g en
t w
in ter
d ec
pl ac
m ark
F or</w>
doc t
p r
re sp
re ac
an t
u s</w>
H o
pe op
g re
u p</w>
c er
re sul
por t
.... ....
w ould</w>
p e</w>
g l
in clud
b ec
st udi
inf ec
di se
1 /</w>
tak e</w>
S t
k ing</w>
d ing</w>
m p
ex am
d os
ris k</w>
e st
c oun
ther ap
am e</w>
f ir
a d</w>
in form
in u
b o
si on
re l
t ec
m an
i on
y s
Com mis
ac t</w>
l on
be t
c ur
blo od</w>
re comm
b le
en ti
i al</w>
s ti
il l
i st
b re
at es</w>
ation .</w>
R e
n um
d ro
re duc
v is
h um
resp on
t ing</w>
fol low
1 9
g iv
ing ,</w>
cl in
chil d
( A
ing .</w>
peop le</w>
O n
EU /</w>
tion .</w>
es t</w>
ap pro
a re
dur ing</w>
de vel
y s</w>
re e</w>
F O
ph armac
ser v
me as
end ed</w>
con tain
con si
Th ere</w>
Ho wever,</w>
effec ts</w>
t .</w>
tion ,</w>
sur e</w>
ar g
A N
g h</w>
f in
f er
b in
ab out</w>
u th
b i
c le
injec tion</w>
he al
cont inu
os t</w>
tim e</w>
sec tion</w>
ne ed
c ent
w e</w>
wh at</w>
p ri
doct or</w>
as es</w>
ch ang
uth or
c or
p ec
s k
( see</w>
c an
inform ation</w>
ne w</w>
ov er</w>
num ber</w>
-- --
ac tive</w>
tw o</w>
1 0</w>
s o
n ec
f act
H A
R I
p er</w>
4 .
T I
sub st
repor t</w>
l a
d ,</w>
th ose</w>
c e
pos sib
0 .
5 0</w>
ul ar</w>
st ud
sh o
Commis sion</w>
devel op
be ing</w>
M E
at er</w>
si gn
produc t</w>
rec e
Th is</w>
tre ated</w>
su p
m g
er g
ri b
av ail
ha d</w>
giv en</w>
b ot
ar d</w>
al u
si de</w>
fir st</w>
ation ,</w>
ste m</w>
id e</w>
A n
do es</w>
the re
s el
lo w</w>
f un
be fore</w>
sul in</w>
clin ical</w>
w om
p ol
em ent</w>
r al</w>
u p
igh t</w>
or y</w>
is h
me di
table ts</w>
cont ro
tak en</w>
d s</w>
medicin al</w>
f l
admini str
ren t</w>
ati ve</w>
ac k
s en
t y
l ess</w>
som e</w>
produc ts</w>
gh t</w>
re ,</w>
l im
a .</w>
hum an</w>
ar i
we en</w>
e f
ne ed</w>
sol ution</w>
m u
m e</w>
r it
ff e
ad e</w>
in v
in e
enc y</w>
em ber</w>
a use</w>
is ed</w>
bet ween</w>
I S</w>
6 /</w>
t u
d ed</w>
c ol
if ic
- 0
re n</w>
v acc
ac k</w>
sy stem</w>
S E
im port
P ro
is ation</w>
incre ase</w>
s ame</w>
or m
g rou
an s</w>
pro vi
o x
d at
an im
m ost</w>
ag ain
at ely</w>
il ity</w>
wh ere</w>
d es
it ed</w>
with out</w>
m s</w>
o ver
t om
in t
b od
se ver
s it
re s
th en</w>
mon th
HA T</w>
00 0</w>
T el
W HAT</w>
recomm ended</w>
incre ased</w>
t ly</w>
at ing</w>
s af
pati ent
g i
com bin
par tic
m l</w>
D o</w>
/ 1
le vel
ic e</w>
ta in</w>
et y</w>
te st
f ul
ar ly</w>
a k
v er</w>
child ren</w>
c ould</w>
in sulin</w>
or s</w>
or der
in al</w>
R E
m at
com p
year s</w>
Wh y</w>
M e
is t</w>
he pati
a z
can not</w>
pro ble
ment .</w>
v en
et ing</w>
therap y</w>
includ ing</w>
di ffe
I N
ul ation</w>
th ro
o f
follow ing</w>
il y</w>
e u
d r
C h
m any</w>
FO R</w>
b en
s )</w>
mp tom
bec ause</w>
ac h</w>
or der</w>
oc i
nec ess
con di
ac h
im pa
oun d</w>
lon g
W e</w>
A L</w>
p s</w>
il e</w>
i de
g ro
e re
tak ing</w>
str uc
requ i
ev en</w>
a uthor
un der</w>
in es</w>
stud y</w>
ol og
th ree</w>
y l
studi es</w>
rece iv
On e</w>
Wh en</w>
x im
e ther</w>
us ing</w>
ser i
M ember</w>
ure s</w>
ma in
i a,</w>
s a
tiv ity</w>
tran s
m ade</w>
e y
1 0
e l</w>
/ 9
st ar
sy mptom
m it
m b
in ,</w>
c al
R O
the m</w>
r on
t y</w>
l y,</w>
hi b
exam ple
Al l</w>
O ral</w>
por t</w>
po in
ex peri
ap pe
th rou
import ant</w>
st em
P ati
ver se</w>
c ap
c ase</w>
administr ation</w>
i z
i es</w>
hy per
N e
ste red</w>
cent r
avail able</w>
E U</w>
u st
em p
su m
l ed</w>
l ab
ation al</w>
ou s
2 0
wor k</w>
f ur
re si
le .</w>
again st</w>
example ,</w>
da y</w>
tion al</w>
a th
f ic
wa y</w>
st er
tim es</w>
is ,</w>
h el
bot h</w>
Euro pe</w>
r ing
me th
kno wn</w>
i p
C on
gen er
h igh
pl ic
le ast</w>
dat a</w>
a vi
p le</w>
on d
dis order
Un ion</w>
g u
ad di
M A
wom en</w>
in dic
du l
Pati ents</w>
ob serv
h our
b as
t ur
sy stem
th em
si ve</w>
e -
fun c
di vi
1 00</w>
gr am
admini stered</w>
........ ........
ren al</w>
S T
o k
repor ted</w>
de m
n orm
1 .
there fore</w>
s w
possib le</w>
3 0</w>
qu es
m en
sever e</w>
h ol
T H
19 9
v ing</w>
u al</w>
t s.</w>
U SE
P h
S P
om e</w>
i x
b el
t al
m ents</w>
du ce</w>
ro s
anc es</w>
d g
in hib
consi de
us ion</w>
tic s</w>
di sp
s or
ent ly</w>
sign ific
heal th</w>
al ,</w>
with in</w>
un der
ig n
0 6/</w>
O N
t e</w>
ben ef
A c
c ul
v ed</w>
t en</w>
impa ir
l y
saf ety</w>
or al</w>
ffic i
p op
l ast</w>
in iti
fur ther</w>
er ,</w>
di rec
A C
wor k
w n
p i
c ell
ut e</w>
re le
pro pos
mil li
bod y</w>
w ell</w>
st o
ig h</w>
ho w</w>
e g
at t
2 .
r ate</w>
P ar
2 0</w>
e y</w>
al .</w>
op er
es s,</w>
ass oci
w ater</w>
lo c
com ple
AN D</w>
re ad
or g
er .</w>
sk in</w>
m un
i l</w>
en d</w>
f ac
po ten
dise as
2 5</w>
ve l</w>
s :</w>
E ME
3 7
w ar
ti me
ti s</w>
r ap
n on
de d.</w>
combin ation</w>
li ke</w>
tran sp
s ite</w>
po si
su g
is e</w>
ac ter
a ffec
im medi
ad verse</w>
1 2</w>
/ 0
symptom s</w>
g et</w>
d am
N o</w>
j ust</w>
f u
effec t</w>
m ic
s ing
s ?</w>
h al
e very</w>
throu gh</w>
con centr
dise ase</w>
ti es</w>
pro tec
mon it
_ _
Me dic
re at
ma in</w>
l u
se t</w>
s m
contro l
USE D</w>
tr a
reac tions</w>
p ub
oun t</w>
ma ke</w>
li st
l it
sen si
wee ks</w>
mu ch</w>
ter m</w>
hy dro
pro ce
pati ent</w>
a dul
le ,</w>
t s,</w>
pro te
level s</w>
- f
op h
n ing</w>
me tab
lo g
le vel</w>
le g
in ation</w>
c are</w>
O N</w>
ty pe</w>
n ational</w>
metab ol
y ing</w>
po w
li f
tr ac
medicin es</w>
ou t
ing s</w>
coun tri
c r
af le
s us
dec re
contain s</w>
l in
e )</w>
di st
st and
in ary</w>
h igh</w>
1 5
ex c
em b
p ack
m l
e qu
r an
im pro
/ 200
resul t</w>
d el
v alu
ca use</w>
Tel :</w>
mg /</w>
im p
c ases</w>
pa red</w>
v es</w>
inv ol
gro w
associ ated</w>
ou gh</w>
gre s
1 4</w>
t ot
du e</w>
to o</w>
spec if
i b
ap p
oc cur
l arg
wh ether</w>
th ing</w>
E R
A U
wee k
pl as
in c
ho wever,</w>
plac e
on ce</w>
ha em
ch o
ab ility</w>
a em
---- ----
hepati c</w>
ed ing</w>
N o
da ys</w>
In ter
ep t
c as
d ru
H um
som e
poten ti
h e</w>
conside red</w>
I I
v ent</w>
sub jec
heal th
sy n
pre gn
coun tr
gl y
ass ess
t ro
sy ring
e ach</w>
tec h
f il
c y
as si
1 5</w>
c all
mic ro
f a
A s</w>
ffic ul
ti l</w>
is m</w>
chang e</w>
c anc
ac hi
da ily</w>
I T</w>
subst ance</w>
u r</w>
pro c
partic ul
l os
ill ed</w>
A T
se qu
necess ary</w>
St ates</w>
C oun
wa st
di fficul
(A 4
t ell</w>
h ar
(A 5
meas ures</w>
l es</w>
l and
fo re,</w>
inhib it
EU /1
le afle
al ity</w>
pa in</w>
p end
o id</w>
milli on</w>
lon g</w>
op en
g e
en z
peri od</w>
com pared</w>
/ 00
com e</w>
I C
- 2
l am
it y.</w>
ent ,</w>
tion s.</w>
cer tain</w>
sing le</w>
resul ts</w>
ha p
per s
it y,</w>
c our
ti s
l y.</w>
appro pri
al ys
us ,</w>
divi du
b ased</w>
al low
a vir
a de
is su
con cer
in ce</w>
for m</w>
requi re
ev alu
pro f
contain ing</w>
develop ment</w>
plac e</w>
m ul
li k
inf usion</w>
at el
specif ic</w>
mark et</w>
ac y</w>
ol e</w>
f r
tion s,</w>
or t</w>
or d
month s</w>
an other</w>
T E
ye ar</w>
non -
m a</w>
in .</w>
S A
E x
A g
v it
read y</w>
ec h
5 %</w>
ex pec
di d</w>
at ory</w>
4 0</w>
sti tu
it .</w>
ar t
tot al</w>
l ish
i ve</w>
in dividu
A L
tic al</w>
in e,</w>
on g</w>
iti es</w>
f ail
da y
T reat
par t</w>
o l</w>
li c</w>
g .</w>
en sure</w>
el ine</w>
e i
dos es</w>
P RO
diffe rent</w>
condi tions</w>
D e
C I
wee k</w>
v ari
s ci
respon se</w>
po st
seri ous</w>
fo od</w>
to x
ti n</w>
ru s</w>
bi o
0 %</w>
reduc ed</w>
observ ed</w>
m al
b u
n ess</w>
ev ents</w>
ri c</w>
ma j
3 6
l or
call ed</w>
r ang
p ut</w>
ca re
Th ere
all erg
2 4</w>
s c
proble ms</w>
incre as
v ol
er i
1 )</w>
wh ite</w>
t t
s al
avi r</w>
sib le</w>
pro gres
p tion</w>
M r</w>
reduc tion</w>
re as
er al</w>
comm on</w>
vi rus</w>
medic ine</w>
% )</w>
n ed</w>
el ec
al ready</w>
1 8
poin t</w>
p at
ati c</w>
3 5
u fact
A r
vi e
s ing</w>
org an
me ans</w>
li ver</w>
d om
tri dg
ti ce</w>
ir c
H e
r y</w>
6 0</w>
ol d</w>
U C
n a
dec is
car ri
O F</w>
pres ent
is .</w>
us es</w>
u ally</w>
tre at</w>
experi ence</w>
er c
ad j
M ark
wor king</w>
wa ys</w>
un til</w>
rel ated</w>
di um</w>
bec ome</w>
hour s</w>
grou p</w>
achi ev
he ar
contro l</w>
H I
G er
min im
fu l</w>
fe w</w>
ad v
ok ine
at ed.</w>
an e
T o</w>
ti g
sec on
impair ment</w>
f our</w>
t le</w>
og en
car tridg
anim als</w>
Q u
sm all</w>
is h</w>
in k</w>
ic k
d ri
chil d</w>
H M
E n
l ine</w>
ex t</w>
est ab
reg ul
at e,</w>
patient s.</w>
e ?</w>
ade qu
sho w
de pend
F r
su ffici
re .</w>
and ,</w>
A n</w>
ren ce</w>
m ov
m ar
a x
Un ited</w>
6 .
w w
vi al</w>
s ed</w>
re s</w>
as s</w>
a in</w>
wh ile</w>
provi ded</w>
medic al</w>
lo b
ei ther</w>
di ab
ci l</w>
on s</w>
f requ
lif e</w>
do wn</w>
2 .</w>
re ad</w>
go od</w>
ent .</w>
de ter
Coun cil</w>
( C
sp e
sit u
y oun
xim ately</w>
ful ly</w>
re duce</w>
re di
k .</w>
disorder s</w>
an ts</w>
mul ti
g ra
ffic acy</w>
vir on
te e</w>
sti l
countr y</w>
at e.</w>
5 .
1 7
’ s</w>
subst ances</w>
norm al</w>
ing redi
fi ed</w>
e ver
b l
tr ain
ob jec
n am
man ag
kno w</w>
in te
d one</w>
ch em
b r
ap plic
receiv ing</w>
dis continu
N ov
p ur
olog ical</w>
ex po
sho wn</w>
pres c
ple ase</w>
ell ing</w>
Y our</w>
Mark eting</w>
FO R
ti vel
potenti al</w>
mark eting</w>
Y P
r as
pharmac okine
b ro
an i
re spec
appro ximately</w>
ter s</w>
li gh
im mun
ic i
ab sor
A d
w .</w>
syn dro
str ic
receiv ed</w>
ment ,</w>
mark et
j o
a y
A uthor
t ed.</w>
need s</w>
gl uc
c at
' .</w>
star t</w>
o e
go ing</w>
ep t</w>
Medic ines</w>
D i
(A4 -0
tr av
emp lo
ant ly</w>
C o
re st
pop ulation</w>
particul arly</w>
infec tion</w>
re se
ra di
oc c
m us
ist .</w>
id enti
ri ght</w>
need le</w>
n at
m y
ac tion</w>
Treat ment</w>
1 3
or .</w>
d ra
as k</w>
-f illed</w>
os is</w>
od .</w>
gre ater</w>
appe ar
TI ON</w>
- term</w>
t on
ren tly</w>
o ther
M r
A R
treat ment.</w>
su c
re d.</w>
bre ast
ast ro
adj ust
si mil
r ac
estab lish
cle ar</w>
cell s</w>
ab le.</w>
0 2
m ix
stil l</w>
produc tion</w>
experi enc
imp act</w>
gi ve</w>
ac tivity</w>
signific ant</w>
m or
ir e</w>
d en
D E
o m</w>
benef it</w>
ol er
g o</w>
ar acter
appropri ate</w>
th ir
ic ally</w>
er ing</w>
are a</w>
H y
v ent
sol u
sensi tivity</w>
en viron
sup port</w>
chang es</w>
1 1</w>
vir al</w>
syring e</w>
ous ly</w>
er y</w>
bo di
am in
a m</w>
P re
we ight</w>
vi a</w>
v al
t ure</w>
sti t
high er</w>
h and
fl u
U se</w>
secon d</w>
grow th</w>
disp os
ren c
p it
mo der
me an</w>
func tion</w>
f t</w>
com mon
vacc ine</w>
plas ma</w>
par ti
p es</w>
os ph
no tice</w>
le ad</w>
control led</w>
ch lor
po t
enz y
ent s.</w>
c lo
There fore,</w>
requi red</w>
prote in</w>
de mon
cur rent</w>
w at
resi st
of ten</w>
effec tiv
e p</w>
a y</w>
1 8</w>
or ing</w>
no w</w>
bel o
ation s.</w>
TH E</w>
s ince</w>
o ff
en ,</w>
ar ch</w>
1 4
ufact ure
ter inary</w>
pr im
low er</w>
effec tive</w>
demon str
B ut</w>
st at
1 2
sel f</w>
o k</w>
expec ted</w>
(A5 -0
rib ed</w>
reg ar
ion s</w>
h or
grou p
exam ple</w>
ex ist
er s.</w>
ac tiv
su ff
sci enti
pre vent</w>
li ed</w>
i a
er s,</w>
en g
pre -filled</w>
c ut
anc y</w>
O L
C YP
A D
wast e</w>
maj or</w>
individu al</w>
- 00
pres ent</w>
m ight</w>
b ur
al s.</w>
on e.</w>
no log
i ally</w>
ag es</w>
P le
Hum an</w>
tain ed</w>
simil ar</w>
sh i
f ound</w>
e fficacy</w>
cont act</w>
vi v
spec ial</w>
rele v
immedi ately</w>
ati s
se en</w>
p en</w>
doc um
com pe
carri ed</w>
c ular</w>
c ha
ar ,</w>
am ount</w>
S E</w>
Pro duc
3 .
sus pen
sug ar</w>
studi ed</w>
l at
includ ed</w>
hel p</w>
cl os
Commis sion
youn g</w>
sto p</w>
bet ter</w>
ar ound</w>
an n
Ph armac
pr in
in struc
ey e</w>
bre ast</w>
allerg ic</w>
H ol
st or
s es</w>
qu ality</w>
b ack</w>
A P
2 00</w>
t or
t em
re t
pharmac ist.</w>
larg e</w>
e vi
de fin
al low</w>
S u
L i
u e</w>
ple ment
is m
in test
f -
es s.</w>
Ple ase</w>
K ing
Com mit
vis ion</w>
t op
pub lic</w>
proce dur
ven tion</w>
ca used</w>
at ric</w>
V E
loc al</w>
h er
al ways</w>
y -
ur ing</w>
so dium</w>
l ic
f ic</w>
en ess</w>
canc er</w>
an alys
us e.</w>
r e</w>
l ing</w>
ingredi ents</w>
pro gram
hap pen
ane ous</w>
Ac cor
ta il
re con
cor rec
am p
) :</w>
list ed</w>
le ad
es pec
countri es</w>
a ver
un g
st ate</w>
pa in,</w>
es ?</w>
continu e</w>
cl es</w>
art an</w>
U K</w>
- fe
ter ms</w>
ron ic</w>
ph ys
in i
fer on</w>
expo sure</w>
ex t
ex p
ex cre
consi der
anc e,</w>
re f
at ,</w>
acc id
o wn</w>
li ght</w>
fi ve</w>
emplo y
b o</w>
anim al</w>
ag e.</w>
3 00</w>
pa th
on .</w>
n er
l and</w>
ev er</w>
diab et
c ell</w>
Accor ding</w>
st s</w>
st ri
li am
cur rently</w>
com par
al co
y ou
wn .</w>
monit oring</w>
i ver
espec ially</w>
con sum
a k</w>
Re port</w>
E X
5 0
1 6
ti vi
re d
n ext</w>
/200 1)</w>
th es
on ,</w>
des ign
ci pi
ut es</w>
ter n
partic ular</w>
leafle t</w>
in e.</w>
com it
7 /</w>
resi d
pri or</w>
pre vi
ph osph
p ass
og n
ne x</w>
y n
time .</w>
st op
in du
e di
anc e.</w>
sign s</w>
ml )</w>
k in
ic ity</w>
h ed</w>
e me
P or
I m
con f
breast -fe
aracter is
ac id</w>
V ir
1 3</w>
ou s,</w>
long er</w>
inf lu
inc id
dru g</w>
EME A</w>
ye t</w>
of f</w>
g e</w>
e :</w>
child ren
1 6</w>
year s.</w>
i red</w>
es tim
en .</w>
No t</w>
An nex</w>
3 0
evi d
co ated</w>
S ec
y t
w ,</w>
pro por
place bo
manag ement</w>
ion ,</w>
di ag
da y.</w>
author isation</w>
B e
( e.</w>
hepati tis</w>
de fic
anti -
G en
v ot
suc c
p an
int ro
hy po
ch ronic</w>
are as</w>
An y</w>
2 5
t og
ma xim
k e
iti s,</w>
intest inal</w>
ab il
__ __
PRO D
Commit tee</w>
0 )</w>
ul es</w>
rece ive</w>
immun e</w>
hear t</w>
f am
diag no
ag ed</w>
a ir
PROD UC
O p
EME A
lik ely</w>
l an
Ag ency</w>
................ ................
% .</w>
and /</w>
I U</w>
ure .</w>
su per
ne uro
micro gram
meas ure</w>
infec ted</w>
en e</w>
bodi es</w>
R o
scienti fic</w>
s ha
r ic
pres sure</w>
pow der</w>
necess ar
es tig
absor ption</w>
R ap
A m
2 7
vi g
th ough</w>
pack age</w>
ou gh
f ar</w>
c le</w>
Th ey</w>
thir d</w>
them .</w>
o id
s ity</w>
impro v
ec on
dis c
addi tional</w>
S ,</w>
On ly</w>
v en</w>
protec tion</w>
pro jec
pres sion</w>
los s</w>
h ou
de b
b ab
ve terinary</w>
v ast
procedur e</w>
o di
n ess,</w>
iti s</w>
il d
health y</w>
ha ving</w>
fact or</w>
es sion
de f
ag re
/9 8
ure ,</w>
table t</w>
provi de</w>
h is</w>
effectiv eness</w>
ca uses</w>
affec t</w>
tri als</w>
repor ts</w>
rec ogn
re main
l ac
aem ia</w>
I tal
2 1</w>
pr ac
or ding</w>
ne g
long -term</w>
intro duc
includ e</w>
g astro
do m</w>
aver age</w>
( P
% ,</w>
v ic
tis su
fac e</w>
dist rib
d ang
c irc
ati n</w>
ad ol
Th ese</w>
tech n
rec ent</w>
proble m
lim ited</w>
ed ?</w>
ca em
avir in</w>
adequ ate</w>
acc ount</w>
I D
C O
4. 4
2 8
or ig
k ed</w>
k ,</w>
ion .</w>
ev a</w>
blo c
at ten
B el
u k
respon sible</w>
recomm en
reac tion</w>
r ati
p ack</w>
on g
mu no
m an</w>
W or
B E
Author isation</w>
( E
w ant</w>
per form
form ation</w>
decis ion</w>
ag e,</w>
St at
/1 3
wh ole</w>
we igh
sup p
se ,</w>
r h
or t
occ ur</w>
maxim um</w>
m ary</w>
it ing</w>
infec tion,</w>
exam in
ech an
acc ording</w>
7 0</w>
t ub
place bo</w>
fi el
er y
d ate</w>
con comit
comple t
M an
EU/1 /00
EU/1/00 /13
8 0</w>
with dra
p ed</w>
ne w
l ist</w>
i x</w>
ation s,</w>
ar r
T a
ME D
w ell
th ink</w>
on e,</w>
m echan
/9 9
o ,</w>
m en</w>
inv estig
inf lam
fr act
dise ases</w>
al s,</w>
ac id
C an
( S
re st</w>
monit o
i e
dos age</w>
ac tivi
II I</w>
I U
sur g
in ten
ge ts</w>
en erg
d es</w>
Par liam
M P</w>
F in
us ually</w>
s '</w>
proc ess</w>
in s</w>
gener al</w>
D is
time ,</w>
ques tion</w>
or r
it ,</w>
inter feron</w>
in trav
e uro
car di
b le</w>
adol es
Wh ere</w>
mon o
ful l</w>
b ut
b or
P resid
L ond
wor l
sub cut
si x</w>
rec ept
mon th</w>
i m</w>
g /</w>
es )</w>
col l
ar th
R es
M P
King dom</w>
HI V
8 /</w>
1 ,</w>
s ;</w>
rese arch</w>
pos ed</w>
o ve</w>
moder ate</w>
ex cipi
dispos ed</w>
de tec
an .</w>
acc ess</w>
M ix
-------- --------
ti l
p ul
difficul t</w>
co -
ch ec
av oid</w>
all y,</w>
a w
S ub
O r
H B
2 ).</w>
situ ation</w>
pre par
pop ul
mit ted</w>
in ess</w>
i a.</w>
ho l</w>
he ad
en ous</w>
dru g
anti bio
ad d
P o
suspen sion</w>
recommen ded.</w>
produc ed</w>
ment al</w>
g en</w>
an y
00 /</w>
t un
mat er
b acter
U N
Nov o
C E
A t</w>
shi p</w>
pot assi
dam age</w>
bas is</w>
ad vis
S o</w>
s mo
or ,</w>
ma k
il i
f act</w>
ca u
b est</w>
ar d
P ol
O RI
vig il
us e
tail ed</w>
ser um</w>
ra z
indic ated</w>
des c
appe ar</w>
t um
s ch
posi tion</w>
lo g</w>
it y
in duc
b one</w>
at h</w>
assess ment</w>
I R
lit tle</w>
test s</w>
stand ard</w>
rit on
re ly</w>
men tion
k ey</w>
experienc ed</w>
decre ase</w>
cle ar
circ um
adul t</w>
a u
L e
+ 4
th i
t arg
sion ,</w>
se e
ide ,</w>
h ,</w>
defic i
belo w</w>
ar c
MED IC
y ro
we ak
re pe
rang e</w>
in t</w>
hy dr
fil m
en ough</w>
em ents</w>
depend ent</w>
acc ord
year .</w>
vi r</w>
v o
u red</w>
signific antly</w>
s ).</w>
pol i
cour se</w>
b an
as cular</w>
MEDIC IN
MEDICIN AL</w>
Ho w</w>
Fr ance</w>
7 )</w>
we b
su mp
sho w</w>
re li
pregn ancy</w>
o p</w>
ne ver</w>
en s</w>
2 /</w>
thro mb
ris ks</w>
par t
hol d</w>
ho e
f at
f ,</w>
ble eding</w>
al is
E C
4.4 ).</w>
3 %</w>
2 8</w>
1 %</w>
u ri
o vigil
lim it</w>
econ om
e as
d ou
an e</w>
allow ed</w>
E N
3 ,</w>
tt p
sion s</w>
resp ir
r ates</w>
r are</w>
proce du
m ou
k g</w>
im in
h ttp
grou ps</w>
eu tic</w>
edi atric</w>
concentr ations</w>
adul ts</w>
I rel
7 5</w>
2 %</w>
1 7</w>
rele ase</w>
propos ed</w>
prin ci
patient s,</w>
p ris
me ,</w>
m ot
hi st
be g
b us
achiev ed</w>
Y O
O S
2 ,</w>
/98 )</w>
ur al</w>
sp o
o .</w>
h os
h ic
fic ation</w>
ex per
compe ti
ar ch
an ,</w>
a id</w>
TI ON
Por tu
PRODUC T
th el
subjec t</w>
se .</w>
ou d
mix ed</w>
instruc tions</w>
im muno
hal f</w>
g al</w>
evid ence</w>
ever y
ab ove</w>
Hy per
3 .</w>
1 ,
tog ether</w>
tic s,</w>
t est</w>
recomm end
r o</w>
pre -
objec tive</w>
mg /
man ufacture
establish ed</w>
de ath
con sequ
clud ed</w>
ac ute</w>
5 -
( H
transp ort</w>
rec ently</w>
injec tion.</w>
gre at</w>
gly caem
disc us
am ong</w>
al fa
S U
sug g
n al</w>
me mb
fe rence</w>
ess enti
con tr
circum st
al tern
Inter ne
- up</w>
t oler
r ing</w>
od ,</w>
m y</w>
ent s,</w>
continu ed</w>
con trac
cle arly</w>
ant .</w>
YO U</w>
S I
vacc in
un c
sever al</w>
ros is</w>
r ules</w>
r at
op ath
o -
ch arg
c ris
am end
alco hol</w>
W est
O R</w>
Ne ther
L u
ro p
need ed</w>
g et
ex ten
develop ing</w>
cartridg es</w>
c rit
add res
tech nolog
subjec ts</w>
reg ard</w>
oph il
ob tained</w>
n ur
j us
issu es</w>
in suffici
bas eline</w>
b al
an ted</w>
G re
re tur
om e
f re
enc es</w>
el ev
dur ation</w>
de x
concentr ation</w>
anti bodies</w>
am ine</w>
adjust ment</w>
activi ties</w>
valu es</w>
t ed,</w>
seri ous,</w>
respir atory</w>
on e
estim ated</w>
W in
Re port
Nether land
D I
A no
2. 5</w>
year s,</w>
vie w</w>
therap eutic</w>
p ig
over all</w>
le ft</w>
kno wn.</w>
hyper ten
deter min
decre ased</w>
cl u
Lond on</w>
A S
6 .</w>
( 9
vari ous</w>
si mp
re main</w>
post -
ovigil ance</w>
o h
it al</w>
gro un
g lob
enzy me</w>
ent al</w>
enc e,</w>
devel op</w>
comm un
b ir
ag ing</w>
S e
FOR E</w>
4 /</w>
pol y
monito red</w>
l ack</w>
k id
it self</w>
inhibit ors</w>
diabet es</w>
at ed,</w>
S w
BE FORE</w>
A v
19 8
t on</w>
respec tivel
pro per
me t
m ine</w>
l act
go ver
f ish
ex tre
cl oud
ca ution</w>
c it
b ar
TH ORI
M on
He al
A b
5 6</w>
tiv es</w>
therap y.</w>
re mov
prof ession
m ol
leafle t,</w>
im plement
gu id
fail ure</w>
excre ted</w>
ev ent</w>
care fully</w>
b es
at in
a me
AU THORI
/ ww
vast atin</w>
ud ine</w>
stitu ted</w>
sol vent</w>
s tim
olog y</w>
inflam m
incre ases</w>
der iv
app lied</w>
analys is</w>
a es
O P
F ir
vi als</w>
re -
qu anti
neg ative</w>
mil k</w>
infec tions</w>
i ed</w>
fact ors</w>
con duc
alfa -2
a ff
De tailed</w>
Ano ther</w>
str ain
se par
s ),</w>
pro duce</w>
presc ri
increas ing</w>
hos pit
f ree</w>
d og
com es</w>
ag ain</w>
S um
Qu es
Bel gi
4 8</w>
v om
un i
sion .</w>
ri gh
re present
re d,</w>
ra ther</w>
pharmacokine tics</w>
p sy
li p
influ ence</w>
i um</w>
ex erc
el s</w>
demonstr ated</w>
cap sul
c op
al one</w>
5 ,</w>
( a</w>
ty pes</w>
syndro me</w>
sel ec
re stric
re fer
plac ed</w>
m bo
m al</w>
m ach
lo x
ir rit
invol ved</w>
energ y</w>
diseas e.</w>
develop ed</w>
concer n
con sul
arr hoe
ac tions</w>
V i
S lo
Medic inal</w>
wh ose</w>
us ed.</w>
prim ary</w>
breast-fe eding</w>
assi st
as ,</w>
ap ar
ag ents</w>
S af
P RE
Li pro
y our
ve hic
tw ice</w>
ti s,</w>
str y</w>
renc es</w>
qu al
pa ediatric</w>
or ity</w>
hou se
da y,</w>
at or
appear s</w>
a ut
Un iver
AUTHORI SA
2 2</w>
vacc ination</w>
ou t.</w>
mil k.</w>
le x
incid ence</w>
crit er
concomit ant</w>
ain ed</w>
affec ted</w>
C HM
si m
produc t,</w>
poin ts</w>
metabol it
me m
mak es</w>
m ph
film -
eme a.</w>
b ra
atel y.</w>
al ised</w>
P en</w>
Lipro log</w>
L im
L E
C E</w>
4 0
w in
um ,</w>
sa y</w>
rib avirin</w>
hydro x
en s
con sump
ca p</w>
Win thro
P er
M y
L et</w>
wa y.</w>
some times</w>
s oci
riton avir</w>
resul ting</w>
reg ulation</w>
pharmacokine tic</w>
meas ure
mater ial</w>
leg is
bi ological</w>
N ame</w>
AT E</w>
vol um
t or</w>
p ose</w>
iv al
h ard</w>
est i</w>
e arly</w>
cho le
bu il
addi tion</w>
S pec
Report :</w>
5 00</w>
4 00</w>
3 8
3 4
sur viv
succ ess
subcut aneous</w>
s is</w>
ro lim
pl an
p al
nam es</w>
mat eri
film- coated</w>
design ed</w>
con fir
comple te</w>
b er
Tel .</w>
St ate</w>
S ol
M any</w>
Gen eral</w>
Com mun
/9 7)</w>
’ .</w>
us h
trans fer
si z
reg ion</w>
no t,</w>
in -
http :</w>
gastro intestinal</w>
f av
defici ency</w>
Winthro p</w>
N or
N G</w>
C ar
z ap
valu e</w>
u l</w>
su ic
progres s</w>
pol ic
per at
orr ha
oper ation</w>
op a
need les</w>
l ation</w>
i k
e ar
der ly</w>
complet ely</w>
b il
accord ance</w>
Re g
O n</w>
Hol der</w>
D r</w>
1 -
you .</w>
ta x
show ed</w>
ro un
r and
ph eral</w>
od s</w>
o ffic
month s.</w>
mention ed</w>
gra du
f ec
exc es
d on
c ir
c ents</w>
am in</w>
acc ept
E esti</w>
throu gh
th re
posi tive</w>
ou ght</w>
ne um
mon ary</w>
mo di
ment s.</w>
m ag
la x
evalu ation</w>
cl ose</w>
af er
Vir afer
R om
Op ti
E l
C irc
3 /</w>
us ual</w>
tran si
st ent</w>
sec ond
produc ts.</w>
ph en
op in
o ste
mil d</w>
kid ne
in sul
ent ly,</w>
der ,</w>
con ver
at or</w>
appro ved</w>
again .</w>
ab dom
a di
T eva</w>
R A
N A
A s
200 0</w>
vit ro</w>
uc le
s -
ru p
o s</w>
initi al</w>
fin al</w>
exist ing</w>
di arrhoe
de .</w>
comm it
cle an
author ities</w>
assess ed</w>
V I
TION S</w>
R en
On ce</w>
I s
B o
- 1
y l</w>
vel y</w>
tur al</w>
tem perat
t -
spec i
s we
relev ant</w>
qu ick
proble m</w>
inter national</w>
h om
for tun
f all</w>
evalu ated</w>
em erg
bre ath
bec om
S y
I s</w>
0 7/</w>
/ww w.</w>
y ?</w>
s on
requ est</w>
na use
leg al</w>
kno w
hel d</w>
fo re
f ut
euro pa
e duc
de st
countri es.</w>
concer ned</w>
clear ance</w>
ad op
S pain</w>
Di rec
AUTHORISA TION</w>
8 00</w>
4 ,</w>
3 A
2 3</w>
( F
( EMEA
vis ual</w>
th at,</w>
parti cles</w>
meth od</w>
me .</w>
le uk
in j
ic es</w>
direc tly</w>
desc ribed</w>
de ma
d ys
ati v
a ir</w>
W ith
Mr s</w>
M ar
Ger many</w>
CHM P</w>
AC T
6 ,</w>
. ,</w>
th ,</w>
stud y,</w>
st ,</w>
remain s</w>
presc ribed</w>
pa ren
in st
improv ement</w>
hist ory</w>
gluc ose</w>
fin anc
e tic</w>
doct or.</w>
F ro
2 9
, 000</w>
(A5 -00
' ,</w>
t :</w>
star ting</w>
st atis
reg im
propor tion</w>
on in</w>
o g</w>
m es</w>
lab elling</w>
l es
inte rest
int ended</w>
house hold</w>
gu ar
equ ival
b on
arth ri
al og
Saf ety</w>
M AN
Fro m</w>
C y
36 8/</w>
1 50</w>
0. 5</w>
wh om</w>
volum e</w>
show s</w>
se x
reac hed</w>
protec t</w>
oc yt
m ed</w>
lab el</w>
iti z
is ations</w>
eu tical</w>
e red</w>
car c
c ent</w>
applic ation</w>
app ly</w>
ac e</w>
L I
wh ere
vent ed</w>
there fore,</w>
ten ance</w>
t ob
su st
st er</w>
sh ort
requ ire</w>
pers on</w>
pers on
p ic
min utes</w>
medicin e.</w>
m ut
m on</w>
ly mph
jus ti
hum an
ha ps</w>
et .</w>
drug s</w>
d en</w>
cont rib
clin ically</w>
as th
as al</w>
addi tion,</w>
a im
Com b</w>
C P
3 5</w>
tr act</w>
t ting</w>
system ic</w>
stor age</w>
intrav enous</w>
id es</w>
f ra
f ast
es :</w>
e ts</w>
com plic
ar ing</w>
adoles cents</w>
Produc ts</w>
7 .
3 9
u g
previ ous</w>
multi ple</w>
injec t</w>
fer ry</w>
dr in
con nec
chole ster
avail ability</w>
U SE</w>
T ran
P eg
Mr  
6 00</w>
zap ine</w>
z er</w>
ti de</w>
s il
ques tions</w>
pl ain
phys ici
perform ed</w>
p on
our c
nat ural</w>
for c
follow -up</w>
europa .</w>
ati ves</w>
Sub jec
SP E
Interne t</w>
1 9</w>
(EMEA )</w>
us pen
thi az
ri x</w>
rand om
op o
f ig
en ing</w>
dr y</w>
de pres
c ros
Parliam ent</w>
P e
F ur
AU C</w>
y r
web site</w>
wast e.</w>
us .</w>
therap y,</w>
th yro
sur ve
st af
staf f</w>
sa id</w>
s /</w>
ro le</w>
resist ant</w>
recon stituted</w>
r y
p ing</w>
occur red</w>
o re
n er</w>
k il
immedi ately.</w>
haem orrha
f arm
day s.</w>
contrac ep
c itiz
b ud
ang u
a king</w>
Irel and</w>
IU /</w>
EU/1 /0
Ch aracteris
Can ary</w>
B ec
2 6
ur g
through out</w>
them ,</w>
sub sequ
spec ific
sh ort</w>
reg ular</w>
pres ence</w>
oc k
lo ok</w>
hor mon
ext ent</w>
avail able.</w>
al e</w>
SPE CI
S er
In formation</w>
Hyper sensitivity</w>
HI V</w>
G u
F ren
7 %</w>
5 ).</w>
3 1</w>
ver thel
stit ution</w>
propos als</w>
og rap
necessar y.</w>
mo ve</w>
is ing</w>
hour s.</w>
follow ed</w>
fiel d</w>
f eline</w>
col our
cas es,</w>
cap ac
arm a</w>
Wh ar
West ferry</w>
V ery</w>
Ger man
00 0
( M
treat ment,</w>
ter .</w>
stim ul
st om
produc t.</w>
f all
ent er
criter ia</w>
con tain</w>
co sts</w>
U F
S .</w>
I F</w>
4 5</w>
u gh
tr on
tic o
tic ally</w>
sh ip
rolim us</w>
pregn ant</w>
pharmac ist</w>
orm one</w>
neum on
market .</w>
li g
gover n
gener ally</w>
e th
dos e.</w>
de gre
c ri
aw are</w>
al k
a c</w>
Univer sity</w>
Sum mary</w>
E 14</w>
% ),</w>
z z
t el
system .</w>
suff ering</w>
reas on</w>
re plac
pre vention</w>
possib ility</w>
pl atel
ot y
ma x</w>
it ch
inflamm ation</w>
fol d</w>
alfa-2 b</w>
ab ly</w>
a ve</w>
P l
C .</w>
A ST
2 -
x emb
ve st
t able</w>
sum an</w>
serv ice</w>
re tro
p es
p ast</w>
meas ured</w>
level .</w>
inhibit or</w>
in hal
form s</w>
comp on
ch ro
att emp
antibio tics</w>
Lu xemb
In suman</w>
In sulin</w>
I X</w>
D os
Circ us,</w>
y el
wh y</w>
train ing</w>
si d
sh e</w>
sel f-
qu e</w>
num b
mis sion</w>
fo od.</w>
enc e.</w>
de ath</w>
de ,</w>
dang er
d y
cor respon
common :</w>
be ha
b an</w>
at .</w>
Whar f,</w>
Th ir
Ta ke</w>
CYP 3A
B r
4 -
vit amin</w>
ro l
ri g
n it
li fe
impair ment.</w>
h ormone</w>
h op
h er</w>
direc t</w>
di g
bot tle</w>
bes artan</w>
aes thes
TE RI
T A
Su ch</w>
S tr
HB ,</w>
8 .</w>
4 HB,</w>
train dic
t ase</w>
rati o</w>
projec ts</w>
potassi um</w>
pl us</w>
pe g
p .</w>
mus cle</w>
l angu
in ogen
f em
essenti al</w>
equ al</w>
dri ve</w>
d ated</w>
car ry</w>
b it
ation )</w>
I ts</w>
A p
6 5</w>
2 )</w>
1. 5</w>
techn ical</w>
t ac
t ?</w>
surviv al</w>
sur face</w>
resist ance</w>
rec or
prepar ation</w>
mo ther
me an
m ig
li qu
ke ep</w>
impro ve</w>
i es.</w>
frequ ency</w>
diffe rences</w>
dem a</w>
coll ec
cloud y</w>
ap pl
al iz
ab or
U L
Ren al</w>
Produc t</w>
F e
4 %</w>
3 2</w>
( 0.
ut ri
tre x
some thing</w>
ris e</w>
oe dema
mechan ism</w>
lead ing</w>
l ess
l ar
k en</w>
introduc ed</w>
in )</w>
identi fied</w>
id al</w>
dem oc
comp ani
as h
accept able</w>
ab le,</w>
Luxemb our
2 6</w>
up per</w>
test ing</w>
studi es,</w>
st able</w>
reas ons</w>
peri pheral</w>
other s</w>
hyper sensitivity</w>
he im
difficul ty</w>
car d</w>
al f
ab ol
Th at</w>
Sw ed
SPECI AL</w>
S A</w>
P )</w>
I T
D ec
um -
ter min
su s</w>
produc ts,</w>
p ap
m id
h arm
discontinu ed</w>
cre atin
capsul es</w>
beha vi
b ul
atten tion</w>
ati c
at e)</w>
UF ACT
UFACT U
Netherland s</w>
MAN UFACTU
L o
DI SP
C ON
10 %</w>
1 ).</w>
wa ste
ti tr
targ et</w>
sto red</w>
ste p</w>
sol v
pro long
p ac
os is,</w>
o il</w>
m ac
lox ac
log ical</w>
fin d</w>
equival ent</w>
diseas e,</w>
di p
cal ci
bod y.</w>
al og</w>
L D
H OL
CYP 2
) ;</w>
withdra w
up dated</w>
un known.</w>
tissu e</w>
re ver
radi o
present ed</w>
po int
or s.</w>
op en</w>
om a</w>
frequ ently</w>
f al
ery thro
emb ol
el derly</w>
con j
co m</w>
benef its</w>
author ised</w>
administr ation.</w>
acc ep
ac tion.</w>
W AST
WAST E</w>
Th ree</w>
Sec tion</w>
OS AL</w>
MA TERI
M al
DISP OSAL</w>
3 3</w>
/200 0)</w>
( for</w>
tic le</w>
th us</w>
stat us</w>
r un
ques tions,</w>
prac tic
o S
meas uring</w>
invol v
i .</w>
ho we
equ ip
diffe rence</w>
ch aracteris
b at
atel y,</w>
MATERI AL
Inter national</w>
Hum alog</w>
DE R</w>
1 .</w>
week s.</w>
w er</w>
tox ic</w>
system s</w>
reac h</w>
pa y
ol ,</w>
inter action</w>
gly cer
fe el
exces sive</w>
e ffici
dos ing</w>
defin ed</w>
cont ent</w>
condi tion</w>
con traindic
c ep
bre ak
b ri
acc oun
ab normal</w>
UN USED</w>
S ever
PRE C
PREC AU
PRECAU TIONS</w>
E ven</w>
B ot
A f
( used</w>
sus pec
se ve
r a</w>
psy ch
p ass</w>
ir y</w>
h our</w>
el imin
ch e
cer tain
R ec
L -
7 0
w rit
under going</w>
tal k</w>
subst anc
regar ds</w>
pro mis
ph ase</w>
oc ial</w>
ner v
mo re,</w>
manufacture r
l ast
iti es.</w>
in a</w>
fol low</w>
f y</w>
et al</w>
et ,</w>
employ ment</w>
dro p
deriv ed</w>
b ed</w>
a -
Portu gal</w>
O f</w>
M et
Lim ited</w>
EU/1/00/13 1
3 -
3 ).</w>
work .</w>
us e,</w>
sub mitted</w>
s cho
mono therapy</w>
is ion</w>
fe el</w>
fe ed</w>
extre m
er ic
distrib ution</w>
der .</w>
consi der</w>
combin ed</w>
c att
b list
an t,</w>
altern ative</w>
In vented</w>
7 ,</w>
.. .</w>
v ul
uni form
trans f
tak es</w>
surg ery</w>
sul ph
star ted</w>
s ligh
rap id
propos al</w>
program me</w>
pre cau
poli tical</w>
p neumon
o pro
medicin es,</w>
main tenance</w>
ma b</w>
inu x</w>
f lo
exc ep
divi ded</w>
de d,</w>
cris is</w>
cont ents</w>
comp an
am oun
ab ine</w>
N A</w>
Man ufacture
HOL DER</w>
Fren ch</w>
ER A</w>
C V
Bec ause</w>
AN CE</w>
8 %</w>
( 1</w>
ut ro
transp l
ton n
see k</w>
require ments</w>
por te
pl es</w>
par ame
observ ed.</w>
n utri
n a</w>
microgram s</w>
medicin es.</w>
main tain</w>
giv ing</w>
exc ept</w>
er 's</w>
e ph
determin ed</w>
ag on
Wor king</w>
O c
w s</w>
ru b
reg i
pur pos
op tim
ond apar
ondapar inux</w>
n ucle
le t</w>
kin d</w>
it ary</w>
is es</w>
inter v
in spec
ib le</w>
ex ce
en h
e ve</w>
d s,</w>
d a</w>
clos ely</w>
be ta
at e
ap h
ant s,</w>
an sw
a im</w>
T ur
S ince</w>
O R
G mb
B ased</w>
8 ).</w>
6 %</w>
3 9</w>
( including</w>
( 0
vol un
un d
suff er</w>
so ft</w>
s in
refer red</w>
ras h</w>
pres su
ph as
ox y
over dose</w>
inter nal</w>
il ,</w>
i tion</w>
for me
ex posed</w>
creatin ine</w>
consump tion</w>
children .</w>
carc inogen
avi ren
al though</w>
a way</w>
TI V
Ph arma</w>
P ark
( N
y me</w>
vi ol
to p</w>
tivel y</w>
ti m</w>
th in
str a
solu tions</w>
ric ul
respon sib
re al</w>
produc tive</w>
proc ess
port un
phosph ate</w>
on az
ing ?</w>
in o
hand s</w>
hal f-
go es</w>
bin ding</w>
b ack
af t</w>
Ques tion</w>
Fir st
EU/1/00/13 2
EU R</w>
ER D
A N</w>
1 000</w>
waste water</w>
ti fic
op portun
om i
minim um</w>
mg )</w>
lan zapine</w>
in clu
ig n</w>
hi bi
f at</w>
ex tr
chec k</w>
at ors</w>
all ,</w>
P fi
O lanzapine</w>
8 ,</w>
6 9
- 1</w>
% ).</w>
v as
ter ,</w>
suffici ent</w>
su n
st ore</w>
st age</w>
so ,</w>
s tic
recommend ations</w>
ph ot
p um
oste opo
o trex
o od</w>
lab or
it able</w>
issu e</w>
invol ving</w>
infec tion.</w>
impa ired</w>
he um
har mon
form ul
fo vir</w>
er t</w>
consider ation</w>
common ly</w>
as .</w>
T ru
T rit
Stat es,</w>
RI SP
I V
D uring</w>
ver .</w>
tox icity</w>
thro mbo
them sel
st .</w>
sk in,</w>
pro per</w>
previ ously</w>
phys ical</w>
ne e
mem ber</w>
m ur
m er
m ,</w>
lo o
inte rest</w>
guid el
g /
ev ent
es ;</w>
en ol
ed ing.</w>
dog s</w>
disorder ,</w>
dec id
correc t</w>
conduc ted</w>
con cluded</w>
clean sing</w>
circumst ances</w>
cent ral</w>
bot t
act ing</w>
ac et
Slo ven
RISP ERD
PRODUCT S</w>
P u
P V
Ne w</w>
M R
D en
A ust
4. 5).</w>
ur inary</w>
um .</w>
ter ro
technolog y</w>
st re
se iz
se d,</w>
s la
ros s</w>
pharmac ovigilance</w>
pa rent</w>
ox ide</w>
out side</w>
ograp h
meth otrex
main ly</w>
le t
ini b</w>
ha z
grow ing</w>
ey el
ed :</w>
deter mine</w>
d ings</w>
com pati
bor n</w>
Un common</w>
T able</w>
S ome</w>
P r
F ol
9 0</w>
5 0%</w>
2 7</w>
x ,</w>
wor ks</w>
uniform ly</w>
u mab</w>
th .</w>
s ocial</w>
reduc ing</w>
re combin
po or</w>
on -
og lob
n ess
min or</w>
mar k</w>
m i
ism .</w>
ism ,</w>
immedi ate</w>
em s</w>
diagno sis</w>
di ure
chlor ide</w>
ar ds</w>
anc ed</w>
ag ricul
adv ice</w>
adv ant
O ffic
F RO
Ar ticle</w>
9 6/</w>
( 4
z heim
withdraw al</w>
vom it
tum our</w>
tox ic
sw elling</w>
ster oid
sh oul
sex ual</w>
s cal
s am
rel ating</w>
recombin ant</w>
quick ly</w>
placebo -
per si
n ation
n ame</w>
injec tions</w>
h ere</w>
f ron
eu tic
el ,</w>
da il
b ru
ation ?</w>
are :</w>
all y.</w>
ad ine</w>
act ually</w>
____ ____
S T</w>
MA R
M emb
Ital y</w>
Al zheim
A ID
(A4 -00
… …
wa y,</w>
w ard</w>
str ation</w>
sligh tly</w>
rap id</w>
r heum
pul monary</w>
ph y
pen s
particul ar,</w>
oc k</w>
m in</w>
m .</w>
l as
kidne y</w>
int oler
injec ted</w>
initi ated</w>
il ep
hypo glycaem
guar an
gr anted</w>
gr ad
ef aviren
docum ent</w>
cat eg
c over</w>
al y
ac u
ab norm
Subjec t:</w>
FOR MA
C )</w>
Aust ri
A B
A ,</w>
6 -
3 6</w>
' t</w>
tiv e,</w>
th ough
t ar
sw ab
sensi tive</w>
retur n</w>
replac ement</w>
relev ance</w>
p as
n i
mal ign
m od
ist s</w>
indu stri
i ro
g a
er cul
environ ment.</w>
degre e</w>
co ord
can di
calci um</w>
bal ance</w>
ad ver
ad ded</w>
P E
Ne verthel
In tro
IN FORMA
I r
Com mon
C lin
C al
C V</w>
5 /</w>
3 4</w>
wor sen
second ary</w>
sec tions</w>
s on</w>
ris k
possib le,</w>
pl an</w>
pharmac eutical</w>
per cent
le dg
le -
jo int</w>
in tr
he av
econom ic</w>
di tional</w>
decid ed</w>
conj unc
cl us
cl er
cl ass</w>
chang ed</w>
capac ity</w>
cap su
ac qu
W e
V III</w>
Th en</w>
S ch
Pre par
Heal th</w>
H ou
First ly,</w>
wat er.</w>
war ning</w>
up on</w>
ul cer
transp or
pregn anc
pat ch</w>
on set</w>
oe dema</w>
nur se</w>
mat ter</w>
ma king</w>
in de
h on
ex act
effec ts.</w>
del ay
ch lo
bus iness</w>
bio availability</w>
ant s.</w>
al isation</w>
U B
RISPERD AL</w>
O ther</w>
M M
L at
L E</w>
K E
I I</w>
8 4</w>
2 4
( the</w>
ver y
temperat ure</w>
super vision</w>
struc ture</w>
st ren
simp ly</w>
regar ding</w>
progres sive</w>
pre c
placebo .</w>
pen s</w>
n ic
le n</w>
inte gr
indu stry</w>
in stitu
fe wer</w>
f ar
excipi ents.</w>
el y.</w>
dist ur
di zz
di ff
d ?</w>
d :</w>
contraindic ated</w>
chlo ro
c ar</w>
alys is</w>
addres s</w>
ac ross</w>
V e
V al
A G
(0 )
yl ene</w>
v s</w>
ti t
thiaz ide</w>
t ou
system ,</w>
stren g
some one</w>
sit e.</w>
re ve
pol l
oglob in</w>
ob vi
metabolit es</w>
mach in
is ol
hol der</w>
har m</w>
go ti
g li
er ro
enti re</w>
des ir
der s</w>
der mal</w>
de l</w>
con ven
az one</w>
arthri tis</w>
Un fortun
S k
O ur</w>
INFORMA TION</w>
I N</w>
G -
E very
Be fore</w>
2 9</w>
- M
(C HM
ver sus</w>
vacc ines</w>
us h</w>
tub ercul
ste ps</w>
spec ies</w>
rapid ly</w>
pri v
pig s</w>
par ts</w>
or ph
loxac in</w>
k ept</w>
is e,</w>
gluc os
glob al</w>
f oc
et ine</w>
end ing</w>
em is
doct or,</w>
d s.</w>
cr im
confir med</w>
children ,</w>
ben z
assist ance</w>
a ys</w>
a red</w>
Tru dex
Pfi zer</w>
Park in
P RI
Opti S
O G
N O
Manufacture r</w>
In cre
I .</w>
EU/1/00/131 /0
Con sequ
9 ,</w>
/99 )</w>
/ 4
(CHM P)</w>
st and</w>
st -
spe aking</w>
sec re
saf e</w>
retro viral</w>
res ourc
recept or</w>
qu in
prolong ed</w>
ou s.</w>
ot e</w>
oph enol
open ia</w>
o z
o ro
ne t
materi als</w>
mark ed</w>
mal e</w>
m ob
know ledg
inform ation.</w>
inf us
in dependent</w>
if ied</w>
ide .</w>
id ov
g es
func tion
examin ed</w>
enc y
en larg
e ff
c ophenol
al most</w>
N E
J un
Fur ther
E L
Com mon</w>
9 8</w>
6 0
5. 2).</w>
( s)</w>
( 3</w>
ur ity</w>
tri al</w>
tic s.</w>
ti ous</w>
sup plement
stom ach</w>
s le
provi ding</w>
possib ly</w>
po e
peri od.</w>
ne goti
jo in
ine -
health care</w>
group .</w>
fi x
feel ing</w>
ey es</w>
extrem ely</w>
ep ilep
diseas es.</w>
cal cul
b rou
b ron
anti gen
adequ ately</w>
Parkin son
Oc tob
Neverthel ess,</w>
Ch in
A B</w>
w id
trac he
tr y</w>
th reat
sum mary</w>
si di
separ ate</w>
ro om</w>
re move</w>
re jec
pub lish
pub lic
ov ered</w>
on es</w>
maj ority</w>
liqu id</w>
li es</w>
k illed</w>
initi ation</w>
indic ate</w>
id ence</w>
hibi tion</w>
head ach
gre at
f ing
ery them
dest ro
dam aged</w>
correc tly</w>
chem o
b ate</w>
and s</w>
abdom inal</w>
Th er
St ud
S )</w>
M us
Gre ec
Gmb H</w>
E T
B er
5 8
4. 8).</w>
---------------- ----------------
(H -0
( hyper
war ds</w>
w ise</w>
up .</w>
ul c
thyro id</w>
t ex
se tting</w>
s low
ro w
rel ation
re ally</w>
pr ice</w>
percent age</w>
parame ters</w>
mou th</w>
month .</w>
m os
lim it
l un
j u
in take</w>
impro ved</w>
il .</w>
hi p</w>
func tion,</w>
fro z
financ ial</w>
dom in
conside red.</w>
consequ ences</w>
co ver
ch es</w>
ch ed</w>
c ru
att ach
ar yn
appro v
an k
act or</w>
ab sol
Wh o</w>
Re ad</w>
Ch ild
CYP3A 4</w>
B ri
4 6</w>
4 2</w>
3 )</w>
wom en,</w>
well .</w>
viv o</w>
tiv e.</w>
th ought</w>
t in
ste ad
rop in</w>
qu ite</w>
potenti ally</w>
pa y</w>
ov ascular</w>
mor tal
m om
le v
l en
import ance</w>
g al
exp lo
em ent
ell ed</w>
dr ink</w>
danger ous</w>
cophenol ate</w>
amoun ts</w>
am ide</w>
alf a</w>
al ong</w>
VE D</w>
H ung
C l
* ,</w>
wh e
vie w
ur on
til ity</w>
table t
sust ained</w>
subsequ ent</w>
sla ugh
pur pose</w>
princi ple</w>
poe tin</w>
per haps</w>
o very</w>
mar ro
insuffici ency</w>
ing s.</w>
ing ly</w>
hum ans</w>
fam ily</w>
environ mental</w>
ec h</w>
dri ving</w>
correspon ding</w>
cor tico
consum ers</w>
cl usion</w>
chem ical</w>
brou ght</w>
becom ing</w>
at eg
ari an</w>
anti body</w>
anim als.</w>
advis ed</w>
achi eve</w>
a wa
There fore</w>
Stud y</w>
R us
M erc
Luxembour g</w>
J oh
G I
FRO M</w>
Commun ity</w>
Common :</w>
C ol
C max</w>
B lo
9 .
. .</w>
vie w,</w>
th al
str ong</w>
stop ped</w>
stand ing</w>
s cre
res uspen
require ments.</w>
progres sion</w>
pro vision</w>
prescri ption</w>
pow der,</w>
orig inal</w>
onaz ole</w>
nause a,</w>
lac tic</w>
j a</w>
ing :</w>
in no
i an</w>
hi m</w>
exp iry</w>
exact ly</w>
erythro po
dos es.</w>
chlor ide,</w>
bloc k
b li
b a
at oid</w>
ag g
Trudex a</w>
T arc
PRODUCT S,</w>
P a
MATERIAL S</w>
M in
Intro n</w>
H er
F or
EU/1/00/132 /0
Coun c
Co -
Clin ical</w>
Af ter</w>
A .</w>
( B
( 5</w>
( 0)</w>
wor d</w>
t end
solu tion.</w>
s ent
reas on
re p
re ference</w>
medi an</w>
le uc
iz ed</w>
it h</w>
i es,</w>
form in</w>
e z
di lu
c all</w>
bre l</w>
b lin
am b
ac ts</w>
W ill</w>
UC H</w>
S h
S UCH</w>
RI VED</w>
RE LE
P i
En brel</w>
DE RIVED</w>
D NA</w>
CP MP</w>
C ,</w>
3 7</w>
z idov
wn ,</w>
well -
ve in</w>
v ess
tion ?</w>
tion )</w>
te red</w>
t ent</w>
studi ed.</w>
smo king</w>
serv ices</w>
ser ot
s cler
s atis
resul ted</w>
rec overy</w>
ot ox
ol s</w>
ml .</w>
mig r
ment :</w>
j ob
it 's</w>
ino trache
high -
haemorrha g
eutic als</w>
en ed</w>
dis order</w>
concentr ate</w>
car b
an u
al ed</w>
U r
Tran s
P reg
P eri
M a
AC E
A t
4 9</w>
1 00
02 2/</w>
  000</w>
wh il
w el
us sel
us ed,</w>
un used</w>
ti p</w>
t as
t a</w>
sw ell
supp ly</w>
sensi tiv
rou gh
rheum atoid</w>
requ est
reduc tase</w>
pre n
pi ec
out come</w>
our s</w>
ol d.</w>
oedema ,</w>
oc cas
neuro path
n =
mo fe
mofe til</w>
memb ers</w>
m arg
li ve</w>
iti es,</w>
is on</w>
ic ,</w>
i b</w>
hi stor
fl ec
fem ale</w>
fac il
f ru
enzy mes</w>
enc our
ed ;</w>
e ;</w>
docum ent
discontinu ation</w>
dis charg
ci al</w>
av oid
alco hol
ad ap
X X
Thir d
TIV E</w>
Peg Intron</w>
Lat vi
G lax
G M
Fin land</w>
CON ST
Br ussel
Am end
9 %</w>
37 2</w>
wor ds</w>
u ff
th is,</w>
techn i
ta st
specific ally</w>
sit es</w>
s wit
rese arch
re solution</w>
pro p
plas tic</w>
oty pe</w>
or s,</w>
ne utro
legis l
j our
high ly</w>
haem oglobin</w>
gr as
fract ure</w>
fr ic
f el
ex cluded</w>
em ent.</w>
e ar</w>
dy sp
dro p</w>
d one.</w>
com promis
com pens
cir cul
ch ar
catt le</w>
allow ing</w>
abil ity,</w>
a )</w>
Un common:</w>
SA R
S har
N T</w>
Further more,</w>
Ex peri
C or
8 .
200 6.</w>
yel low</w>
year ,</w>
weigh t.</w>
us al</w>
th ings</w>
t aneous</w>
supp lied</w>
success ful</w>
sp on
ro ut
prof ile</w>
proc ess.</w>
per man
ou ter</w>
og lit
o fovir</w>
medi a</w>
m ith
m it</w>
le ar
k g/</w>
in vest
ie ve</w>
ic s</w>
guidel ines</w>
gra m</w>
gr ant
froz en</w>
fr ag
for get</w>
embol ic</w>
ed )</w>
di et</w>
decre as
d -
ag u
ag en
With in</w>
Unfortun ately,</w>
T ra
Ro ad</w>
Rap id</w>
Preg n
P ub
Octob er</w>
Merc k</w>
K ar
In du
I B
HM G-
E ffec
E R</w>
D oc
Consequ ently,</w>
B M
20 %</w>
199 7</w>
(9 5%</w>
’ ,</w>
y cl
worl d</w>
transp a
t old</w>
t ation</w>
sub stit
st on
respectivel y.</w>
pow er</w>
pass ed</w>
osteopo rosis</w>
ob tain</w>
oS mith
mo del</w>
min ut
metabol ite</w>
m ix</w>
lo p
le d,</w>
is on
injec tions.</w>
id ,</w>
i atric</w>
g lo
g el
g ,</w>
fo od
en si
el se</w>
drin king</w>
dos e,</w>
dig ital</w>
difficul ties</w>
d op
cortico steroid
commun ic
com plain
bod y
bir th</w>
bab ly</w>
anti retroviral</w>
ang i
alog u
T r
S ept
PRO PRI
PROPRI ATE</w>
M ix</w>
M ay</w>
M ad
Jun e</w>
HMG- Co
Glax oSmith
D -
C ha
Al though</w>
Ad verse</w>
AP PROPRIATE</w>
7 6</w>
6 7</w>
2 50</w>
1 60</w>
. '</w>
( such</w>
z er
your self</w>
un less</w>
to m</w>
th ous
th is.</w>
su itable</w>
struc tion</w>
sol id</w>
so on</w>
ra rely</w>
ra ised</w>
partic ip
o si
nerv ous</w>
m mol
ion al</w>
howe ver</w>
happen s</w>
gi a,</w>
fav our</w>
f ondaparinux</w>
f ight</w>
enz a</w>
di ver
death s</w>
de grad
day )</w>
d in
cour se,</w>
cl aim
bl ad
bel ieve</w>
at es,</w>
ar y,</w>
ar di
activ ated</w>
Un der</w>
T ri
T re
T )</w>
Swed en</w>
Sever e</w>
P al
P ack
M S
M IR
Joh n
GlaxoSmith K
Fr ance,</w>
Experi ence</w>
A fric
6 )</w>
200 2.</w>
- related</w>
( as</w>
y ed</w>
week ly</w>
w ide</w>
tem por
ta x</w>
sugg est
su d
ster ile</w>
remov ed</w>
recogn ised</w>
re serv
provi des</w>
pro mot
polic y</w>
pe t
occur s</w>
o st
no thing</w>
mon ey</w>
man ufact
main tained</w>
inter pre
injec tion,</w>
ing s,</w>
fav our
emb ry
ed ly</w>
eas ily</w>
diab etic</w>
desir able</w>
de al
consi st
cholester ol</w>
chloro thiazide</w>
cartridg e</w>
c ost</w>
bacter ial</w>
amp ou
Th e
SP ON
Rus si
Reg ulation</w>
RE SPON
L ev
He pati
HMG-Co A</w>
G F
D ose</w>
C H</w>
B ar
AC R</w>
A SE</w>
9 /</w>
3 8</w>
00 2</w>
0. 0
w ron
volun te
v ice</w>
us hed</w>
te ach
struc tions</w>
st y
st ated</w>
spe ak
smo k
s co
represent ative</w>
repe ated</w>
rel ative</w>
ref ers</w>
re sol
re flec
ras h,</w>
pro vis
pend it
ou red</w>
n e</w>
mortal ity</w>
level s.</w>
her pes</w>
func tion.</w>
frequ ent</w>
fra me
expo su
es sion</w>
em ent,</w>
ell it
distrib u
d ine</w>
ch est</w>
ch ,</w>
ca using</w>
bra in</w>
att ack
ar ter
anti viral</w>
ang e</w>
al ities</w>
agre ed</w>
ag lip
ag e
T ell</w>
S tre
S al
Pro top
Novo Mix</w>
En gl
Alzheim er's</w>
ye th
x i
w all</w>
vic tim
ver te
ur it
transi ent</w>
themsel ves</w>
sup pres
sugg est</w>
si vely</w>
s qu
s !</w>
ro t
ro ad</w>
repor t,</w>
relation ship</w>
r s</w>
pro bably</w>
pri l</w>
pre fer
pol ys
physici an</w>
pes tic
opin ion</w>
nee ded.</w>
lun g</w>
lo ad
li ving</w>
le d.</w>
lam iv
k ill
ir a</w>
half- life</w>
fron t</w>
fin dings</w>
ex pendit
ex pen
enc y.</w>
do ing</w>
direc tive</w>
countri es,</w>
circumst anc
cardi ac</w>
capsu le</w>
c am
an a</w>
a uc
Y Y
T R
T A</w>
R ep
Or g
Mix 25</w>
M E</w>
In structions</w>
EX UB
B I
B AT
A /</w>
6 5
00 1</w>
( 1
vir uses</w>
val id</w>
v ascular</w>
ud e</w>
trans dermal</w>
stric t</w>
se d.</w>
sch e
ques tion
produc t
pro v
pos t</w>
pl ant</w>
peop le
pen ,</w>
pa inf
oc y
me at</w>
low ing</w>
le ak
labor atory</w>
la w</w>
in ity</w>
il ly</w>
id .</w>
heav y</w>
he ad</w>
groun d</w>
gly co
fam il
f ever</w>
elev ated</w>
diffe ren
contain ed</w>
consum er</w>
con stitu
cas e,</w>
bro ken</w>
bo x
blist er</w>
an tic
amend ment</w>
ag rap
Virafer on</w>
Third ly,</w>
T y
Rep ub
RI NG</w>
R ib
Pharmac ovigilance</w>
N eu
My cophenolate</w>
M y</w>
H ep
GlaxoSmithK line</w>
German y,</w>
F er
F ac
4 1</w>
work ers</w>
us ers</w>
up ,</w>
u tr
tubercul osis</w>
transf er</w>
stic k</w>
sor i
se ven</w>
p ir
p ed,</w>
organ is
or bate</w>
odi c</w>
o dium</w>
ne l</w>
metabol ism</w>
m other</w>
ish ed</w>
inclu de
ic k</w>
group s.</w>
gl ass</w>
fun gal</w>
enc ies</w>
emp ty</w>
el etal</w>
ef ul</w>
e ).</w>
docum ents</w>
defin ition</w>
com ing</w>
ch ing</w>
certain ly</w>
benef it
behavi our</w>
b ility</w>
amin o</w>
allow s</w>
ac ks</w>
V A
U sing</w>
SI B
SIB LE</w>
RELE ASE</w>
Pre vention</w>
P lac
N -
In tron
I ,</w>
H e</w>
H O
Ger man</w>
D es
CYP2 C
C T
BAT CH</w>
Am eric
9 0
4. 2).</w>
work ed</w>
ur y</w>
t ext</w>
sul f
ro logical</w>
repe at</w>
reac h
radi ation</w>
pre ci
pers ons</w>
patient s)</w>
our ce</w>
oc ular</w>
n 't</w>
my el
metabol ised</w>
low est</w>
iz ation</w>
investig ated</w>
in hibition</w>
ig e</w>
ic e.</w>
i er</w>
fo od,</w>
f lex
eu /
eu/ .</w>
ent ally</w>
enc y,</w>
distur b
deb ate)</w>
de pression</w>
d ar
cros s-
cr imin
coun ts</w>
consi stent</w>
conf idence</w>
compati ble</w>
cardi ovascular</w>
ar m</w>
al one,</w>
TI NG</w>
SU B
S Y
RESPON SIBLE</w>
Par ty</w>
P ri
MANUFACTU RING</w>
M ore</w>
Im port
F actor</w>
wor se</w>
w ik
ur ine</w>
ul in
tr ade</w>
syndro me,</w>
suspec ted</w>
rel ap
quanti ty</w>
pre h
par ties</w>
p ite</w>
ot al</w>
open ing</w>
necessar y,</w>
n es
medic ation</w>
m ess
loo ks</w>
lo ad</w>
li v
leuk aemia</w>
legis lation</w>
l )</w>
k et
k a</w>
il is</w>
hy p
high est</w>
harm ful</w>
haem at
h u
h es
g er</w>
fall ing</w>
fail ure,</w>
f ill</w>
ey e,</w>
excre tion</w>
e f</w>
dispos al</w>
di e</w>
dec ide</w>
de al</w>
cre di
contr ast</w>
con ges
con c
clos ed</w>
ch ance</w>
c ig
bu ild
bron ch
b ral</w>
aut om
ari es</w>
applic ations</w>
ap parent</w>
an s,</w>
Wh ile</w>
U /</w>
Res pon
Q U
O Ü</w>
O b
M ic
L illy</w>
Europe .</w>
B i
Ad mini
3 0%</w>
00 4</w>
   </w>
y c
v ag
t y.</w>
sup port
studi es.</w>
stud y.</w>
so -
sal t</w>
roun d</w>
ro ute</w>
rh inotrache
respon ses</w>
reduc es</w>
pre serv
por ts</w>
poin ted</w>
per fec
p ut
ox ib</w>
ogen ic</w>
n ight</w>
men opa
lo t
life -
la w
l ess.</w>
ion s.</w>
inhib its</w>
ide a</w>
id s</w>
i ,</w>
hospit al</w>
hap pen</w>
h ab
function ing</w>
fi br
f ish</w>
f ast</w>
ep is
efaviren z</w>
e .
dou b
dos e-
discontinu e</w>
def ec
comm er
cl ar
canc er.</w>
bacter ia</w>
at o
appro ach</w>
and /
and/ or</w>
an -
amend ments</w>
aglip tin</w>
acc um
a ?</w>
Th ro
T w
Sept ember</w>
SUB ST
S yn
S ver
S ome
S ci
Rib avirin</w>
Pack age</w>
Nov ember</w>
M il
In fec
CONST A</w>
@ m
4 7</w>
2 5%</w>
0 4/</w>
vot e</w>
vehic les</w>
u ated</w>
tri glycer
treat ing</w>
to ok</w>
titr ation</w>
swab s)</w>
subst anti
str um
spe ak</w>
so- called</w>
sim vastatin</w>
sh all</w>
serot onin</w>
sche du
require s</w>
qu ot
pre vent
pass eng
oun d
on to</w>
om et
ol ys
o ti
o int
ne tic</w>
ne ph
n ia</w>
les ions</w>
l d</w>
im ag
exerc ise</w>
ex pres
es ).</w>
el .</w>
ec u
condi tions,</w>
competi tion</w>
cl on
ch all
bel i
as pec
an rix</w>
agricul tural</w>
acqu ired</w>
ac compani
W ith</w>
Tarc eva</w>
Sver ige</w>
St ar
R em
Parkinson 's</w>
N ob
Indu stri
E E
D oh
C ent
Av oid</w>
AC TIVE</w>
8 0
6 3</w>
1 1
( n=
yeth ylene</w>
y :</w>
where as</w>
weak ness</w>
we b</w>
war n
u v
trans l
tra vel
tr ic
t oc
syring es</w>
suic ide</w>
ro ad
publish ed</w>
popul ation.</w>
po ver
persi stent</w>
ov ere
or ies</w>
or ic
open ed</w>
numb ers</w>
no ted</w>
n ess.</w>
mil k,</w>
mil est
met formin</w>
ma il
it e,</w>
in adequate</w>
ic h,</w>
gen e</w>
fun dam
every thing</w>
et h</w>
es '</w>
er ated</w>
effec t.</w>
ed s</w>
dis ast
dilu ted</w>
conver ted</w>
col our</w>
chro mos
centr e</w>
cal cit
bud get
bri dg
bod y,</w>
bel ong
av ing</w>
at s</w>
an aem
af il</w>
Virafer on
Ve terinary</w>
U p
Shar p</w>
S im
Pharmac euticals</w>
P -
A mon
200 1</w>
/99 ):</w>
( D
vis ion,</w>
ure s.</w>
tur n
tis h</w>
table .</w>
t y,</w>
t ors</w>
surve ill
sur roun
suic idal</w>
str ain</w>
sp read</w>
siz e</w>
resul t,</w>
respec t</w>
resi du
r ine</w>
procedu re.</w>
per forme
per cent</w>
pass es</w>
ol .</w>
o t</w>
n or</w>
n one</w>
mat ure</w>
low .</w>
ir besartan</w>
inhib it</w>
ing u
increas ed.</w>
in side</w>
hy poten
hou se</w>
fin ding</w>
environ ment</w>
e tr
e !</w>
diarrhoe a</w>
diabet es,</w>
coun t</w>
continu es</w>
condi tion
compar able</w>
compan ies</w>
comp any</w>
cl es.</w>
chall eng
c ust
blo od
bli ster
b s</w>
b order</w>
aryn g
ar rang
ar ily</w>
an ia</w>
ampou le</w>
adoles cent
accompani ed</w>
USE R</w>
Sk in</w>
Org an
Mix 50</w>
Memb ers</w>
Incre ased</w>
Import ant</w>
G rou
B us
B en
An d</w>
3 3
( 4</w>
zidov udine</w>
z on
z i
vomit ing,</w>
vi al
to -
ti es.</w>
syndro me
swell ing,</w>
situ ations</w>
se p
regim en</w>
re fe
psych iatric</w>
problem s,</w>
pro mo
pre sid
pr urit
po ison
pl ay
pen .</w>
par agrap
painf ul</w>
p H</w>
oun c
organ ic</w>
order s</w>
occur .</w>
o ffici
mut agen
ment s,</w>
market ,</w>
m ellit
iro n</w>
immuno deficiency</w>
im ination</w>
i or
haem ophil
gradu ally</w>
fut ure</w>
exc ess</w>
em ul
el imination</w>
educ ation</w>
e ight</w>
di oxide</w>
demonstr ate</w>
de ad
con sci
cell s.</w>
cas es.</w>
c od
br ing</w>
bot tom</w>
beg in
an aesthes
al ist</w>
ag gres
Ta king</w>
MAR KE
MARKE TING</w>
L O
L ,</w>
King dom
J e
Ir besartan</w>
H a
Characteris tics,</w>
CI :</w>
C z
C M
Author isations</w>
A pril</w>
6. 6.</w>
6. 3.</w>
5 .</w>
5 )</w>
4 4</w>
................................ ................................
( range</w>
wom an</w>
w der</w>
v e,</w>
ur o</w>
udi es</w>
ud g
u ly</w>
tri als.</w>
tiv a</w>
st ag
s /
resourc es</w>
renc y</w>
re s.</w>
profession al</w>
procedu res</w>
pre domin
porte ur</w>
pe p
or i
opath y</w>
op ha
ob lig
nat ure</w>
mother s</w>
minim is
milest one</w>
mg .</w>
meth yl
me et
m as
lo ok
lo dip
l ater</w>
in strum
in ess,</w>
ide d.</w>
hydro chlor
hop e</w>
grant ing</w>
fl ush
fac e,</w>
ech nolog
e. g.</w>
e k</w>
e ep</w>
de ep</w>
cy cle</w>
cartridg e.</w>
care ful</w>
bre ak</w>
ati vely</w>
appro ach
an xi
an aemia</w>
am ma
agre ement</w>
T RI
St udies</w>
S c
Pregn ancy</w>
Pe g</w>
P AR
L t
L abor
L )</w>
Ital y,</w>
Hepati c</w>
H aem
E r
E V
De po
Commission 's</w>
B asal</w>
B .</w>
4. 3).</w>
19 7
18 0</w>
- C
( debate)</w>
( V
( HIV
v ents</w>
tr ag
tim es.</w>
ther .</w>
th o
t al</w>
st uff
spo on</w>
sim ple
sec urity</w>
recon stitution</w>
re productive</w>
propor tion
precau tions</w>
phy lax
perman ent</w>
od y
o le
nutri tion</w>
norm ally</w>
ne utr
minimis ation)</w>
me al</w>
manufacture r</w>
m ist
li ber
lead s</w>
langu age</w>
inf ants</w>
indu str
in form</w>
ha m
h as
gal act
establish ed.</w>
epis od
e tax
dem and</w>
d re
coun ter
control .</w>
condi tions.</w>
compar ison</w>
ch ick
ch aracter
c ess
bl ack</w>
bil li
b lu
av o
at or.</w>
as is</w>
al ity.</w>
ag end
abol ism</w>
W il
T .</w>
R is
R MP</w>
Po wder</w>
H ar
EXUB ERA</w>
EU R
E m
Doh me</w>
Chin ese</w>
5. 1).</w>
4 .</w>
200 7</w>
200 0
00 3</w>
week .</w>
wat er,</w>
vot es</w>
vis ible</w>
verte bral</w>
vacc ine.</w>
un known</w>
tur n</w>
tre s</w>
th en
sy ru
su ffe
require d.</w>
rel ation</w>
reac tion,</w>
r ul
r im
post- marketing</w>
pa in
p ra
ox id
ox etine</w>
or ts</w>
on ium</w>
ogen ous</w>
nause a</w>
min d</w>
lin ked</w>
l ys
l ines</w>
l in</w>
l f
l es,</w>
invol ves</w>
inno v
inf o
individu als</w>
include :</w>
h in
h im
frame work</w>
forc ed</w>
for g
fix ed</w>
exten sion</w>
effec ts,</w>
democ r
del ay</w>
cor ne
consul t</w>
cl im
citiz ens</w>
cha in</w>
ch ol
breath ing</w>
bas ic</w>
asth ma</w>
ani um</w>
adop ted</w>
U k
The ir</w>
Pu h
Protop y</w>
Pl an</w>
P ot
P os
Le afle
LD L</w>
L U
K wik
F our
EU/1 /99
EU/1/99 /1
D an
Bot h</w>
4. 4</w>
00 6</w>
0. 00
. :</w>
(S )</w>
ï ve</w>
w ill
vi al.</w>
tain ing</w>
t ol
syru p</w>
super vis
stit ute</w>
sec tor</w>
righ ts</w>
rever sible</w>
res s</w>
recor ded</w>
rec ur
rec over
reac tions.</w>
prescri p
pos ite</w>
pers ist</w>
peop le,</w>
paren ts</w>
oper ating</w>
me eting</w>
is ed,</w>
inhal ed</w>
includ es</w>
in ated</w>
hypoglycaem ia</w>
hydr ate,</w>
group ,</w>
for ce</w>
fo ot
f ent
f .</w>
extr a</w>
excipi ents</w>
ex clu
er ation</w>
ed ed</w>
e ase</w>
di hydro
detec ted</w>
dem enti
complic ations</w>
com preh
characteris tics</w>
care ful
c overed</w>
c id
b ag
ation :</w>
at ure</w>
as one</w>
am us
al ine</w>
accid ents</w>
ac avir</w>
Viraferon Peg</w>
Uk ra
S S</w>
Re Fac
ReFac to</w>
R A</w>
J o
In jec
In f
Hy dro
Heal th
F lex
E fficacy</w>
An ti
Amon g</w>
AID S</w>
5 5</w>
( ≥</w>
( pharmacovigilance</w>
z o
yl ated</w>
y p
week )</w>
vaccin ated</w>
v ar
tion :</w>
t ure
symptom atic</w>
sty le</w>
sh or
sen s
se tt
sal e</w>
run ning</w>
random ised</w>
r am
pre dic
platel et</w>
p =
p ,</w>
orig in</w>
oglit azone</w>
objec tives</w>
o wn
nucle ar</w>
n ine</w>
men ing
memb ran
land ,</w>
l eng
it ation</w>
introduc tion</w>
induc ed</w>
in ser
implement ation</w>
im aging</w>
he pat
guaran te
gu e</w>
f ying</w>
f ri
etax el</w>
emplo ye
dou ble
diseas es,</w>
diagno sed</w>
de p
dang er</w>
concern s</w>
coll ap
cl assi
cho ose</w>
ch .</w>
ce re
b our
appe ared</w>
app li
ap hy
and .</w>
amp oul
am lodip
ag ent</w>
ag ement</w>
absor bed</w>
ab s
T rac
T N
T ,</w>
S ide</w>
P ul
P en
O s</w>
MA H</w>
Lo ok</w>
IC AL</w>
I ).</w>
EU/1/0 8
EU/1/08 /4
E ach</w>
Depo Cy
C H
Blo od</w>
9 5</w>
15 0
+ 35
your sel
y s.</w>
us er</w>
ur y,</w>
tu be</w>
tri als,</w>
treat ments</w>
tic ,</w>
thre sh
th is
termin al</w>
str ateg
sp aring</w>
sor t</w>
sm all
sc ore</w>
rough ly</w>
recept ors</w>
re ich</w>
prote in
pa id</w>
p sori
oc ardi
neutro pen
n igh
my c
methotrex ate</w>
low ering</w>
l ung
k g/
infec tious</w>
impair ment:</w>
h und
gu e,</w>
g n</w>
g est
g em
form ed</w>
fi ed.</w>
f our
f en
es opha
eph al
do wn
disorder s:</w>
dis appear
delay ed</w>
cre ate</w>
concer n</w>
co- administered</w>
chem ic
c ough
beli ev
beg in</w>
b om
ass ess</w>
al ity,</w>
adul ts.</w>
W ar
Treat y</w>
Tel z
Stat es.</w>
Presid ent</w>
Portu g
Per haps</w>
N um
Me th
Mad ri
MA O
M ost</w>
M o
Is ra
Gu id
F -
Every thing</w>
Europe ,</w>
EMEA .</w>
DepoCy te</w>
D y
Bri tish</w>
9 )</w>
200 3</w>
2 2
Ö ster
Öster reich</w>
y s,</w>
wom en.</w>
whil st</w>
ver s</w>
tre n
trans mission</w>
thromb ocyt
techni qu
te en</w>
t rou
syn thes
sus cep
subcut ane
sk á</w>
s ource</w>
s ound</w>
rub ber</w>
ris k.</w>
ri st
ri a</w>
reve aled</w>
respon d</w>
regul arly</w>
r ying</w>
por ted</w>
peg interferon</w>
p ush</w>
oun ds</w>
os ensi
optim al</w>
op e</w>
ond el
oint ment</w>
offic ial</w>
ob es
o ver,</w>
minim isation</w>
m m
is )</w>
ir ub
industri al</w>
inde ed</w>
increas ed,</w>
in ess
i es
i el
i di
har d
gly c
fer tility</w>
f um
exper im
expendit ure</w>
erythropo ie
erg ic</w>
elec tr
e /</w>
develop ment.</w>
decre ases</w>
de x</w>
de vice</w>
countr y,</w>
con vul
compe tent</w>
com for
co operation</w>
cig are
c ut</w>
blad der</w>
b iv
az ep
asth en
ar s</w>
ar dis
antic ip
al -
accid entally</w>
a meth
Y ondel
T M
T -
Slo v
S -
Rap tiva</w>
Presid ent,</w>
PRODUC T</w>
O ver
J ust</w>
J uly</w>
Intron A</w>
F ax
C ap
Bo x</w>
B as
Ar e</w>
9 00</w>
- like</w>
un likely</w>
un it</w>
un desirable</w>
tw o-
treat ment
ton .</w>
th at.</w>
th at
t an
stand ards</w>
sit e,</w>
sh oc
ser ve</w>
resul ts.</w>
restric tions</w>
ref rig
recogn ise</w>
re view</w>
predomin antly</w>
pr o</w>
pol yethylene</w>
placebo- controlled</w>
pl ans</w>
pi pet
perform ance</w>
organ isations</w>
oc lon
no ti
no te</w>
ner ve</w>
n or
n asal</w>
mmol /</w>
ml /</w>
menopa usal</w>
me t</w>
mag netic</w>
los artan</w>
li ves</w>
leak age</w>
l ost</w>
jo b</w>
inv as
intr amus
inter actions</w>
inter act</w>
ing )</w>
indic ation</w>
inc in
in ic</w>
im pl
i ble
i .
hyperten sive</w>
he par
for ward</w>
eyel id</w>
exerc ised</w>
ex ac
equip ment</w>
elec tron
dis car
depend ing</w>
de ep
cor por
concer ning</w>
con st
ca st
c iv
c ic
bo x</w>
bo ard</w>
attach ed</w>
are ,</w>
ar ia</w>
appropri ate.</w>
an s
alog ue</w>
al loc
al ism</w>
ad al
acid s</w>
acc ur
acc o</w>
Wor ld</w>
U K
Su omi
Par k</w>
M IU</w>
L y
L am
Hou se</w>
HA R
F ood</w>
EUR  
E qu
Commission ,</w>
C an</w>
C a
C CI
Belgi um</w>
B oe
Ac ute</w>
8 -
(hyper sensitiv
( 1.
y ;</w>
worl d
wh ich,</w>
we ar</w>
vom iting</w>
vir us,</w>
vir us
v e.</w>
ut ing</w>
under stand</w>
ulc ers</w>
tri c</w>
table ts,</w>
sub sidi
slow ly</w>
sh el
se ems</w>
s ess
s chem
s an
repor ted.</w>
red ness</w>
re s,</w>
r in
prof loxacin</w>
pro of</w>
pe ak</w>
over -
opath y,</w>
obvi ous</w>
o tide</w>
men tion</w>
machin es.</w>
long -
la z
l ish</w>
j udg
iz e</w>
interv als</w>
inform ed</w>
ine )</w>
in duce</w>
ific ation,</w>
id om
ia ),</w>
hel ps</w>
get ting</w>
fre e
fig ure</w>
fam ili
exam ination</w>
et y,</w>
elimin ated</w>
e poetin</w>
death .</w>
day s,</w>
com b
co st
calcit onin</w>
c u
c ro
c ame</w>
but ton</w>
bud get</w>
bro ad
blin d</w>
ble ed
belo w
avo ided.</w>
attemp ts</w>
at ropin</w>
at es.</w>
as e,</w>
ann ual</w>
ag ul
ag en</w>
act .</w>
abnorm alities</w>
Y ET
Wh ite</w>
W y
V ANCE</w>
Telz ir</w>
T e
S uspen
S ing
Ques tions</w>
P R
NA ME</w>
Fol lowing</w>
D u
D o
Belgi um,</w>
Ag ency
7. 5</w>
4 )</w>
200 8.</w>
( another</w>
( G
year s)</w>
year -
work ,</w>
week s,</w>
ver sion</w>
val s
v ac
un iver
un its</w>
ulin um</w>
tox in</w>
tig mine</w>
there by</w>
the tic</w>
ta r</w>
sust ain
sup ple
si gn</w>
ris ti
require ment</w>
re verse</w>
re :</w>
quanti ties</w>
qu ar
potassi um-
plas ma
pipet te</w>
phylax is</w>
peop le.</w>
pe ac
os is.</w>
om er
ol der</w>
off -
no e
neph ro
n ing.</w>
n al
ml ,</w>
micro biological</w>
men ,</w>
m and
m 2</w>
ly ing</w>
le ave</w>
l s</w>
l ,</w>
join ed</w>
it er
irrit ation</w>
inter vention</w>
inform ation,</w>
in ver
has n't</w>
happen ed</w>
haemorrhag e,</w>
h and</w>
gener ation</w>
g sk
g ently</w>
fish er
fast ing</w>
exper t</w>
expec t
en rol
dou ble</w>
disp la
deb ate</w>
dat ab
cy to
corne al</w>
bu y</w>
bas is.</w>
as se
am pren
am ended</w>
ad ding</w>
T lf
Suspen sion</w>
Spec ial</w>
S il
Respon se</w>
Pub lic</w>
Prepar ation</w>
OL OG
Neu pro</w>
N G
Injec tion</w>
Hum ira</w>
E ston
E F
E .</w>
Den mark</w>
Co- administration</w>
Characteris tics</w>
C R
B re
B YET
9 9
9 0%</w>
8 5</w>
7 -
6 6
4 4
3. 5</w>
10 -
00 7</w>
y a</w>
worsen ing</w>
wh at
w ent</w>
w anted</w>
transfer ase</w>
top ical</w>
ti cles</w>
ther ,</w>
te c</w>
t ures</w>
t ing
suscep ti
surroun ding</w>
ste p.</w>
st ed</w>
sp ir
si x
shoul d:</w>
short -term</w>
se ud
se min
rot ated</w>
ret in
ras h
radio active</w>
r al
psy cho
projec t</w>
parti al</w>
ot ec
os ,</w>
on going</w>
on e-
occur ring</w>
na ïve</w>
n on</w>
n ,</w>
mus cle
mg ,</w>
meth ods</w>
man ner</w>
mach ines</w>
lor at
lim its</w>
ligh t.</w>
l .</w>
inst ance,</w>
induc tion</w>
ic e,</w>
ic .</w>
hydro gen
hydr ate</w>
hab it
h ot
h ec
gl ut
g ain
forg ot
exac er
ep ide
enlarg ement</w>
enc ephal
e '</w>
double -
disp er
diarrhoe a,</w>
deter ior
des pite</w>
d le</w>
conven tional</w>
contrib ute</w>
conf us
compon ent</w>
col oured</w>
cir rh
candi di
canc er,</w>
cal ici
buil ding</w>
appl ying</w>
ap pointed</w>
ampoul es</w>
affec ting</w>
acu ity</w>
accid ental</w>
absol ute</w>
Yondel is</w>
SP C</w>
OLOG ICAL</w>
Leafle t</w>
IC H</w>
I ris
G li
G l
Fax :</w>
E -
D ub
D ev
D )</w>
Cz ech</w>
Child ren</w>
Be ta
Amend ment</w>
A F</w>
9 1</w>
4 50</w>
( 6</w>
( 1.5</w>
” .</w>
viol ence</w>
ur tic
under stand
tri g
transpl ant</w>
tog e
to day</w>
tic .</w>
thrombo embolic</w>
t ure.</w>
surveill ance</w>
statis tics</w>
sh op
scler osis</w>
scal e</w>
respon se.</w>
regul ar
re l</w>
proper ties</w>
pris on
popul ations</w>
polys orbate</w>
peri od,</w>
ody nam
minim ise</w>
me ti
m ir
m ic</w>
las tic</w>
lamiv udine</w>
lab elled</w>
l es.</w>
k er
is ed.</w>
is c
is ation.</w>
ir ing</w>
ion s,</w>
interv al</w>
inter rup
insuffici ent</w>
ing ;</w>
im pression</w>
ild agliptin</w>
il e
id es,</w>
ho od</w>
haemophil ia</w>
haem odi
ha ir</w>
great ly</w>
gras tim</w>
fut ure,</w>
fl u</w>
fact ,</w>
exclu ded.</w>
ex a</w>
et an
es p
em ia</w>
dos ing.</w>
discus sed</w>
dis appear</w>
del iv
cont amin
citiz en
carcinogen ic</w>
carb on</w>
calcul ated</w>
c ou
breast-fe eding.</w>
bil irub
becom es</w>
answ er</w>
all .</w>
ad one</w>
activ ity.</w>
abil ity.</w>
ab acavir</w>
a x</w>
V er
V acc
Tlf :</w>
T im
S ou
S an
S ON</w>
Num ber</w>
N ag
MANUFACTU RE
M A</w>
L ith
L .</w>
El i</w>
Den mark
CCI D
BI OLOGICAL</w>
B ay
@ gsk
5 5
4 9
4 2
20 ,</w>
. com</w>
(hypersensitiv e)</w>
( with</w>
ο υ</w>
ί ου</w>
y )</w>
wa iting</w>
w on
victim s</w>
vi rological</w>
v es
us eful</w>
un treated</w>
u c</w>
transpl ant
ti es,</w>
th an
ten ofovir</w>
surg er
sum m
sol id
sit y.</w>
seve re,</w>
s light</w>
re t</w>
rang ing</w>
r .</w>
prim arily</w>
porte ur
pack age.</w>
pac ks</w>
p y
oxy gen
other s.</w>
os k
oph thal
on ly.</w>
om en
ne ,</w>
mix ture</w>
mix ing</w>
malign ant</w>
m el
ly -
los por
lo t</w>
larg er</w>
l a</w>
k er</w>
issu ed</w>
im migr
ib er
hormon es</w>
h ring
gra v
g ir
for war
flu id</w>
fe ver,</w>
fe eding</w>
fe eding.</w>
f f</w>
ex pression</w>
ent an</w>
en ough
ed -
dys function</w>
de -
dam ag
cre am</w>
corticosteroid s</w>
coord ination</w>
concomit antly</w>
con currently</w>
cap it
c el
avoid ed</w>
atic ally</w>
as e.</w>
are a,</w>
any l</w>
anim als,</w>
angi ot
an alogu
am ination</w>
air cr
adv anced</w>
achiev ing</w>
a b</w>
U S</w>
R )</w>
Portug al,</w>
P an
Offic e</w>
OP TI
O ver</w>
Lith u
Kwik Pen</w>
IN I
Greec e,</w>
Ch risti
Ch ang
C HA
B y</w>
B a
Ap plic
Admini stration</w>
7 5
15 %</w>
1 A
( O
( I
( <</w>
z ,</w>
y !</w>
wh o
weigh t,</w>
w ish
urg ent</w>
un stable</w>
un it
u z
to wards</w>
ti gh
ter s.</w>
st ates</w>
s en</w>
ro ph
ris ing</w>
rhinotrache itis</w>
reli able</w>
reduc tions</w>
qual ific
purpos es</w>
pro hib
pres ents</w>
pow er
plac e,</w>
pl a
phen yl
pan cre
pal ms</w>
ous ness,</w>
ot echnolog
opro x
op raz
om s</w>
om al
oclon al</w>
o esopha
multi -
mor ning</w>
mob il
mil k
m uc
ly :</w>
ke ep
is ms</w>
invas ive</w>
il legal</w>
headach e,</w>
hand ling</w>
gen otype</w>
galact ose</w>
g ast
g as</w>
fent anyl</w>
fat al</w>
fact ory</w>
f low</w>
f la
et ary</w>
erythropoie tin</w>
ent y</w>
ent or
ens in</w>
end s</w>
elec tro
effici ent</w>
e uro</w>
drop ped,</w>
dis sol
dis oprox
di ed</w>
dex ameth
detec tion</w>
control s</w>
consul t
consider able</w>
con clus
compar t
circul ating</w>
cic lospor
character ised</w>
cha ir
ch e</w>
bur den</w>
buil d</w>
belo w.</w>
bat ter
b um
as h</w>
ar ri
ar rest
angiot ensin</w>
an i</w>
ag ree</w>
af ter
aem ia,</w>
adi ly</w>
a u</w>
With out</w>
V ,</w>
Trit anrix</w>
Trac le
Ther ap
TI N</w>
S pan
S and
R i
OPTI SON</w>
M er
I X
G astro
Ex cipi
E very</w>
E ff
Can di
CHA MP
Al l
7 4</w>
7 1</w>
6 8</w>
2. 0</w>
10 ,</w>
00 5</w>
( n</w>
( e.g.</w>
( L
( 3
' and</w>
win do
w ish</w>
vess els</w>
vacc ine,</w>
tum ours</w>
tra ditional</w>
tr ad
ter s,</w>
tas ks</w>
sur pris
subsequ ently</w>
stimul ates</w>
ste ad</w>
som no
sol d</w>
so f
si rolimus</w>
si des</w>
seri ously</w>
scho ol</w>
s ’</w>
s  
s ent</w>
ri p
retur ned</w>
respectivel y,</w>
reac t</w>
program mes</w>
profession als</w>
prin t</w>
pri or
plac e.</w>
par ty</w>
par liam
pack ag
observ ation</w>
o side</w>
n ar
n .</w>
mutagen ic</w>
mov ing</w>
mist ak
mechan isms</w>
me d
marro w</w>
mac ro
lorat adine</w>
lit er
l o</w>
l ine
it ems</w>
ist s,</w>
isol ates</w>
is tic</w>
involv ement</w>
initi ative</w>
indic ations</w>
hydro chlorothiazide</w>
health .</w>
he im</w>
govern ment</w>
giv en.</w>
fish ing</w>
fi ed,</w>
far in</w>
ex ist</w>
evalu ate</w>
end er</w>
em phas
ell a</w>
ech n
discus sion</w>
dic t
democ rac
de red</w>
cont in
con ce
clo tting</w>
circumstanc es.</w>
cess ation</w>
bus iness
bloc king</w>
bin ds</w>
behavi our
b order
avir /</w>
at ing,</w>
arg um
are as.</w>
aph ane</w>
antigen s</w>
al ert</w>
advant ages</w>
administr ative</w>
admini ster</w>
admini ste
acet yl
Y et</w>
T O</w>
Spec ification,</w>
S ur
R a
Pul monary</w>
Man agement</w>
MIR C
MANUFACTURE R</w>
M ab
Lt d</w>
J anu
In gel
H EX
G e
Fur ther</w>
F ree</w>
Dos age</w>
C am
C L
B al
B ,</w>
Ad ditional</w>
AL T</w>
AD RO
9 5%</w>
7 0%</w>
6 0%</w>
50 ,</w>
200 2</w>
( 800</w>
( 6
( 2
withdra wn</w>
wat er
vol u
vehic le</w>
under sto
un employment</w>
ty -
tric it
tion ary</w>
th ing,</w>
ten uated</w>
tempor ary</w>
t )</w>
sy m
sulph on
suffici ently</w>
sud den</w>
sa ying</w>
s y</w>
s al</w>
recur rent</w>
rec ycl
rec ru
r ation</w>
produc tion.</w>
prescrip tion.</w>
pres ent,</w>
practic e.</w>
platel ets</w>
per mitted</w>
patient 's</w>
p un
orph an</w>
on c
modi fication</w>
metabol ic</w>
low -
look ed</w>
lit ax
lif e.</w>
lif e,</w>
li ver.</w>
li fer
lab our</w>
lab el
knowledg e</w>
justi fied</w>
ingredi ent</w>
infec tions,</w>
ili ary</w>
hyperten sion.</w>
health ,</w>
h ous
gly col
giv es</w>
form er</w>
fore ign
fin ally</w>
fi b
ff ic</w>
fail ure.</w>
fact or
f if
effec tively</w>
e m</w>
contain er</w>
concern ed,</w>
commer cial</w>
chemo therapy</w>
chang es.</w>
bre ath</w>
bin d</w>
beta -
bat ch</w>
awa ren
ativ e,</w>
as is,</w>
any thing</w>
al le
affec ted.</w>
adul ts,</w>
adolescent s.</w>
achiev ed,</w>
accid ent</w>
acc ept</w>
ab le
Z i
U l
T i
SE N
S t</w>
S eri
S ).</w>
R u
R are</w>
Nag laz
MIRC ERA</w>
Kingdom .</w>
Iris h</w>
I ra
G r
Eff entor
EU/1/99/1 27
D O
Brussel s</w>
At tenuated</w>
Ac tr
8 9</w>
6 /
200 6</w>
1. 0</w>
- treated</w>
- based</w>
(9 0
( 2.
z em
y clin
v an</w>
ure auc
under taken</w>
ty p
tra ffic</w>
tra -
ti le</w>
th s</w>
sw ol
succ ess</w>
substanc es,</w>
spon taneous</w>
spe ed</w>
solv ent,</w>
sol vent
so di
sle ep
show ing</w>
sen se</w>
secon ds</w>
sa ys</w>
s ourc
s low</w>
ro c
responsib ility</w>
requ iring</w>
regim e</w>
re fu
pum ps</w>
prote ase</w>
proper ly</w>
procedur al</w>
posi tions</w>
pol ice</w>
per for
or th
opportun ity</w>
norm al.</w>
nec k</w>
ne t</w>
mot or</w>
mon oclonal</w>
mis sing</w>
minut es.</w>
meth adone</w>
medi ated</w>
lik a</w>
li x</w>
ity ?</w>
irrit ation,</w>
inter ven
insul in.</w>
in trac
if ic</w>
id og
ic in</w>
hy th
hring er</w>
go t</w>
gluc uron
gl it
gener al,</w>
fun ds</w>
fo re.</w>
fl ic
farm ers</w>
f oun
f illed</w>
experienc ing</w>
ex plain
ex hib
enti s</w>
enrol led</w>
en su
employ ed</w>
ed er
ear li
e ye
e ating</w>
direc ted</w>
da ys
connec tion</w>
con dem
comple ted</w>
col on
co ast
clo sure</w>
cle an</w>
chec k
cer tific
car ton</w>
bet a</w>
at tri
are as,</w>
ar .</w>
an tico
an s.</w>
an os
am s</w>
al te
al ise</w>
aesthes ia,</w>
acid ,</w>
V ic
SUBST ANCE</w>
ST EL
STEL AR
S te
S ain
Ris k</w>
Qu ality</w>
Pro gram
Pal est
P ax
P D
N ote</w>
N a
Met abolism</w>
Me di
M ay
K ine
Ingel heim</w>
In trav
II I
Hep B</w>
F ran
Europe ans</w>
ER S</w>
Bus iness</w>
Bot ulinum</w>
Bay er</w>
B ul
@m erc
7 3</w>
7 2</w>
6 4
6 1</w>
18 0
1 20</w>
/ Tel:</w>
-f ree</w>
youn ger</w>
w o
v es.</w>
v ary</w>
ul in</w>
trav el</w>
tr ue</w>
top otec
tissu es</w>
t ly.</w>
t elev
swol len</w>
str ong
statis tically</w>
st ages</w>
sol di
se a</w>
sa quin
ru n</w>
regul atory</w>
reg ions</w>
refrig er
reac tions,</w>
re new
problem ,</w>
pro ved</w>
pro pose</w>
priv ate</w>
pre- existing</w>
pre mature</w>
posi tion,</w>
pneumon ia,</w>
plac es</w>
piec e</w>
peg ylated</w>
patient -
pa in.</w>
p up
ou t,</w>
ot inic</w>
os in</w>
oric onazole</w>
or ally</w>
ol ab
mou th,</w>
mat ory</w>
market ed</w>
m ati
lev od
k al
j a
it ate</w>
injec tion
inhibit ors.</w>
ide ation</w>
ic on
ia )</w>
hyp oc
he at</w>
h un
guaran tee</w>
fum ar
fract ures</w>
fore ign</w>
fil ter</w>
fig ures</w>
exacer b
estab lish</w>
er n</w>
enh anc
emis sions</w>
disoprox il</w>
cul osk
cop y</w>
conjunc tion</w>
commit te
co- infected</w>
child 's</w>
bur n
bas el
bab y.</w>
b ureauc
avir ,</w>
at ur
at r
as se</w>
anaesthes ia</w>
amin o
aly se</w>
] ,</w>
W a
V IR
Trit ace</w>
Tel .:</w>
Seri ous</w>
Se biv
S a
Res e
Re duc
R -
Qu al
P I
Naglaz yme</w>
M D
L ong
L a
IN VE
IN G
II ,</w>
Health care</w>
H el
Direc tor
Con t
CV MP</w>
CHAMP IX</w>
Boe hringer</w>
Bo ard</w>
BYET TA</w>
As sess
8 00
1. 0
you ,</w>
y m
worl d.</w>
we ap
vit amin
vir tu
valu ation</w>
un fortun
tonn es</w>
toler ance</w>
thrombo tic</w>
terro ris
tac rolimus</w>
sur ge
substit utes</w>
stop ping</w>
stead y</w>
st ock</w>
st av
sp ap
somno l
some what</w>
si glit
sh are</w>
sec u
responsib il
residu es</w>
recommend ation</w>
re vision</w>
re pub
re member</w>
protec tive</w>
produc ing</w>
pro mp
pr ices</w>
possib le.</w>
ph il
ph an</w>
peri od
pen etr
paragrap h</w>
pan leuc
other .</w>
os ing</w>
organ iz
ol ed</w>
og en</w>
no t
mu nolog
mean ing
mac ular</w>
m oun
m ber</w>
lact ation.</w>
la id</w>
l um
kno wn
it ?</w>
is :</w>
ion ally</w>
involv ed.</w>
inver ted</w>
ini um</w>
in si
implement ed</w>
ill ness
identi fy</w>
i. e.</w>
i or</w>
hydrox y
hydrochlor ic</w>
hu ge</w>
hor ses</w>
guid ance</w>
glucos e-
gi es</w>
g one</w>
g el</w>
free zer</w>
fa ir</w>
f ati
ey es,</w>
eu /</w>
erythem a</w>
end point</w>
el op
el i
el ements</w>
ef ul
e at</w>
doct ors</w>
diure tics,</w>
dis ab
dexameth asone</w>
develop ments</w>
den afil</w>
dail y.</w>
cy cles</w>
culosk eletal</w>
credi t</w>
compreh en
cle ar,</w>
chromos ome</w>
categ ory</w>
car s</w>
cap able</w>
c um
c os
c .</w>
bridg e</w>
bo ok
blist ers</w>
belong s</w>
be hin
be .</w>
b y-
ant agon
analogu es</w>
alk onium</w>
al idom
administr ation,</w>
addres sed</w>
accep ted</w>
ac char
Y t
V ER
Un ion
T ox
Sy stem
Sloven ská</w>
S ign
S even</w>
Po st-
OR ACE
O ther
M ore
M B
K ap
John 's</w>
G al
F eline</w>
EU/1/99/127 /0
Dec ision</w>
Car di
C our
C -
Assess ment</w>
ADRO VANCE</w>
7 .</w>
5 2</w>
4 1%</w>
37 3/</w>
37 2/</w>
37 1/</w>
3. 0</w>
199 8.</w>
00 9</w>
/9 6)</w>
- on</w>
( called</w>
( %)</w>
wron g</w>
wor th
wh ite,</w>
week ,</w>
we g</w>
vot e)</w>
v oriconazole</w>
ure s,</w>
u d</w>
tra ffic
threat ening</w>
thre e-
tho roughly</w>
th ing.</w>
table ts.</w>
t ure,</w>
t ing,</w>
supple ments</w>
sub -
sion s,</w>
seve rely</w>
see m</w>
sec ret
s l
s es.</w>
rou s</w>
ro d
ret inal</w>
remov al</w>
re vis
qu i
problem s.</w>
pro xim
pr ic
pot ent</w>
pl ay</w>
ph aryng
pack aging</w>
p il
out com
ot h</w>
oper ative</w>
oper ate</w>
offici als</w>
offic e</w>
no w
new spap
nat ur
n el
mus cular</w>
month s,</w>
mom ent</w>
modi fied</w>
min ority</w>
meth ox
medi um</w>
mat ters</w>
malign anc
la y
l '
intramus cular</w>
inf ra
indic ating</w>
human s.</w>
her pes
hear ing</w>
he red
gen ital</w>
ge al</w>
g .,</w>
fre ed
fl av
favour able</w>
f igh
erro r</w>
er s'</w>
ent er</w>
en orm
emul sion</w>
e x</w>
disorder s,</w>
dis semin
del a
contracep tive</w>
contr act</w>
cont amination</w>
conges tion,</w>
competi tive</w>
clud e</w>
cl um
bre a
bloc ks</w>
associ ation</w>
ar tific
ann ounc
an aphy
ad a</w>
activ ity,</w>
acid osis</w>
acc el
ab sc
a :</w>
Wy eth</w>
W at
U TE
U R
Thro mbo
T o
S pain,</w>
Repub lic
R am
Qual ified</w>
Pro f
Pharmac eutical</w>
Peri odic</w>
P ack</w>
P O
Or phan</w>
OptiS et</w>
Offic ial</w>
ON AL
Novo Rapid</w>
N SA
Mab Ther
M ed
M INI
IN G</w>
HB V</w>
G 1</w>
Flex Pen</w>
Direc tive</w>
Denmark ,</w>
BM S</w>
B SE</w>
9 7</w>
8 3</w>
8 1</w>
4. 5</w>
.. ..</w>
' the</w>
…… ……
x .</w>
warn ings</w>
w ine</w>
vas cul
v es,</w>
tro p
topotec an</w>
tissu e.</w>
th ly,</w>
ten ,</w>
t am
synthes is</w>
symptom s,</w>
suspen sion.</w>
sur vi
support ing</w>
supp li
subcutane ously</w>
sub str
sp ring</w>
som atropin</w>
solu tion,</w>
sing le-
simp li
sha red</w>
ro d</w>
ri vas
ri sts</w>
resuspen d</w>
repub lika</w>
rele as
regul ated</w>
reac tion
pressu re.</w>
pregnanc y.</w>
pr an
parti cles.</w>
p seud
over weight</w>
other wise</w>
orig in
oph ob
odynam ic</w>
occur s,</w>
ocardi al</w>
nur sing</w>
no tic
nit ro
neuropath y</w>
neuro logical</w>
n y</w>
meth od
me tres</w>
man n
ly n</w>
ly mp
lung s</w>
litax el</w>
li xim
le f
land .</w>
job s</w>
inten si
inhibit or
infus ion.</w>
immuno suppres
il tr
if i
id er
i ther</w>
i ous</w>
hyperten sion</w>
hour s,</w>
hol ding</w>
hered itary</w>
he re.</w>
gl and</w>
g ent
g ate</w>
form e</w>
f os
evalu ated.</w>
et ro
est ro
enti al</w>
em o
e an</w>
e ),</w>
dr am
discharg e</w>
dihydro gen</w>
detec t</w>
def end</w>
cr ushed</w>
cough ,</w>
comp u
common .</w>
cit abine</w>
chang ing</w>
car bo
blu e</w>
bi g</w>
bec ame</w>
b y
b ov
att ack</w>
as e-
ar com
approv al</w>
antico agul
and -
analys is.</w>
an ia,</w>
ampren avir</w>
am bi
al um
ag o</w>
ad ren
ad just</w>
a e</w>
Un ion,</w>
TM Z</w>
T em
T RE
Ser vic
Sec ret
S ix</w>
RI ST
Pro tec
Ph il
Parliam ent
P el
P E</w>
P .</w>
ORACE A</w>
No s</w>
Mr s 
Mix t
Min ist
L is
Is lam
In activated</w>
I L
H ,</w>
Gastro intestinal</w>
F IR
Effec ts</w>
EX P</w>
E LI
Dy sp
Dos ing</w>
Dis orders</w>
Dev elop
D E</w>
Counc il
Candi da</w>
B ud
A S</w>
9 -
6 4</w>
5 8</w>
4. 9</w>
2 ,
0. 25</w>
/ E
- to-
+ 37
wor t</w>
vul ner
vo ice</w>
vals artan</w>
u ric</w>
tri al,</w>
tr ying</w>
to ols</w>
thous ands</w>
there af
there .</w>
th ick
surve y</w>
surg ical</w>
struc tur
stric tly</w>
speci alised</w>
soci ety</w>
siz es</w>
sit e:</w>
selec tive</w>
sec tor
se d
sam pl
sal mon</w>
s ou
s av
s '.</w>
ri al</w>
recover y.</w>
recogn ises</w>
radi olab
pro phylaxis</w>
prefer ably</w>
post s</w>
poli tic
poison ing</w>
plan ning</w>
placebo- treated</w>
pl ung
phot osensi
ph a</w>
performe d.</w>
pen s,</w>
patient .</w>
pat ent
pap er</w>
ous ly.</w>
org e</w>
open ia,</w>
op ol
op a</w>
off- white</w>
o w
nucle oside</w>
multi forme</w>
mol ec
mis s</w>
mil itary</w>
ma r</w>
m ass
limit ed.</w>
ligh ts</w>
life- threatening</w>
li ver,</w>
lam y
k s,</w>
jo int
itch ing,</w>
it ors</w>
inflam matory</w>
inf iltr
increas ingly</w>
in depend
impa ir</w>
il d</w>
ic y
ic h
i pr
i fe
hol id
he art
haemorrha ge</w>
h ome</w>
gen ic</w>
fu el</w>
formul ations</w>
forgot ten</w>
fir e</w>
f ed</w>
extre me</w>
examin ation.</w>
ev en
estim ate</w>
end ron
end ogenous</w>
electron ic</w>
el ap
ec zem
dizz iness,</w>
disorder s.</w>
del eg
def enc
day :</w>
d less</w>
cy cl
cri tic
cour ses</w>
con flic
comple x</w>
clo ts</w>
cigare tt
cas e.</w>
cam pa
c is
bloc k</w>
begin ning</w>
beg an</w>
be fore.</w>
b ,</w>
att acks</w>
asthen ia,</w>
ast a</w>
ap point
any one</w>
anti psycho
anti c</w>
ang ina</w>
ag grav
affec ts</w>
advis able</w>
addi tives</w>
ad d</w>
abs ence</w>
abdom y
a ud
Wh ether</w>
W ould</w>
W om
V AN
Ur inary</w>
Un it
Se e</w>
Sci enti
Sc ot
STELAR A</w>
S ust
S hel
Rese arch</w>
Rap porteur</w>
Pati ent</w>
Op in
Ob jec
O r</w>
Novo Let</w>
N R
M en
L eu
Irel and,</w>
In di
Im muno
H am
G ONAL
E vents</w>
E M
E D
Dec ember</w>
D ut
D 3</w>
Commission er</w>
CCID 50</w>
C N
B ur
B rit
B et
Al ways</w>
A de
A F
9 2</w>
8 6</w>
25 ,</w>
199 8</w>
1 0.
( vote)</w>
( one</w>
( T
( R
é l
  million</w>
year- old</w>
wom en
w ar</w>
volunte ers</w>
vi rosis</w>
ven ous</w>
vast at
vari ability,</w>
ure a</w>
un employ
ud in</w>
tur ning</w>
tis ing</w>
ti al</w>
thromb in</w>
ther n</w>
test ed</w>
tak e,</w>
table ,</w>
t s:</w>
t or.</w>
t ing.</w>
subjec ts.</w>
stra ight</w>
ste p
sle ep</w>
siglit azone</w>
sh ire</w>
scho ol
sch eme
sc ope</w>
s ession
s ac
rout ine</w>
ri f
rh abdomy
refe ren
ran ts</w>
quin ol
prurit us,</w>
produc tion,</w>
princi ples</w>
pre ven
pl ants</w>
ph r
panleuc openia</w>
p u
organ isation</w>
opro st</w>
on ance</w>
oc occ
ob last
ne on
n ers</w>
mov ement</w>
mot or
monito red.</w>
minim al</w>
mer cur
membran e</w>
me tr
me tast
manufacturer (s)</w>
ma de.</w>
lin k</w>
la un
l on</w>
l er</w>
known :</w>
kno wn,</w>
kil ome
kil og
k ne
k g
k ers</w>
itch y</w>
investig ation</w>
inj ury</w>
ing ly.</w>
inf lation</w>
inf ant</w>
im possible</w>
ill s</w>
h is
gen e
gast ric</w>
g am
g ain</w>
fun ding</w>
flu oro
expen sive</w>
excep tion</w>
episod es</w>
end .</w>
emerg ency</w>
eas y</w>
do wn.</w>
dis odium</w>
dis card</w>
di et.</w>
del ays</w>
datab ase</w>
dail y,</w>
consequ enc
comp ul
commit tee</w>
care .</w>
car rying</w>
c up</w>
bleed ing,</w>
b ound</w>
b ig
awaren ess</w>
ation s?</w>
arm s</w>
ar ity</w>
amma dex</w>
alk aline</w>
alis ing</w>
al bum
absol ut
a p</w>
Y ERS</w>
W IT
V enous</w>
V .</w>
U S
Tre vac
Tracle er</w>
TI C
T S</w>
Sy stem</w>
Sy mptom
Sust ained</w>
Star lix</w>
Slov ak
Sebiv o</w>
S i
S QU
SQU IB
SQUIB B</w>
Reg ul
R et
R T</w>
Plac e
P L
OL -M
OL-M YERS</w>
O x
Netherland s,</w>
More over,</w>
Meth od</w>
M ain
Li et
Kar ve
Inter action</w>
I sc
I g
Hol der.</w>
HIV -1</w>
G o
Fe bru
EU/1 /98
EU/1/98 /0
Dis ease</w>
D ,</w>
C ould</w>
C P</w>
Bul g
An y
A tri
A M
5 3</w>
4. 2</w>
36 4/</w>
35 8</w>
200 5,</w>
2 3
00 8</w>
0 4
/ 199
+4 6</w>
+ 372</w>
(A ID
( 200</w>
â nia</w>
y '</w>
ve ?</w>
under lying</w>
ulc er</w>
uc tu
transfer red</w>
tob acco</w>
thromb osis</w>
this ?</w>
ter rit
tech no
tast e</w>
tab ility</w>
t ary</w>
syring e,</w>
symptom s.</w>
suscepti bility</w>
surger y.</w>
sugg es
st ro
st oc
specif ied</w>
simp le</w>
serv ic
seiz ures</w>
sco res</w>
s n
s a</w>
s ):</w>
rou gh</w>
rivas tigmine</w>
ring ing</w>
rhabdomy olys
refer ral</w>
re view
re adily</w>
re ?</w>
rang ed</w>
ra m</w>
r at</w>
pum p</w>
provis ions</w>
pressu re,</w>
prac tical</w>
poll ution</w>
poll ut
ph al
pestic ides</w>
pay ments</w>
pan dem
pack .</w>
p iv
piv otal</w>
oti tis</w>
opa que</w>
ong st</w>
on ic</w>
on d</w>
om yc
om at
odi azep
occas ionally</w>
oc or
o dic
nic otinic</w>
ne verthel
nam ely</w>
n om
mov ements</w>
mit ting</w>
milk y.</w>
mid dle</w>
micro gram</w>
mellit us</w>
lymph ocyt
lik ely.</w>
lifer ative</w>
legisl ative</w>
lat est</w>
jour ne
iter ran
interest s</w>
inj uri
infec tion
inf lixim
inc en
in stead</w>
in es.</w>
in ).</w>
immun ity</w>
idog rel</w>
ic ial</w>
i tive</w>
i j
i e</w>
http :
hormon al</w>
ho t</w>
go od
glyco protein</w>
gl u
gen u
g ar
foc us</w>
fal len</w>
ext ended</w>
ex port</w>
ex plan
ex clus
er s?</w>
er a
epilep tic</w>
ep ider
ell ular</w>
e ti
document ation</w>
doct or
diagno s
den sity</w>
deal t</w>
cy t
cul tural</w>
countr y.</w>
cl ass
ciclospor in</w>
centr alised</w>
careful ly.</w>
car ton.</w>
c ore</w>
c m</w>
blo od.</w>
billi on</w>
benef icial</w>
behin d</w>
b ar</w>
as ked</w>
appear ance.</w>
an th
amlodip ine</w>
am ongst</w>
al pha</w>
al endron
ag ulation</w>
ag o.</w>
activ ation</w>
ab ov
ab ,</w>
a ;</w>
a 's</w>
Zi agen</w>
Wom en</w>
WIT H</w>
Un ion.</w>
T er
T as
Span ish</w>
S uc
S L
Rom ânia</w>
Re ference</w>
RIST OL-MYERS</w>
Prepar ing</w>
Pol and,</w>
ON SY
O M
No w</w>
Ne uro
NA ME
MabTher a</w>
M c
In no
IN E</w>
I ONSY
H PV
H D
GONAL -
GONAL- f</w>
Fin land,</w>
F ri
F S
El derly</w>
E valuation</w>
E con
D on
Con cer
Commission er,</w>
Col leg
Ben e
B RISTOL-MYERS</w>
An im
Al so,</w>
A ug
A -
9 6</w>
8 4
7 7</w>
6 2</w>
5 -0
37 /</w>
2 1
0 14</w>
0 10</w>
. )</w>
(A4-0 4
( U
( 12</w>
µ g</w>
° C</w>
ys el
y 's</w>
wat ch</w>
w arm
w .
ve get
ul ts</w>
ud ra
transpa rency</w>
tou ch</w>
toler ated</w>
tim es,</w>
thro at</w>
ta il</w>
t s
syndro me.</w>
swit ched</w>
suffe red</w>
suc ce
stimul ating</w>
stav udine</w>
st abil
sp a
small er</w>
sk in.</w>
sever ity</w>
se al</w>
s ely</w>
ru ption</w>
ro b
ric h
rib avir
ri t</w>
ri es</w>
resuspen ded.</w>
respec tive</w>
regar dless</w>
regar ded</w>
refu ge
reflec t</w>
referen du
re pa
put ting</w>
pur ch
prec is
phen omen
pharmac ological</w>
p el
os in
om as</w>
off er</w>
occur rence</w>
occ up
no ise</w>
muscle .</w>
min ute</w>
microgram s/</w>
mg/ day)</w>
mg/ 24</w>
measure s,</w>
mater nal</w>
mal absorption</w>
los s,</w>
li po
leng th</w>
langu ages</w>
l p</w>
intoler ance,</w>
influ enz
in som
in habit
ill ness</w>
http: /
h ur
group s,</w>
groun ds</w>
gr ap
gr an
g on
func tional</w>
flush ing</w>
fe ar</w>
fal se</w>
f le
exten sively</w>
expec t</w>
excipi ents,</w>
ex pl
ex emp
esp o</w>
ent s:</w>
econom y</w>
e u</w>
du raz
doc etaxel</w>
dizz iness</w>
diseas e)</w>
discus sions</w>
dis cre
develop ment,</w>
depres sion,</w>
de tail
de gener
d ;</w>
coord in
contracep tives</w>
comp li
communic ation</w>
col d</w>
clum ps</w>
chro me</w>
cell s,</w>
carbo hydrate</w>
bir ds</w>
benz alkonium</w>
ativ e.</w>
at a</w>
assess ing</w>
as c
artific ial</w>
ar y.</w>
anticip ated</w>
am .</w>
al op
agon ist</w>
aff inity</w>
adjust ment
accum ulation</w>
accord ingly.</w>
ac onazole</w>
a udi
Un it</w>
Ty pe</w>
T él
T ev
T c
Symptom s</w>
Sol o
Scienti fic</w>
S OL
Re member</w>
RE AC
R ev
R as
Puh /Tel:</w>
Pro me
Ph ase</w>
P 450</w>
ON AP
Ne oc
N espo</w>
Mal ta</w>
MM ONAP
MINI ST
Leu k
Kine ret</w>
K E</w>
Isc over</w>
In j
I V</w>
Fr anc
F il
F ab
F 2</w>
Ex c
Effentor a</w>
Do es</w>
De part
D ue</w>
D K
CE PRO
C ro
C at
Austri a,</w>
Al duraz
AN Y</w>
AD MINIST
A MMONAP
9 .</w>
6 6</w>
5 00
1 2.
( 5
y li
y ).</w>
x in</w>
wor th</w>
wom an.</w>
where .</w>
w al
vitamin s</w>
vi al,</w>
vaccin ation.</w>
v ildagliptin</w>
under standing</w>
un likely.</w>
un born</w>
ul tr
ul ative</w>
ub le</w>
tre mor
travel ling</w>
to s</w>
thresh old</w>
thous and</w>
though ts</w>
ter m
t ack
syring es,</w>
sup pression</w>
sup por
substanti al</w>
st ac
solvent )</w>
so il</w>
si a,</w>
ship .</w>
sh ock
sh e
sh ar
sent enc
sa y,</w>
s opraz
res c
rel atively</w>
regul ations</w>
re present</w>
psori atic</w>
promo tion</w>
prof it
process ed</w>
pre pared</w>
prac tice</w>
pol lu
peri odic
pen al
ord ination</w>
oper ation.</w>
op posite</w>
om al</w>
ol an
oblast oma</w>
obes ity</w>
no w,</w>
my ocardial</w>
my al
mo ist
men .</w>
medicin e,</w>
me et</w>
me ant</w>
marro w.</w>
m ation</w>
m ass</w>
lot inib</w>
lop idogrel</w>
loc k</w>
lan sopraz
l er
l ap
l ad
it or
it ed.</w>
ist ,</w>
ish ed.</w>
int el
instruc ted</w>
in corpor
in come</w>
in clusion</w>
ide )</w>
i od
hydrox ide,</w>
hydrogen ase</w>
howe ver.</w>
haz ard
h n
h em
go ods</w>
gli oblastoma</w>
gastro enter
fo rec
fil m</w>
f light</w>
f it
examin ations</w>
eu .</w>
et s,</w>
es sive</w>
es p</w>
era dic
epider mal</w>
environ ment
en e.</w>
el ement
eg al
effec t,</w>
du lox
do ?</w>
dissol ved</w>
di hydrate,</w>
di go
design ated</w>
decreas ing</w>
decis ions</w>
decis ion.</w>
de tailed</w>
de hydrogenase</w>
dam aging</w>
d ust</w>
d )</w>
cyto chrome</w>
con tra
con sti
con serv
ci profloxacin</w>
cholester ol,</w>
chem i
charg e</w>
c k
buil t</w>
br and</w>
bo ar
bl ur
bi otechnolog
benz odiazep
believ ed</w>
ban ned</w>
ba g</w>
at inib</w>
aspec t</w>
arthri tis,</w>
ar t</w>
anos ine</w>
an hydro
alop ec
all er
al ter</w>
al an
again ,</w>
ag ents.</w>
act ual</w>
ac tion
ac ted</w>
absolut ely</w>
ab er
a g</w>
V ol
V is
V AT
Trevac lyn</w>
Th yro
T otal</w>
T en
T al
T E</w>
Suomi /
Suomi/ Finland</w>
Spec ific</w>
Sing le</w>
SAR L</w>
S o
Re pe
R ue</w>
R econ
Pu gh</w>
Presid ent
P A
O X
Nov ar
N orge</w>
N ic
M ac
L iv
L V
K ep
K eep</w>
Jo int</w>
Isra el
In fl
I D</w>
HPV -
H CV
F ondaparinux</w>
EX J
ELI SA</w>
Counc il,</w>
Com bin
Ch lamy
C lopidogrel</w>
C i
C S
C D
Bene F
AU C
AR E</w>
A pro
A ir
1 1.
0. 2</w>
0 11</w>
/199 9)</w>
- derived</w>
+4 9</w>
(AID S).</w>
(A5-0 4
( approximately</w>
λ λ
zer o</w>
vel y,</w>
vari es</w>
un wanted</w>
u lo
tra vir
tra di
tivel y.</w>
tit anium</w>
ti te</w>
th en,</w>
test s,</w>
ter fen
t s?</w>
t etan
t ed
t ap
sym path
stop s</w>
st ress</w>
sp ra
sp er
saf e
s ession</w>
restric ted</w>
res onance</w>
rele ased</w>
regi stered</w>
recor d</w>
reac tion.</w>
re x
re placed</w>
re min
rat s</w>
r ate.</w>
program m
profession al.</w>
proc ess,</w>
pro -
prevent ing</w>
potassium- sparing</w>
pic ture</w>
physici ans</w>
phosph at
per .</w>
pay ment</w>
pat ches</w>
paren ter
pac litaxel</w>
p= 0.00
p unc
ord inary</w>
or i</w>
ophthal m
open -
on ia
on a</w>
om a,</w>
olog ically</w>
ograph ic</w>
off .</w>
oesopha g
od y</w>
ob struc
o estro
need le.</w>
nat al</w>
n ex
mor ning.</w>
monit or</w>
microgram s/
methotrex ate.</w>
measure ment</w>
marg in</w>
manufacturer s</w>
m ium</w>
m end
loc yt
lo y
lo s</w>
level s,</w>
le y</w>
le av
le agu
lar ity
larity n</w>
keep ing</w>
ir reversible</w>
ir is</w>
ip raz
ion -
inu ria</w>
intrav en
interest ed</w>
inten tion</w>
ing '</w>
inf arc
incid ences</w>
in sec
in s,</w>
in active</w>
immun isation</w>
im munolog
identi ty</w>
id ation</w>
ic ill
ic ally,</w>
headach e</w>
haemodi alysis</w>
h and,</w>
gen it
fundam ental</w>
food stuff
fo rest
fo etal</w>
fe at
exist ence</w>
ex ecu
every one</w>
et y.</w>
essenti ally</w>
er )</w>
equip ped</w>
en vis
electr icity</w>
ed rine</w>
e b
dys function,</w>
dr aft</w>
dist ance</w>
dis rup
dis h</w>
dis crimin
destro yed</w>
dec lar
de hydr
de fer
dat a.</w>
dam age.</w>
d ol
cru cial</w>
counter fe
contrib u
continu ous</w>
cont ext</w>
conjunc tivi
compon ents</w>
compart ment</w>
comm od
comit ant</w>
ci meti
carcinogen icity</w>
breath ing,</w>
bov ine</w>
b it</w>
b ad</w>
b ad
b .</w>
av en
ap preci
anti bodi
anim al
anc er</w>
anaem ia.</w>
an swe
amb ris
alidom ide</w>
al ism.</w>
aircr aft</w>
adjust ments</w>
act ,</w>
X /</w>
W )</w>
V ICH</w>
U .</w>
Tur k
TH ER</w>
Syn dro
S p
Republic ,</w>
RA TION</w>
R el
R are:</w>
R Y
Pr ad
Peg as
P ut</w>
Novar tis</w>
Nor th</w>
Neoc larityn</w>
Me an</w>
Madri d</w>
K iv
K ent</w>
Hung ary,</w>
HIV -
H igh
Grou p</w>
G D
Fol low</w>
F R
Engl ish</w>
EV RA</w>
EU ,</w>
EME NT</w>
E ,</w>
Develop ment</w>
D e</w>
Chang es</w>
CEPRO TIN</w>
B u
Al b
AS C
ADMINIST RATION</w>
AD E</w>
A Z
A VA
9 %)</w>
6- month</w>
5 1</w>
37 7/</w>
37 5/</w>
36 9/</w>
20 -
199 6</w>
14 6/</w>
1, 000
1 %)</w>
0. 3</w>
0 8
( i.</w>
ß e</w>
µ g/</w>
yl ac
year }</w>
writ ten</w>
wid ely</w>
wh en
vomit ing.</w>
ve in.</w>
ut sch
us tin</w>
trans mitted</w>
toler ated.</w>
to .</w>
thereaf ter.</w>
th um
th -
tend ency</w>
telev ision</w>
t ly,</w>
syn thetic</w>
sy mb
sw allowing</w>
sur fac
supplement s,</w>
success ful
su n</w>
su me</w>
stand ardis
sp ot
sp ent</w>
sor bit
shoc k,</w>
shi ps</w>
schem e</w>
s ick
s es,</w>
s can
s '
rub b
ro c</w>
respon ded</w>
rejec tion</w>
ref er</w>
red ness,</w>
re solv
ras tim</w>
random ized</w>
rac e
ra dic
pro spec
pris on</w>
princi ple
pres s</w>
poin ting</w>
po oled</w>
pi oglitazone</w>
person al</w>
periodic ally</w>
peri odic</w>
oxid ase</w>
onc e.</w>
ol ig
oe ph
occur ,</w>
oS tar</w>
o tic</w>
no t.</w>
ne igh
ne ar</w>
n s</w>
mo tiv
milli on.</w>
methox y</w>
meet ings</w>
me d.</w>
ma il</w>
m ysel
m s
lot ted</w>
loo king</w>
li de</w>
lat er.</w>
la red</w>
l uc
l av
l ate</w>
kno w,</w>
k y</w>
k i
iz umab</w>
is ation
intel lig
initi atives</w>
ing -
in yl</w>
in th</w>
implement ed.</w>
immuno glob
im plic
ill ness,</w>
ill ing</w>
id ity</w>
id ine</w>
i ent</w>
hyperten sion,</w>
herpes virus</w>
happen ing</w>
ha m</w>
h ence</w>
gradu al</w>
glycol -
glycer ol,</w>
gen etic</w>
fru it</w>
fro sted</w>
form ulation</w>
fo et
fing er</w>
fe ed
f are</w>
exper ts</w>
exce ed</w>
ex change</w>
ev ents,</w>
ess or</w>
erythem a,</w>
er :</w>
ent y-
ent r
end oc
eg g
e 's</w>
du ty</w>
du n
dis comfor
di c</w>
dementi a</w>
dec lared</w>
de t
d l</w>
contracep tion</w>
con v
colour less.</w>
collec ted</w>
cis pl
cho ice</w>
chang e,</w>
cha mber</w>
ch -
ca us
bro vascular</w>
bon es</w>
b ub
b is
b al</w>
avi roc</w>
at s,</w>
at ard</w>
assess ment.</w>
ar le
and ing</w>
agg reg
adv ice.</w>
a er
TA KE</w>
T RA
Subjec ts</w>
Sol oStar</w>
Sh ould</w>
SP RY
SPRY CE
S ud
S imp
RE N
R h
Peri pheral</w>
Pegas ys</w>
Pax ene</w>
Palest ini
P ,</w>
Opti C
OG EN
OGEN ATE</w>
O y</w>
N ut
N on-
M arch</w>
M ag
M S</w>
Liet uv
Latvi ja</w>
LI F
L ab
K OGENATE</w>
Inj ury,</w>
IONSY S</w>
I mp
Har mon
G a
G L
Fir st,</w>
En viron
E p
E lim
E f
E ar</w>
Dos es</w>
D el
Con tro
Con comitant</w>
Commit te
CO 2</w>
C ur
C er
Americ an</w>
? '</w>
9 7/</w>
9 7
6 7
37 6/</w>
35 /</w>
2 ),</w>
180 °</w>
15 /</w>
12 -
( MAO
λλ ά
λλά δ
η λ
Ε λλάδ
we a
w ise,</w>
vit al</w>
vir us.</w>
vi l</w>
ure ly</w>
tum our
triglycer ides</w>
tren d</w>
to day,</w>
tion ally</w>
tern al</w>
ten tion</w>
tel uk
tel eph
techno lo
ta m</w>
sug ammadex</w>
sud den
sub mit
stim ulation</w>
speci al
sp read
sp inal</w>
sp ace</w>
so .</w>
sit ting</w>
simple x,</w>
si mul
si de.</w>
sh ock</w>
seri ous
sa w</w>
s z
s cap
ru le</w>
research ,</w>
remain ing</w>
rel ates</w>
regi stration</w>
rap porteur
r is</w>
r ab
quick ly.</w>
qu ate</w>
protec ted</w>
program me,</w>
produc ers</w>
problem .</w>
pro ve</w>
pro gram</w>
pro fil
ple as
passeng ers</w>
pas sp
part ner
pa st
p ill
p ha
ov arian</w>
ophil a</w>
olog ic</w>
okine tic</w>
ograph y</w>
off spring</w>
of -
no se</w>
net work</w>
mo l</w>
mb ud
man ,</w>
main tain
ma de,</w>
m ice</w>
li br
levod opa</w>
justi fi
it sel
it ed,</w>
inter f
interf ere</w>
institu tions</w>
influ enza</w>
inf ants,</w>
in adequ
if e</w>
ib ility</w>
ib .</w>
hy gi
hund red</w>
gr ade</w>
gem citabine</w>
g ol
follow -
flu oxetine</w>
fl uctu
fil grastim</w>
fer ti
fa ec
f res
f low
ey e.</w>
experienc e.</w>
et ed</w>
est onia
es ti
es !</w>
enti t
ent ering</w>
ent ed</w>
emis sion</w>
em tricit
elec oxib</w>
el y,</w>
effici ency</w>
eff orts</w>
e str
e en</w>
duc t
double- blind</w>
dist ingu
desc ri
des er
der mati
democr acy</w>
defic it</w>
cul tiv
cre ated</w>
cover ing</w>
continu ed.</w>
continu e/</w>
confus ion,</w>
conduc t</w>
concern ed.</w>
con genital</w>
claim s</w>
cl aim</w>
civ il
child ,</w>
categ ories</w>
c ough</w>
bom b
body 's</w>
ben ec
be y
be ?</w>
b os
atten tion.</w>
at ing.</w>
ar is
ar bit
appear ance</w>
ap o</w>
ant ly.</w>
am ,</w>
al lotted</w>
al i
ag es,</w>
ad hes
accum ul
ab use</w>
ab and
a qu
a ).</w>
Vi ani</w>
Vacc ines</w>
Ukra ine</w>
Tri zi
TE NT</w>
T echn
St ock
Sand w
Sain t</w>
S we
S TI
Rom ania</w>
Rec om
R ou
Prome tax</w>
Pro t
Post- marketing</w>
Pel zon
P rac
O mbud
Med iterran
ME RI
MATERIAL S,</w>
M ul
Lietuv a</w>
Labor ato
L T
K ey</w>
Industri al</w>
IU /
Hydro chlorothiazide</w>
He ad
H u
Gl ustin</w>
G E</w>
Fran k
F ast
Equ ilis</w>
Elim ination</w>
Econ om
Dut ch</w>
D em
Cont inu
Con si
Con ference</w>
Commission .</w>
Cent re</w>
C e
C are</w>
C Y
As soci
Apro vel</w>
Ade quate</w>
A ran
A TION</w>
@merc k.</w>
9 N
9 9</w>
8 2
8 )</w>
5 9</w>
4. 6</w>
4 31</w>
18 .
12 ,</w>
10 3</w>
1, 000</w>
1 1.</w>
0. 2
0 12</w>
-------------------------------- --------------------------------
(E 17
( 50</w>
( 10</w>
( 1,000
” ).</w>
ο ς</w>
Ελλάδ α</w>
á n
{ month
y iel
wor ds,</w>
what ever</w>
we ak</w>
war farin</w>
vis its</w>
v a
up take</w>
tw are</w>
travir ine</w>
transp ort
tot ally</w>
to o,</w>
to ,</w>
thin king</w>
tex t.</w>
ta ,</w>
sus p
suggest s</w>
suc ro
su re.</w>
stom ach
statis tical</w>
sp ond
spond yli
sp as
solu tions.</w>
signific ance</w>
secre tion</w>
sec tors</w>
se x</w>
schedu le</w>
sam ples</w>
s ory</w>
s ell
s arcom
ros is,</w>
ris on
reg res
re ven
re alis
r ite</w>
pul l</w>
provi ded.</w>
produc es</w>
process ing</w>
pregn ant,</w>
practic es</w>
pr am
pover ty</w>
post menopausal</w>
popul ation,</w>
pharmac ology</w>
ph ylac
p ink</w>
p ed.</w>
oxy gen</w>
orig in.</w>
oper ational</w>
one x</w>
ol y
ol der.</w>
o ter
no se,</w>
neverthel ess</w>
neutropen ia</w>
mun ic
milli ons</w>
ment ation</w>
measure ments</w>
me rely</w>
mark s</w>
mark ets</w>
man ife
mail :</w>
lit re</w>
ligh t,</w>
lic en
li thi
leg ally</w>
lat ter</w>
larg ely</w>
l ens
l af
laf ax
iv e.</w>
itch ing</w>
ist ax
is o
invest ment</w>
infec tion)</w>
indic ated,</w>
immunolog ical</w>
imag ine</w>
im print</w>
if t</w>
identi fied,</w>
id es.</w>
id en
hec ta
h id
h an
gram s</w>
go al</w>
glycol- epoetin</w>
g ri
g ia</w>
g ender</w>
fumar ate</w>
fres h</w>
foreign 'and</w>
fer til
famil ies</w>
fa ir
f- life</w>
f end</w>
exten sive</w>
exist s</w>
ex act</w>
estonia @gsk
es ul
es pre
es is</w>
er v
enorm ous</w>
enh anced</w>
en forc
en able</w>
elec tric</w>
elec ted</w>
el s,</w>
dog s.</w>
do x
do ,</w>
distribu ted</w>
disper sible</w>
digo xin</w>
di ox
di d
des ired</w>
des ign</w>
der og
der ing</w>
de ad</w>
de ?</w>
d ophila</w>
cul ture</w>
cro ps</w>
crim inal</w>
cou ple</w>
cos me
contro ver
con current</w>
compens ation</w>
comp ly</w>
col i</w>
chick ens</w>
ch ann
cell ul
c t</w>
build ings</w>
blo od,</w>
bl ing</w>
benefit /</w>
avir .</w>
author ities.</w>
app lies</w>
ap ol
al tered</w>
aggres sive</w>
agend a</w>
ag es.</w>
ag ency</w>
administe red.</w>
accur ate</w>
acc es
ac ter</w>
ac knowledg
a .
Wh ich</w>
V fend</w>
UL N
Tim e</w>
Th ose</w>
TRI SE
TRISE NO
Some times</w>
SU TENT</w>
S ix
Rem ic
RE Y
Prad ax
Po st
Plac e</w>
Par t</w>
PV C</w>
P ent
NR TI
NO T</w>
Main tenance</w>
MS D</w>
M ast
L os
L e</w>
Karve a</w>
Intrav enous</w>
He ad</w>
H ist
H and
H amp
G over
Four thly,</w>
Febru ary</w>
Fe w</w>
Every one</w>
E g
De utsch
Chlamy dophila</w>
Cal ici
CP MP
C ub
Ber lin</w>
B AS
Av onex</w>
Ac cid
AS T</w>
AMMONAP S</w>
A z
A cl
A R</w>
A I
5 4
35 7
199 5</w>
10 ,000</w>
1 40</w>
1 /2001)</w>
+4 7</w>
(H D
(F CV</w>
(A4-0 2
( p</w>
( blood</w>
' -
yl osing</w>
x bridge</w>
wor ding</w>
vulner able</w>
vari ant</w>
val osin</w>
v ill
us u
tub ular</w>
tr u
top ic</w>
to ys</w>
tiv es.</w>
tiv al</w>
thro wn</w>
though ,</w>
th igh
ter at
tal king</w>
tak e.</w>
t us
sum ed</w>
struc tural</w>
stra ße</w>
spec tr
solu tion
sof tware</w>
so ya</w>
situ ation.</w>
sib le.</w>
sh eep</w>
scre ening</w>
sc en
satis factory</w>
s ick</w>
s cr
s anc
ri ed</w>
represent atives</w>
reg ist
reg ional</w>
reduc ed.</w>
recycl ing</w>
rec ip
reas on,</w>
re volu
re ti
psych ological</w>
propor tional</w>
princi p
pri ority</w>
presc rib
prepar ations</w>
precis ely</w>
preci pit
precau tionary</w>
por tion</w>
polic ies</w>
placebo ,</w>
peri ods</w>
pep tide</w>
out put</w>
organ ised</w>
op tic</w>
one 's</w>
on y</w>
olog y,</w>
ol d
oc ol
obvi ously</w>
ob stac
o ffe
o con
ne ed,</w>
n ia,</w>
mus cles</w>
mis sible</w>
micro -
mean ing</w>
me als</w>
mar aviroc</w>
manufact ure</w>
m es
lin .</w>
lens es.</w>
l ess,</w>
l ec
l antic</w>
jour nal
j e
ish ,</w>
ir udin</w>
ir regular</w>
invol ve</w>
inter fer
inspec tion</w>
ini stry</w>
ing !</w>
infec tions.</w>
industr y,</w>
incin er
in ev
impa i
im age</w>
il s</w>
if y</w>
icon otide</w>
ible ,</w>
i dis
hypoc ris
hypo kal
hydro lys
hospit al.</w>
haz ard</w>
h r
glycaem ic</w>
glut am
glucose- galactose</w>
glo ves</w>
for ge</w>
follow s:</w>
flo or</w>
fl ur
fin ished</w>
fi bro
f us
f ine</w>
exper ti
excep tional</w>
es cap
er up
er ship</w>
ep i
enter pris
ent ail
em ents.</w>
elimin ate</w>
elev ations</w>
el s.</w>
e ez
e dema</w>
dra w</w>
discar ded</w>
diagno sed,</w>
di min
di gn
di alysis</w>
defenc es)</w>
de vic
damag ed.</w>
d u</w>
d '
crim ination</w>
cre d
control led,</w>
contra dic
consul tation</w>
compani es.</w>
comp ut
co agulation</w>
ce f
carri es</w>
carri er</w>
cap ital</w>
cal ves</w>
cal caem
c ity</w>
c at</w>
c ab
ble .</w>
be ,</w>
bar ri
bab y</w>
b us</w>
b )</w>
az ide</w>
ation s:</w>
asse mb
arm .</w>
are a.</w>
arc el
ant ine</w>
ank ylosing</w>
anc es.</w>
alum inium</w>
alte red.</w>
aliz ation</w>
al one.</w>
al ism,</w>
al ing</w>
al es</w>
al ?</w>
ag it
adjust ed</w>
ad en
ad dic
accep table.</w>
ab sur
a ),</w>
W ed
Vir us</w>
V )</w>
U xbridge</w>
U MA
Thyro gen</w>
TE SL
TESL ASC
TE D</w>
T ac
Stre et</w>
Sever al</w>
S ta
S S
Res ults</w>
REY AT
Pol ish</w>
PE )</w>
P requ
P as
P T</w>
Opin ion</w>
O VI
O .</w>
O -
N U
N AT
Mus cle</w>
Mixt ard</w>
May be</w>
M art
Long -term</w>
L uc
L ou
Ira q
Inter feron</w>
I M
Hy po
Haem ophil
Ha arle
H is</w>
H al
Gen er
G i
G ar
G R-
G A</w>
Fir st</w>
Fast ur
F o
EU/1/0 6/
EME N
E S
E MA
D .</w>
Con stitu
CO M
C are
BAS AL</w>
B ro
B SE
B -
Austri a</w>
Anim al</w>
Alduraz yme</w>
Al most</w>
A sp
A .,</w>
9 3</w>
7 8
4 35/</w>
38 6</w>
3 5%</w>
28 00</w>
27 6/</w>
200 5.</w>
20 )</w>
199 9</w>
150 /</w>
15 1/</w>
02 6</w>
000 ,</w>
/200 2)</w>
-2 4</w>
- B
(V TE
( E</w>
! '</w>
é s</w>
ycl ine</w>
wor st</w>
withdra wn.</w>
weak ened</w>
w ood</w>
w ing</w>
w av
vo ted</w>
vis it</w>
v od
v an
up set</w>
uni form</w>
un usual</w>
un certain
un acceptable</w>
tur ned</w>
trans cri
tol cap
toge ther.</w>
to oth</w>
to o.</w>
thre at</w>
terfen adine</w>
system s.</w>
supplement ary</w>
subjec ts,</w>
su it
streng th
strain )
st ly</w>
st ations</w>
st ate,</w>
st aff
sp i
sin us
si de,</w>
sha pe</w>
selec ted</w>
sec ure</w>
se t
sci ence</w>
scheme .</w>
sc and
rop in
ropin A
ro w</w>
risk -
ri l</w>
request ed</w>
repor t.</w>
recon stitu
re place</w>
race tam</w>
ra w</w>
r ich</w>
r hyth
qual ified</w>
pun ish
provi ded,</w>
proce ed
pro b
presid ency</w>
poin t.</w>
plung er</w>
physici an.</w>
performe d,</w>
per spec
path y</w>
pat ent</w>
pat ch
p oul
p ent
ous ly,</w>
osin ophil
os por
orth opa
orthopa edi
orthopaedi c</w>
orr he
on es.</w>
on ary</w>
omi me
oeph edrine</w>
o x</w>
o th
numb ness</w>
noe a</w>
necessar ily</w>
na il</w>
mov ed</w>
mon e
modi fying</w>
mis sion
mig rants</w>
mess age</w>
measure s.</w>
meaning ful</w>
marg in
main taining</w>
ma y
m osph
m mol</w>
load ing</w>
line ar</w>
lin e.</w>
lin e,</w>
lim iting</w>
level ,</w>
leg s</w>
le gi
l ing,</w>
l -
k e.</w>
it real</w>
inter im</w>
inten sity.</w>
ing ).</w>
increas e,</w>
in s.</w>
in n</w>
in din
in activ
imp rison
im umab</w>
il it
hist amine</w>
hepati c
he ard</w>
gu n</w>
gene tically</w>
gen s</w>
gen oty
g er
g all
fract ory</w>
form al</w>
forec ast
follow ed,</w>
financ ing</w>
fiel ds</w>
famili ar</w>
fa ul
f it</w>
exce eding</w>
examin ed.</w>
ex ha
eth n
establish ment</w>
er ?</w>
er -
ent ?</w>
embry os</w>
element s:</w>
el se
e able</w>
e -</w>
drin ks</w>
do or</w>
divi de</w>
disp ose</w>
disab led</w>
dis crimination</w>
di sh
deterior ation</w>
dest in
d ing.</w>
d ates</w>
d ark
cy tar
cy an
cr ush
connec ted</w>
conc ept</w>
comput er</w>
clim ate</w>
chec ked</w>
ch el
categ or
campa ign
bro ach
bre ed
br ut
bott le.</w>
benec id</w>
be aring</w>
batter y</w>
avi an</w>
aut o
attemp t</w>
ation ).</w>
ation '</w>
ati vely,</w>
at ul
at tit
at mosph
at edly</w>
at az
ari at</w>
ar ti
anti diabetic</w>
and ed</w>
an nel</w>
an aes
ambris entan</w>
am ph
aliz ed</w>
al ter
ad es</w>
accel erated</w>
ac om
X A</w>
X -
W HO
VIR ACE
VE N</w>
V ia</w>
V el
Ul tr
UTE (S)</w>
Tem od
TESLASC AN</w>
T ηλ
T u
T or
St ar,</w>
Sou th</w>
Sloven i
Sec ond
S ad
S K
Repub lic</w>
RO UTE(S)</w>
REN CI
R ob
R AP
Pradax a</w>
Pi oglitazone</w>
Pharmac okinetic</w>
Pelzon t</w>
P ap
P ak
P L</w>
O per
O T
O RENCI
Nut ropinA
N or</w>
N one
M U/</w>
M I
Luxembour g,</w>
Laborato ire</w>
L ess</w>
Janu ary</w>
J ap
J ans
HIV /
H O</w>
H .</w>
GF R
F A
Excipi ents:</w>
Ex forge</w>
EXJ ADE</w>
Depart ment</w>
D ata</w>
D V
D RE
Ch ar
CT 13</w>
C ho
C etro
Beta feron</w>
BeneF IX</w>
BM D</w>
Atri pl
Al co
Accid ental</w>
A vi
9N J</w>
8 7
7 7
7 4
6 ).</w>
5 4</w>
200 4</w>
199 0</w>
1. 4</w>
04 6/</w>
0 13</w>
................ ........
( and</w>
( 200
( 100</w>
" .</w>
Α γ
yr inth</w>
y e</w>
writ ing</w>
we red</w>
w ip
w i
viv al</w>
virtu ally</w>
vial )</w>
ve t</w>
v oc
us i
urtic aria</w>
under tak
un necessary</w>
un commonly</w>
u x</w>
tri um</w>
train ed</w>
tr uth
ton gue,</w>
tic ul
ti tion
there ,</w>
techni que</w>
teach ing
teaching 'the</w>
sw allow
sustain able</w>
sur ance</w>
sum mar
substanc es.</w>
su m</w>
stre am</w>
ster ing</w>
stat ement</w>
squ eez
sp he
slaugh ter</w>
sit es.</w>
si de-
seri es</w>
selec tively</w>
s is,</w>
s ad
ro utes</w>
ro siglitazone</w>
reli g
re mission</w>
r um
quot a</w>
pur su
proxim al</w>
prote ins</w>
promp t</w>
promot e</w>
pro ven
pri me
pres sed</w>
pregn ant.</w>
post natal</w>
posi t</w>
pol ici
plac ing</w>
pl y.</w>
pl ate</w>
phy si
per mit</w>
pas sive</w>
pa rently</w>
p ush
p in
otox ic</w>
ot ine</w>
os is)</w>
oro dispersible</w>
or ange</w>
opin ion,</w>
open ha
of u
ococc al</w>
o le,</w>
nutri tional</w>
non -</w>
new bor
neuro toxin</w>
neigh bour
n g
n as
mo re.</w>
mis leading</w>
met al</w>
men str
me ?</w>
mass ac
market ed.</w>
manufact uring</w>
mann er.</w>
manag ed</w>
mag nit
lit res</w>
le th
le b
law y
lab ell
know s</w>
kill ing</w>
k es</w>
ju dic
j um
it y-
it !</w>
infec t</w>
induc ing</w>
inclu ded.</w>
in o</w>
in contin
im posed</w>
illness es</w>
ig u
ici an</w>
ic al
ic a</w>
ia /</w>
hypoten sion</w>
hydro chloride</w>
he re,</w>
hazard ous</w>
ha ir
g ame</w>
g ad
fla g</w>
fast er</w>
facil ities</w>
f er</w>
exposu re.</w>
exces sively</w>
ex ternal</w>
ex .</w>
ev ent,</w>
et s.</w>
est ,</w>
er lotinib</w>
environ ment,</w>
ent ary</w>
enh ance</w>
eng ine
end -
en ia</w>
en ab
earli er</w>
e travirine</w>
dop amine</w>
diure tics</w>
disp ens
del iver
de struction</w>
control s.</w>
contamin ated</w>
consump tion.</w>
const antly</w>
consci ousness,</w>
con cep
comprehen sive</w>
complain ts</w>
comp rising</w>
com prim
colour less</w>
col leagu
cimeti dine</w>
chemic als</w>
cau ght</w>
cal c
bureauc rac
budget ary</w>
bl ack
bi ofu
bey ond</w>
be ings</w>
ban k</w>
b iliary</w>
b id</w>
b att
b ann
b A
bA 1
atic s</w>
ataz an
at e-
at -
assist ant</w>
assess ments</w>
ass ay</w>
aspec ts</w>
as pir
as cul
arrang ements</w>
ari a,</w>
applic able</w>
appe tite</w>
apar t</w>
ap s</w>
anxi ety,</w>
antipsycho tic</w>
anhydro us,</w>
and a</w>
anc yt
amino transferase</w>
am ine,</w>
all -
ag on</w>
adjustment )</w>
adj uv
ad el
ac tions.</w>
aband on
ab .</w>
a ur
________ ________
] .</w>
Z im
Y or
Y es,</w>
Wed nes
VER SY
VERSY L</w>
Unit s)</w>
UL N</w>
U N</w>
Thrombo embolic</w>
Th i
Techn ical</w>
TI W)</w>
T all
Syndro me</w>
Solo Star,</w>
ST AT
S up
S tra
S en
S el
Ro y
R an
Prequ enza</w>
Pot assi
Por te</w>
Pen fill</w>
Pak ist
P res
OptiS et.</w>
NAME }</w>
N ever</w>
N erv
N ational</w>
N TED</w>
Mon t
MR L
MIR AP
MIRAP EX
M s</w>
M T
M I</w>
Lev em
L I</w>
Kiv exa</w>
K os
Im prov
INVE NTED</w>
I F
Haarle m</w>
H CV</w>
H C
Greec e</w>
GM Os</w>
Fastur tec</w>
F ,</w>
Er bit
EU .</w>
E S</w>
E P
E D</w>
Di acom
D NA
D ATE</w>
Cap su
Ca ution</w>
CO VERSYL</w>
CE L
C openha
C AR
B uc
B os
B A
Atripl a</w>
Alzheim er
AN CE
AD R
A dul
8 2</w>
7 5%</w>
7 00</w>
69 800</w>
6. 1</w>
6 9</w>
6 -0
4. 3</w>
4 5
4 3</w>
30 -2
30 -
199 7,</w>
17 4</w>
10 4</w>
1. 7</w>
1  
02 8</w>
02 7</w>
02 1</w>
0 16</w>
0 15</w>
+4 5</w>
(A L
( which</w>
( at</w>
( 2</w>
τ ρ
τρ ίου</w>
μ η
μη τρίου</w>
η μητρίου</w>
Δ ημητρίου</w>
Αγ ίου</w>
z one</w>
z lo
z in</w>
yl -
win d</w>
wid espre
whe re,</w>
wel come</w>
wel com
we re:</w>
wa it</w>
w ound</w>
w oun
w ild</w>
ur ation</w>
un ion</w>
un changed</w>
un able</w>
ul tim
transpor ted</w>
transplant ation</w>
transcri p
to l</w>
tiv es,</w>
titr ated</w>
ti s.</w>
ti d
thin k
technolo gies</w>
te trac
te am</w>
targ ets</w>
t ;</w>
swe ating,</w>
surge on</w>
sur ing</w>
sump tion</w>
studi es?</w>
streng th</w>
stat ements</w>
st y</w>
st ret
st ers</w>
spe ech</w>
sp len
sourc es</w>
smo ke</w>
slaugh tered</w>
shor ter</w>
serv ed</w>
sep tic</w>
sens ation</w>
sen ior</w>
sen -C
sen-C il
sen-Cil ag</w>
se ts</w>
sam ple</w>
s gate</w>
s at
resol ve</w>
repor ting</w>
relev ant.</w>
reg ion
red ap
recomm end</w>
reach ing</w>
re r
re production</w>
rap porteur</w>
ra ise</w>
ques tion,</w>
qual ity,</w>
present .</w>
pregnanc ies</w>
pre vented</w>
pr a</w>
point s.</w>
po or
ple ment</w>
phylac tic</w>
phr ase</w>
people 's</w>
pati on,</w>
path ogen
p yl
overe d.</w>
ou ris
otox ic
other ,</w>
orr hoe
or d</w>
opath ic</w>
on es,</w>
offe red</w>
o ts</w>
o ch
n á</w>
myal gia,</w>
muc os
mono amine</w>
mon teluk
mis artan</w>
micro sphe
metr e</w>
medicin e)</w>
man .</w>
m am
lop in
log ic</w>
liv es.</w>
lik eli
likeli hood</w>
li vest
lat er,</w>
lansopraz ole</w>
lamiv ud
lafax ine</w>
l ose</w>
kg/ week</w>
it s.</w>
it arian</w>
ist s.</w>
is -
investig ations</w>
initi s,</w>
inf ants.</w>
ine /</w>
in- line</w>
in activated</w>
im esul
im ages</w>
il y.</w>
identi fication</w>
ide as</w>
ic s,</w>
i ans</w>
hear t,</w>
hap p
gr anu
govern mental</w>
go ,</w>
glycaem ia</w>
gastro -
g ave</w>
fun g
fract ures.</w>
fo rese
flav our
fir st-
fir m</w>
fibro z
fel is</w>
fe as
fati gue,</w>
f as
exposu res</w>
explain s</w>
exce eded</w>
ex agg
es cal
es -
es ),</w>
erythropo ies
er a</w>
epide mic</w>
enough .</w>
enhanc ing</w>
end ,</w>
employe es</w>
emo tional</w>
embry o</w>
em ents,</w>
effectiv e.</w>
eas ier</w>
e k
dysp ep
dun d
dulox etine</w>
doub t</w>
discontinu ed,</w>
direc tive.</w>
differen ti
diff er</w>
di l
des per
der s.</w>
depres sive</w>
democr atic</w>
degener ative</w>
deal ing</w>
de posit</w>
dat e.</w>
dat a,</w>
cross- border</w>
cover s</w>
continu ation</w>
consider ation.</w>
con struction</w>
compul sory</w>
comp ound</w>
comp oun
commun ity</w>
comb at</w>
ci vil</w>
children 's</w>
ch os
cent res</w>
cartridg e,</w>
candidi asis,</w>
c oc
breast-fe ed.</w>
be poetin</w>
bar rel
ation ),</w>
as bour
ar ticles</w>
ar sen
approv ed?</w>
ap parently</w>
answ ers</w>
anc ial</w>
alys is,</w>
allerg y</w>
al lo
al leg
aim ed</w>
aem ic</w>
aem ia.</w>
advant age</w>
adop tion</w>
ad in</w>
achiev ed.</w>
acet ate</w>
accoun ts</w>
acchar ide</w>
ac ul
ac ne,</w>
ac i
ab at
ab ap
a ke</w>
a i</w>
YY YY
W el
V om
V en
V F
TN F</w>
T redap
T ob
T it
T ab
T AN
Str asbour
Sloveni ja</w>
SUBST ANCE
STAT EMENT</w>
ST R
SPRYCE L</w>
S odium</w>
S in
S he</w>
S ev
S ME
Russi an</w>
Rou te</w>
Rom ani
Ram sgate</w>
Pub lic
Protec tion</w>
Program me</w>
Prof essor</w>
Pos aconazole</w>
Ph ot
Pe op
Pa ediatric</w>
P ure
P M
P HAR
OptiS et,</w>
Objec tive</w>
Novo Seven</w>
None thel
Nob ilis</w>
No ,</w>
MERI AL</w>
M u
M or
Lim ited,</w>
Kep pra</w>
K no
J .</w>
In spec
In iti
In duct
II .</w>
Hand ling</w>
Gover n
Fin ancial</w>
F ung
F requ
F our</w>
F CV</w>
Europe 's</w>
Eston ia</w>
Erbit ux</w>
EU/1/06/ 357
EU/1/0 7
EU 's</w>
EC )</w>
E- mail:</w>
E spo
Deutsch land</w>
D R
Cour t</w>
Ch ange</w>
Cetro tide</w>
B raz
B arcel
B an
Ar ticles</w>
Alco hol</w>
Afric a</w>
Ab normal</w>
A si
@m s
80 ,</w>
35 8/</w>
3 /2001)</w>
200 5</w>
2 /2001)</w>
19 ,</w>
13 .
1. 25</w>
0 17</w>
-1 ),</w>
) -
(H-0 4
(C max</w>
( 2)</w>
% ;</w>
µ g/
windo w</w>
wel fare</w>
week s)</w>
war ds.</w>
w ash
w ant
ver sions</w>
vent ric
ve ter
var ic
vag inal</w>
vaccin ated.</w>
v inyl</w>
ut ed.</w>
uri a</w>
u til
tub es</w>
trans amin
trac e</w>
tr im
tr a</w>
toxic ity.</w>
ton gue</w>
tolcap one</w>
to wn</w>
tim ic
tig otine</w>
ti fication</w>
thes e,</w>
than ks</w>
temperat ures</w>
techniqu es</w>
te l</w>
t ell
t ed?</w>
t 's</w>
swe ating</w>
sup posed</w>
sub stitution</w>
stoc ks</w>
sti ff
st res
st en
st ak
squ are</w>
spo ts</w>
spo ke</w>
sol ely</w>
sk eletal</w>
sil denafil</w>
sho t</w>
sent ence</w>
seiz ure</w>
se t.</w>
se as
sal icy
salicy lic</w>
sal es</w>
saf ely</w>
s ors</w>
s ore</w>
s ell</w>
ring s</w>
ri d
retin opathy,</w>
ret ard
respon se,</w>
resist ance.</w>
repor ts,</w>
regular ly.</w>
reach es</w>
re m
re im
reim bur
re fractory</w>
re dund
re ality</w>
re act
rat es.</w>
ra ising</w>
program me.</w>
prin ted</w>
pre -</w>
pra vastatin</w>
plic ation</w>
plan ned</w>
pla ying</w>
person nel</w>
per id
parenter al</w>
p yr
ou d</w>
ot es</w>
orrhe a,</w>
organiz a
ore x
omat ous</w>
om egal
olog y.</w>
ocor tic
net works</w>
ne ur
n il
mysel f</w>
mus culoskeletal</w>
mur dered</w>
moder ate,</w>
mob ile</w>
mm H
mal a
magnit ude</w>
ma .</w>
m ing</w>
m er</w>
m Tc
m )</w>
lymphocyt es</w>
lymp h</w>
ly ?</w>
loc ation</w>
liter ature</w>
li e</w>
let ter</w>
le ast
last ing</w>
lact ation</w>
label /</w>
lab yrinth</w>
la ws</w>
la an</w>
l ingu
kilog ram</w>
kil led.</w>
k ill</w>
justi fy</w>
jus tice</w>
join ts</w>
iti es?</w>
isc haem
is ot
ir o</w>
investig ated.</w>
intoler ance</w>
instrum ents</w>
inj ure
inhal ation</w>
ing ),</w>
inflixim ab</w>
indic ators</w>
indic ator</w>
in i</w>
in es,</w>
in c</w>
in :</w>
impro ving</w>
im per
ic ul
ic idal</w>
ible .</w>
i o
hyper sensitive</w>
hydr ation</w>
hy s
high ligh
her o
hard ly</w>
ham ster</w>
h ost</w>
gu il
gr aph
gastroenter itis,</w>
g ence</w>
fut ure.</w>
fundam ent
forme d.</w>
for d</w>
fol lic
fl ushed</w>
fing er
feat ures</w>
fat ty</w>
fa ther</w>
exten d</w>
experti se</w>
example .</w>
exam ples</w>
ex trac
ex er
ex cell
ev ents.</w>
eth an
est .</w>
es tic</w>
equ ally</w>
ep tic
ent ly.</w>
ent ec
encour ag
embol ism</w>
elec tion</w>
el ines</w>
efaviren z,</w>
educ ational</w>
ec tin</w>
e go
dos e)</w>
do g</w>
diver sity</w>
distribu tion.</w>
disp lac
disp en
dig es
diffe rently</w>
di alogue</w>
detail s</w>
deriv atives</w>
der s,</w>
del to
degrad ation</w>
d i</w>
cut aneous</w>
cour t</w>
coun ted</w>
contrac ts</w>
const ant</w>
consequ ence</w>
confir m</w>
compar ator</w>
comp are</w>
com posed</w>
col um
col itis</w>
civ ili
cispl atin</w>
cirrh osis</w>
cholester ol
chol in
che ap
characteris tic</w>
cha mp
ch ances</w>
cent uri
cat s</w>
can n
c li
c hap
bronch itis,</w>
break down</w>
bo w
bi os
be ar</w>
bA1 c</w>
b ringing</w>
b on</w>
b ic
author ity</w>
author isations</w>
ation ;</w>
ati de</w>
at ine</w>
as per
ar thro
ar ise</w>
appropri ate,</w>
antibodi es.</w>
anti hypertensive</w>
an timic
an orex
al pha
al )</w>
ag o,</w>
ag ents,</w>
aff air
advis e</w>
addi tive</w>
ac tion,</w>
ab ine,</w>
a i
Z YP
XX X</w>
Wil zin</w>
Wh ere
We ight</w>
VI STI
VE R</w>
V imp
U G
Tev ag
TRISENO X</w>
Syn ag
Sur vival</w>
Stock hol
Sim ul
Servic es</w>
S prime
S et
Remic ade</w>
Rem ove</w>
REAC H</w>
R adi
Prot aphane</w>
Presid ency</w>
Prac -
Prac- tic</w>
Por c
Pol ys
P C
ORENCI A</w>
O D</w>
Ne ed
Medic al</w>
MRL s</w>
M un
M inistry</w>
Kos ov
Jans sen-Cilag</w>
J os
Infl am
IU )</w>
I f,</w>
I B</w>
H old</w>
German y.</w>
GI VEN</w>
G Y
Fung al</w>
F un
F orm
EU -
EMEN D</w>
E ast</w>
Doc etaxel</w>
DRE SS</w>
Concer ned</w>
Colleg e</w>
Christi an</w>
Cha ir
C ateg
C RI
B on
B S
Amend ments</w>
Actr aphane</w>
AD DRESS</w>
AB I
A u
8 8</w>
5 %,</w>
4 15/</w>
30 ,</w>
17 %</w>
15 2/</w>
13 4/</w>
10 .</w>
1 ),</w>
/ 2
, 200</w>
(hyper glycaem
(N =
(MAO I
(HIV -1),</w>
(A5-0 3
(90 Y
( or</w>
’ ).</w>
μ ος</w>
λ ι
λι μος</w>
Ά λιμος</w>
{ MM
z ed</w>
z e</w>
z al
ye ster
worth y</w>
with ,</w>
weap ons</w>
w rite</w>
w age</w>
volun tary</w>
ve c</w>
vastat in,</w>
v a</w>
ur ine.</w>
understo od</w>
ul l</w>
u gre
ty pe
tri ax
transpor ters</w>
transfer ring</w>
trac e
tr ack</w>
ting ling</w>
tig ec
thrombocyt open
therap ies</w>
tetan us</w>
terro rist
te z
tab ly</w>
ta p</w>
ta .</w>
t ed:</w>
system s,</w>
syndrome )</w>
sy mbo
symbo l</w>
swit ch</w>
suspec ted,</w>
subsidi es</w>
sub stitu
sub sid
strateg ic</w>
sti pul
sti g
spondyli tis</w>
spectr um</w>
sp end</w>
sib le,</w>
si ve.</w>
ship ,</w>
sha ken</w>
sal mon
s car
ro tic</w>
ro myc
ri tis,</w>
resul ts,</w>
rest aur
respon ding</w>
resol ved</w>
resi due</w>
rep lied</w>
remain ed</w>
reason s.</w>
re rs</w>
re presents</w>
re mitting</w>
re g</w>
rat s,</w>
rat es,</w>
rang e.</w>
r y,</w>
quar ter</w>
qu o
proper ly.</w>
prop ylene</w>
process es</w>
pre cur
prac tition
pr on
pneumon ia</w>
photosensi tivity</w>
phosph or
per pe
per it
peop les</w>
pen sion
pat ri
paragrap h
p a</w>
p .
out ?</w>
org ans</w>
or )</w>
opportun ities</w>
opin ions</w>
oper ation,</w>
op s</w>
omet a</w>
olan zapine</w>
oglit az
ocy tic</w>
oblig ation</w>
ob al
o v</w>
num er
newspap er</w>
neuropath y,</w>
neuro muscular</w>
nec rosis</w>
ne ither</w>
n u
n g/</w>
multi pack</w>
moun tain
month s)</w>
mon opol
ml ).</w>
mic ron
metabolit e.</w>
ment ?</w>
mening iti
mem antine</w>
mellit us,</w>
medi a,</w>
me tric</w>
me tal
me t.</w>
me als.</w>
m us</w>
m ask</w>
ly ophil
ly ).</w>
low ,</w>
loc ated</w>
lithi um</w>
legi tim
lay er</w>
k s.</w>
k o</w>
k m</w>
ju ven
joint s,</w>
iv ely</w>
ith romyc
ish .</w>
ip ex
ipex ole</w>
investig ate</w>
inv en
inten d</w>
integr ation</w>
insul in)</w>
inst all
inser ted</w>
injuri es</w>
inj ured</w>
inf ring
industr y.</w>
individu als.</w>
inadequ ate.</w>
improv ements</w>
implement ing</w>
im plement</w>
ili ation</w>
il oprost</w>
il ity,</w>
ific ation</w>
iden tical</w>
ic s.</w>
ia ).</w>
hyper calcaem
hygi ene</w>
hum an.</w>
http:/ /ww
http://ww w.
histor ical</w>
hi a</w>
haz ards</w>
h o</w>
h at
gu ard</w>
gre en</w>
gluc ocortic
fun ded</w>
formul a</w>
flo od
flex ible</w>
fl ag
fiel d,</w>
fic ations</w>
fib rosis</w>
fail s</w>
fac ed</w>
f ate</w>
es c
er o
ep istax
enti n</w>
ent ry</w>
encour age</w>
en jo
electr ical</w>
elap sed,</w>
effectiv en
ed !</w>
e ties</w>
e ous</w>
e igh
e arth
e (s)</w>
drop ped</w>
dro w
dre am
dr af
dist inc
diseas e-
discharg e,</w>
disappear .</w>
dis col
dis abil
did anosine</w>
dic ated</w>
diarrhoe a.</w>
diabet es.</w>
di pl
detec table</w>
destro y</w>
destro y
delto id</w>
de pos
days )</w>
dat e,</w>
dang ers</w>
da m</w>
d ying</w>
d res
d ental</w>
d as
cy c
cum ulative</w>
cre ation</w>
conv inc
consum ers.</w>
concentr ations.</w>
con vic
con solid
con secu
con s
con cre
compromis e</w>
compli ance</w>
complet ely.</w>
competi tiv
compati bility</w>
col i.</w>
cod e</w>
cloud y.</w>
cle are
classi fied</w>
chromos omal</w>
charg es</w>
cau ti
catt le.</w>
cat ch</w>
cat astro
catastro ph
car box
capsul es,</w>
call s</w>
ca re,</w>
breast -</w>
brea ks</w>
bre aking</w>
box .</w>
bon d</w>
bilirub in</w>
below :</w>
be tol</w>
ban ks</w>
bacter i
back ground</w>
b ase</w>
aw a</w>
avir )</w>
aven ue</w>
avail able,</w>
auto immune</w>
attri but
ati tis</w>
atazan avir</w>
at e?</w>
assist ance.</w>
arth ral
ar ial</w>
an o
altern atives</w>
allerg y,</w>
all uc
al ia</w>
al '</w>
agricul ture</w>
ag ue</w>
adv ance</w>
admini stering</w>
adel ph
ad ing</w>
acid osis,</w>
ac ept</w>
a us
Zim bab
ZYP RE
ZYPRE XA</w>
Z yr
Z ometa</w>
Yt trig
Wil son
West ern</w>
W AL</w>
Vi rological</w>
Vi read</w>
Vi et
V ascular</w>
Un less</w>
U su
U SA</w>
Tu es
Tevag rastim</w>
Temod al</w>
Tall inn</w>
TRA VAT
Swe dish</w>
Sol iris</w>
Sec urity</w>
Sandw ich</w>
SI ON</w>
S pain.</w>
S om
S it
S cal
S ar
S an</w>
S O
Ro che</w>
Res ist
Reduc tion</w>
Recom mend
Re betol</w>
R iv
R NA</w>
Puh /</w>
Pre -filled</w>
Pr im
Polys orbate</w>
Phil adelph
Parliam ent,</w>
P y
P hys
Opti sulin</w>
O ut</w>
O edema</w>
NutropinA q</w>
Nonethel ess,</w>
Ne o
Mal ign
Madri d,</w>
LI ST
K al
J ul
Israel i</w>
Inter vet</w>
In v
In stitute</w>
In din
Imp ri
HEX AL</w>
H bA1c</w>
H aving</w>
H V</w>
H )</w>
Gli vec</w>
GR- 174</w>
G ood</w>
G em
G AN
GAN FOR
G ,</w>
Frank fur
Fr ance.</w>
FS H</w>
F re
F ort</w>
F lu
F ig
F armac
Ex ta
Em sel
EMA D
EMAD INE</w>
Dis k
D ate</w>
D ar
Commission ’s</w>
Com bi
Co ordination</w>
Cl ose</w>
Child -
Child- Pugh</w>
Ch rist
Calici virosis</w>
CYP 1A
CEL SEN
C A</w>
C /</w>
B ut
B or
B R
Aug ust</w>
Ap pro
Anti -
Al pes</w>
Agency ’s</w>
Af gh
Ac tive</w>
AL T
ADR s</w>
ABI LIF
A T</w>
7 %)</w>
58 1</w>
5 9
4 0%</w>
30-2 10</w>
3 000</w>
20 .</w>
2 2%</w>
2 %)</w>
10 8</w>
1, 200</w>
0 7
0 25</w>
0 24</w>
0 19</w>
0 18</w>
0 1
/1 ,200</w>
/00 3</w>
-2 -
-------- ----
(VTE )</w>
(M RI
(E EC)</w>
(A4-0 3
(1,000 /1,200</w>
(0. 9%)</w>
(0. 2%</w>
( un
( particularly</w>
’ )</w>
ó n</w>
{month /</w>
zon is
zlo ž</w>
your s.</w>
yl ation</w>
yclin es</w>
y n</w>
y ),</w>
writ ing.</w>
world wide</w>
withdra w</w>
wh it
weak ness,</w>
war r
war ned</w>
w ife</w>
w ed</w>
vot ing</w>
volunte ers.</w>
vit ro
v enti
ut h</w>
ust ,</w>
us ?</w>
ur anium</w>
un common</w>
u xim
tu red</w>
treatment -
transi tional</w>
transcrip tase</w>
trad ing</w>
ti tle</w>
thyro idis
thro m
thes ia,</w>
ther m
them ?</w>
th ri
th in</w>
test .</w>
terat ogenic</w>
technolog y,</w>
technolog ical</w>
tablet s)</w>
t ose</w>
t ank
sz awa</w>
sympath omime
sun light</w>
sulphon yl
sudden ly</w>
strain ):</w>
ste ar
speci alist</w>
sp ort
sorbit ol</w>
somnol ence</w>
sidi c</w>
se l</w>
scen ari
sal ts</w>
s s</w>
s or</w>
s mu
smu g
s hap
shap ed</w>
s )
ro g
ri end
ri de</w>
rhinotrache itis,</w>
respon se
reg ion.</w>
re structur
re no
re a</w>
r il
r ation
r ated</w>
r .
r -
quanti t
qual ity.</w>
pseud oephedrine</w>
propos al.</w>
promot ing</w>
procedu re,</w>
pro genit
prim e</w>
prec ed
pre vents</w>
pram ipexole</w>
pow ers</w>
poin t,</w>
po t</w>
pl ays</w>
pit ting</w>
piec es</w>
pi oglitaz
phenyl but
phen y
ph ther
ph thal
perfec tly</w>
per tus
pat h</w>
pass ing</w>
par aesthesia,</w>
pap ular</w>
pancre atic</w>
pal pit
p t
p ip
p age</w>
ox one</w>
oter icin</w>
ost atic</w>
osi tion</w>
os e,</w>
orph ine</w>
organiza č</w>
org an</w>
oper ators</w>
open- label</w>
op i
op ed</w>
on om
om ,</w>
ol d,</w>
off ers</w>
of ,</w>
od en
ob ser
ob ese</w>
o Tra
new born</w>
negoti ations</w>
ne ti
natur ally</w>
n g</w>
mou th
mon ey
mol ecu
moder ately</w>
mo x
mo re
min er
mg/ ml</w>
mg/ l</w>
mercur y</w>
mem be
manufact ured</w>
m m</w>
m ad
m L</w>
m -
lo vastatin</w>
lo ose</w>
lin ed</w>
lim bs</w>
lim b</w>
less ness</w>
less ness,</w>
le p
land s</w>
lact ate</w>
l' Avi
kne e</w>
iv ac</w>
iti dine</w>
ish ing</w>
is land</w>
is ation,</w>
intrac ellular</w>
insul in,</w>
instrum ent</w>
initi s</w>
initi ated.</w>
infiltr ates,</w>
ine ;</w>
indic ated.</w>
in tim
in qu
in ner</w>
in ing</w>
in adver
impai red,</w>
if loxacin</w>
ic al,</w>
human s,</w>
hour .</w>
hor iz
histor y,</w>
her bal</w>
hepar in</w>
hel ping</w>
harmon ised</w>
harmon isation</w>
happen s,</w>
haemorrhag ic</w>
h ex
guarante ed</w>
grow th,</w>
gro w</w>
great est</w>
gr aft</w>
gover ning</w>
glyco sidic</w>
gl omer
gastro- intestinal</w>
gain .</w>
ga p</w>
g y
fru c
fri end
freed om</w>
form .</w>
fo ods</w>
flur ane</w>
flu vastatin</w>
fel t</w>
fam ous</w>
fall s</w>
facil it
fac ial</w>
f lights</w>
f iv
f ell</w>
experim ents</w>
ex port
ethn ic</w>
eth ical</w>
et c.</w>
es ’</w>
es om
erythropoies is</w>
erg ill
erg er</w>
erc ent</w>
epilep sy</w>
ent s)</w>
endoc rine</w>
encephal opathy</w>
enc ies.</w>
en vel
egg s</w>
effectiv e,</w>
effec ts:</w>
educ ation.</w>
e on</w>
dri vers</w>
dos e).</w>
don es
displa yed</w>
disp ut
discar ded.</w>
dis infec
dict ator
di alogu
di al</w>
design ation</w>
depres sed</w>
den ied</w>
dem ands</w>
deliv ered</w>
delay ed.</w>
defin it
defec ts</w>
def ence</w>
cy cle
cust om
cur rency</w>
cri tical</w>
cost s.</w>
continu ing</w>
contain ers</w>
consi sts</w>
conj ug
con struc
con stitute</w>
comple x
compani es,</w>
comm ents</w>
com posite</w>
com ment</w>
collec tion</w>
co he
cloud y,</w>
circumstanc es,</w>
chemo therapy.</w>
cha ins</w>
ch i
candidi asis</w>
c ogn
c ast</w>
c ad
c )</w>
bur den
broach ed,</w>
behaviour al</w>
bas is,</w>
back ,</w>
b rel
b les</w>
b ath
b a</w>
au ti
ati call
ath ec
at en</w>
ast ern</w>
ass a
arter ial</w>
art an
arrest ed</w>
arm y</w>
ari an
are s</w>
ar ly,</w>
ar k</w>
appe tit
antibio tics.</w>
antibio tic
anti epileptic</w>
answe red</w>
an o</w>
an n</w>
an aly
amph otericin</w>
alu )</w>
alluc in
alloc ated</w>
alle vi
all y-
aliz umab</w>
album in</w>
al arm
al :</w>
ag encies</w>
af ra
ad ,</w>
accid ent.</w>
ac e
abap entin</w>
ab r
ab duc
We ek</w>
War szawa</w>
Vom iting</w>
Vir al</w>
VISTI DE</w>
VI I</w>
V ial</w>
V R</w>
Tur key</w>
Trizi vir</w>
Tredap tive</w>
Thro mb
TH OD</w>
T AC
Stockhol m</w>
St atis
Sim il
Shel f</w>
Sci ence</w>
ST E
S on
S oci
S ha
S av
S ant
Re gi
RE NE
RENE WAL</w>
R os
R ome</w>
R ipraz
Public ations</w>
Place bo</w>
Philadelph ia</w>
Palestini an</w>
P sy
P at
P C</w>
Organ isation</w>
OS SE
Nob ivac</w>
Nerv ous</w>
Mul ti
Medi an</w>
Me ier</w>
MIRAPEX IN</w>
ME THOD</w>
MA G
M os
Levem ir</w>
L en
L ap
John son</w>
Inv estig
Inflam mation</w>
Indin avir</w>
In hib
In dones
In dividu
Impri da</w>
I cel
I S
I G</w>
I -
Harmon isation</w>
HEX AVA
HEXAVA C</w>
H ave</w>
H UMA
Guid eline</w>
F U
Exc essive</w>
Eg yp
EU/1/08/4 84
EU/1/07 /4
EU/1/07/4 25
EU RO
E pi
E S,</w>
Dub lin</w>
Du oTra
Cy an
Combin ation</w>
Cho le
Capsu le,</w>
C re
C ity</w>
C ere
C ast
C C
Bar ro
B e</w>
B alk
Aran esp</w>
Ag e</w>
AN O
AN D
A ir</w>
A Z</w>
A E
@ms d.</w>
800 ,000</w>
6. 2</w>
6 /98)</w>
50 -
5 7</w>
36 6/</w>
3 2
200 8</w>
20 7</w>
2 4-
17 ,</w>
10 9/</w>
02 3</w>
02 2</w>
0 6</w>
0 3</w>
0 20</w>
/00 2</w>
/ 3
-f riend
- site</w>
- 4
, 5</w>
(P LI</w>
(HD PE)</w>
(C N
(90Y )</w>
( under</w>
( mean</w>
( cells</w>
( 300</w>
ä r
zidov ud
z inc</w>
z a</w>
worsen ,</w>
with :</w>
will ,</w>
where by</w>
we l</w>
w ounds</w>
vi de
ve ti
valu es.</w>
val id
v ec
ur ic
under take</w>
un anim
ul a</w>
ty ros
two- year</w>
tro ph
tri ed</w>
transpa rent</w>
transi tion</w>
transf us
trag ic</w>
trag ed
tra um
tra in</w>
tou ris
toge ther,</w>
to wn
ti bi
throm bin
thro w</w>
thick ening</w>
ther s</w>
th usi
terroris t</w>
terro rists</w>
ter ?</w>
tech neti
t ext
t ask</w>
sus pic
surve ys</w>
supp lies</w>
sup ported</w>
summ er</w>
su cr
stor age,</w>
st s,</w>
st ock
speak ing,</w>
speak er</w>
sp or
somnol ence,</w>
soldi ers</w>
sol uble</w>
sol ,</w>
six -
sin us</w>
si st
si gh
shi re,</w>
sh ell</w>
sh ell
separ ated</w>
sen d</w>
see ing</w>
saquin avir</w>
s oun
s elling</w>
s ants</w>
ro n</w>
riton avir,</w>
rif amp
ri z
revis ed</w>
reve al</w>
restric tion</w>
reserv o
repor t
remov ing</w>
reli ef</w>
regul ation.</w>
red den
red ?</w>
re mind</w>
re membe
re memb
re mark
re in
rati os</w>
rash es</w>
rash )</w>
ra il
r :</w>
prurit us</w>
protec tion
prote inuria</w>
prote in.</w>
prote in)</w>
pron ounc
promot es</w>
progenit or</w>
pro ven</w>
prepar ing</w>
prec ise</w>
potassium- containing</w>
pos ing</w>
pneumon itis,</w>
pl at
pl ase</w>
phosph on
phil os
pharyng itis</w>
pharmac odynamic</w>
perfec t</w>
per mit
pen icill
pe tro
pe ace</w>
par t,</w>
par as
pandem ic</w>
packag ing.</w>
pa res
p ation</w>
p -
ox ib.</w>
ot roph
ot inib</w>
oper ations</w>
op tions</w>
op t-
op posed</w>
om ?</w>
ogen etic</w>
oc r
o king</w>
o il,</w>
o il
no w.</w>
no vel
nigh t,</w>
new ly-
n ick
n app
n M
mono hydrate,</w>
molec ules</w>
mod els</w>
mo stly</w>
mis sed</w>
min eral</w>
microsphe res</w>
me mor
man n</w>
mac ulo
ma ,</w>
loc ked</w>
loc k
load ed</w>
list at</w>
li ps</w>
let ters</w>
legisl ation.</w>
le veti
larg est</w>
kidne ys</w>
kg/ week)</w>
iv ed</w>
is ers</w>
is e.</w>
is ?</w>
ir rig
intrav itreal</w>
intr athec
inter medi
inten sity</w>
injec table</w>
inhibit ors,</w>
in a,</w>
impro ves</w>
import ant.</w>
immunoglob ulin</w>
im ports</w>
il ity.</w>
il ing</w>
ic /</w>
i vi
hypoten sion.</w>
human itarian</w>
hol ders</w>
happen ,</w>
hand .</w>
h il
groun d
gran ul
go .</w>
glyc ine,</w>
gl in
gl as
gir ls</w>
genu ine</w>
g ill
g ained</w>
fra ud</w>
fra ud
for .</w>
foodstuff s</w>
follow .</w>
fol d.</w>
fo rest</w>
fisher ies</w>
fir st
fir m
fibroz il</w>
fi re
farm er</w>
fal si
fac ing</w>
fa il</w>
ext ending</w>
exp ose</w>
exacerb ation</w>
ex ec
event s/</w>
es e,</w>
es '.</w>
erro rs</w>
enzy m
ent h</w>
en )</w>
emphas is</w>
emerg ence</w>
ement ?</w>
effec tively.</w>
ec te
e- mail</w>
e dema
e /
du mp
dom estic</w>
do reg</w>
dissemin ation</w>
dispens er</w>
disease- modifying</w>
dis ci
disci pl
di men
di ame
dem and.</w>
dela y.</w>
del iber
degre es</w>
dec om
de ple
de d
dar k</w>
dar bepoetin</w>
cy clo
crimin als</w>
cre ating</w>
cor onary</w>
controver si
contr ast
cont ent.</w>
consequenc es.</w>
conjunctivi tis,</w>
conf identi
conf id
condition s:</w>
conclus ions</w>
compar ing</w>
comp ounds</w>
comm is
combin ations</w>
co w
clos ing</w>
clo tt
claim ed</w>
chemi str
chec ks</w>
ch ur
cauti ously</w>
cast or</w>
canc ers</w>
c ure</w>
bur ic
bro ad</w>
breath ,</w>
bre eding</w>
br ad
bo ok</w>
blur red</w>
block er</w>
be fore
be ef</w>
bag s</w>
b ac
az ole</w>
az ol
autom atic</w>
ati tis,</w>
ass es</w>
ass ass
asper gill
as k
arter y</w>
arm ,</w>
ard )</w>
ar y
appli ed,</w>
appetit e,</w>
anti fungal</w>
anti d
anaphy lactic</w>
analys is,</w>
analys ed</w>
an al
ambi ent</w>
am en
allerg ies</w>
all ing</w>
alis ed.</w>
alf a.</w>
alcohol ,</w>
al together</w>
ain .</w>
ain ,</w>
ag us</w>
ag e-
ade fovir</w>
ad ox
ad mitted</w>
acetyl salicylic</w>
accep table,</w>
acc used</w>
abol ic</w>
a way.</w>
a j
[ N</w>
Zyr tec</w>
Z en
Yttrig a</w>
W ell
W I
W HO</w>
V ec
V A</w>
Ultr atard</w>
Tw enty-
Tur n</w>
Ten ofovir</w>
Tac rolimus</w>
T erro
T P</w>
System s</w>
Suomi /</w>
St ev
Sprime o</w>
Sin us
Sign ific
Sh ire</w>
SAR L,</w>
S o,</w>
S ING
SING UL
Ran exa</w>
R ules</w>
Q T</w>
Psy ch
Pro du
Pharmac ology</w>
Peop le</w>
Parliament 's</w>
P AC
OptiC lik
On going</w>
Ombud s
O THER</w>
O ,</w>
Ne utro
Ne ul
NSA ID</w>
N atur
Met alyse</w>
Mediterran ean</w>
Manufacture r:</w>
ME P
M ari
Luc entis</w>
Lithu ania,</w>
LD L-
L ong</w>
L j
L and
L a</w>
L Y
J our
Ital ian</w>
Inhib itors</w>
Incre ase</w>
In tr
In te
Improv ement</w>
IN O
I ran
I bra
Hung arian</w>
Hol dings</w>
H igh</w>
H Be
GD P</w>
G M</w>
Fil grastim</w>
FIR ST</w>
F uz
F os
F .</w>
EU /0
E udra
Diacom it</w>
D ru
D ep
D G</w>
Copenha gen</w>
Con vention</w>
Combi vir</w>
Ci profloxacin</w>
Cha mb
Ch ina</w>
Categ ory</w>
Car doreg</w>
CYP2 D
CY ST
CI AL
CI )</w>
C hi
C ).</w>
Author isation
At lantic</w>
Asp ergill
Any one</w>
Am ster
Alb ani
Agency 's</w>
Ab sol
AI R</w>
A th
6 %)</w>
5 %)</w>
40 -
4 00
4 ).</w>
3 20</w>
3 %)</w>
25 -
200 1.</w>
2. 6</w>
199 0
17 .
15 .
13 5</w>
1 37/</w>
1 30</w>
1 11</w>
000 .</w>
0. 8
/00 1</w>
.... ..</w>
- resistant</w>
- in-
- av
(E 4
(A5-0 2
( glucos
( by</w>
( N</w>
( 9</w>
( 8
( 3.
( 18
( 15</w>
é n
° C)</w>
§ ,</w>
{MM /</w>
zonis amide</w>
z iconotide</w>
worl d,</w>
won der</w>
with .</w>
wish es</w>
whil e,</w>
when ever</w>
whe ez
well ,</w>
weigh ed</w>
weak ness
weak er</w>
wea ther</w>
wa ys,</w>
w est</w>
vig en</w>
vie ws</w>
vic tim</w>
vi ro
veter in
vari able</w>
val pro
v ical</w>
v et
v ation</w>
ut in
usu al.</w>
us s</w>
us age,</w>
uri a,</w>
ur a</w>
un known,</w>
un controlled</w>
um ab,</w>
ultr as
ulcer ,</w>
ugre l</w>
u locyt
toxic ity,</w>
tor ate</w>
tonn es.</w>
tion ed</w>
ti go,</w>
thum b</w>
thrombocyt openia</w>
the ore
the -
tez omi
tezomi b</w>
territ or
ter m,</w>
te en
tak en,</w>
t te</w>
t oral</w>
t ness</w>
t ane
swe et
sulphon am
substanc e(s)</w>
submit ted:</w>
subjec t
ster ,</w>
st ory</w>
st in
st ay</w>
st ate.</w>
specific ,</w>
sp ort</w>
sp ac
sodi um,</w>
sm an</w>
sk ills</w>
siz ed</w>
sion s.</w>
single- dose</w>
sim pl
side- effects</w>
short -
shock )</w>
sho p</w>
shi el
ser otype</w>
second -
sec ut
sec tor.</w>
se vo
se g
scler osis,</w>
schedu led</w>
scal e,</w>
sc rap
safe guar
saf e,</w>
s y.</w>
s ing.</w>
s bo</w>
s ant</w>
ro se</w>
risk- benefit</w>
righ tly</w>
rib os
ri ving</w>
rh in
request s</w>
represent ed</w>
repor t?</w>
releas ing</w>
regres sion</w>
reg ion,</w>
reduc tion,</w>
reduc ed,</w>
rec y
rec ur</w>
reaction ).</w>
re ds</w>
ras buric
radio activity</w>
rac e</w>
ra y</w>
pur pur
pub er
propos ing</w>
prohib ited</w>
pro gest
priv il
privil eg
pres sing</w>
pren orphine</w>
pre filled</w>
pot -on</w>
post pon
pep ti
passeng er</w>
part ners</w>
p s.</w>
ov ary</w>
osi 's</w>
os is
os ex
oper ator</w>
op tion</w>
op position</w>
on s.</w>
om yel
om in
om as
ol ol</w>
ol ic</w>
og ly
of <</w>
od ge</w>
ob taining</w>
o ?</w>
new s</w>
negoti ating</w>
neg lig
necess ity</w>
ne uri
ne ed.</w>
ne arly</w>
n ing,</w>
mor ph
mis sions</w>
min ,</w>
mid -
microgram /
mg/ day
mg/day ),</w>
meth yl</w>
metast atic</w>
me pi
me d,</w>
may be</w>
mas sive</w>
man ual</w>
man ip
mal nutrition</w>
maj or
mag nes
m ere</w>
los ses</w>
livest ock</w>
life style</w>
lead ers</w>
le ?</w>
land fill</w>
l j
l ing.</w>
ki ren</w>
justi fication</w>
je op
j unc
iv ing</w>
iti s)</w>
it es</w>
issu e.</w>
ir respective</w>
ir ,</w>
ion ?</w>
intoler ant</w>
interrup ted</w>
interest ing</w>
inter val
insuffici ency.</w>
inspec tions</w>
inser t</w>
innov ative</w>
inhabit ants</w>
infra structure</w>
inflamm ation,</w>
inev it
indic ates</w>
incre tin</w>
in tran
in stitution</w>
in ed</w>
import ant,</w>
immunosuppres sive</w>
imesul ide</w>
im pres
im atin
ig no
ifi ed.</w>
id s,</w>
hund reds</w>
hous es</w>
hom osex
him self</w>
heim er</w>
hand ed</w>
haemat omas</w>
ha ul
h ung
h allucin
h /</w>
gradu ate</w>
gr and
gr ac
go als</w>
gli oma</w>
gi ous</w>
gen es</w>
g est</w>
fu r</w>
fruc tose</w>
fre ez
forwar d.</w>
fo ot</w>
flush ing,</w>
flu o
fibr ill
fi st
ferti lit
fe renc
fat ality,</w>
f ill
f atten
expec ted.</w>
exist s.</w>
ex en
evid ent</w>
ev ol
ev es</w>
establish ed,</w>
est er
ere d.</w>
er s;</w>
er re</w>
er ;</w>
entit led</w>
ent ation</w>
ent an
end rix</w>
en ox
em ed</w>
ell ul
electro ly
el ement</w>
eg g</w>
eczem a,</w>
e- mail
dur al</w>
dri ver</w>
dist or
discus s</w>
disast er</w>
dis colour</w>
dis colour
dis appoint
direc tor
direc tion</w>
dic ul
diagnos tic</w>
di es</w>
di es
degrad ed</w>
de vast
de d?</w>
d n
d an
cut ting</w>
cust oms</w>
cur ren
crit eri
cre sol,</w>
correspon ds</w>
conver sion</w>
contrib ution</w>
contrib utes</w>
committe es</w>
commit ted</w>
commer ci
collap se</w>
co st-
co ffe
clos er</w>
chick en
characteris tics.</w>
cha mb
cha ired</w>
ch ron
ch oler
cer vical</w>
ce phal
care rs</w>
cal ori
cal ib
c rop
c en
c elecoxib</w>
but ,</w>
business es</w>
bureaucrac y.</w>
bu ted</w>
bott le
border line</w>
bon ds</w>
bo wel</w>
biotechnolog y</w>
beta -1
be auti
barri er</w>
bal anc
auc as
attri buted</w>
atten uated</w>
ator y,</w>
ativ es.</w>
atis lav
at roph
at er
at ed?</w>
at ed)</w>
at an</w>
ash es</w>
as y
aryn geal</w>
are .</w>
applic ant</w>
appe al</w>
ap lastic</w>
anth rac
an other.</w>
an ese</w>
am ps</w>
am ples</w>
al in</w>
al /</w>
aim s</w>
af ung
aesthes ia</w>
adver tising</w>
adver sely</w>
adi ol</w>
adal imumab</w>
adal afil</w>
accoun ting</w>
ac tively</w>
ac in</w>
ac compan
abor tion</w>
ab ly.</w>
ab les</w>
a rel
________________ ____
Z e
Yt trium</w>
W ine</w>
Vic e-
Vi en
Vec tibi
V otes</w>
V it
Up date</w>
Tw o</w>
Trans fer
Tarc ev
Tab let
TR I</w>
T e</w>
T an
T ORI
Su per
Su g
Str asse</w>
Slov ak</w>
Signific ant</w>
SA .</w>
S wit
S pot-on</w>
S m
S ep
S .
Roy al</w>
Rap porteur
REYAT AZ</w>
Pro ce
Pri vigen</w>
Pi erre</w>
Parliam ent.</w>
P ost</w>
P op
P acks</w>
Other wise,</w>
Oper ation</w>
O s.</w>
O f
Neul asta</w>
Ne ed</w>
NSA ID
NAT O</w>
Mus culoskeletal</w>
Met formin</w>
MR I</w>
M is
M at
M as
M U
Lj ub
Liv er</w>
Li ke</w>
Lab elling</w>
LO G</w>
L um
L A
Kap osi's</w>
K G</w>
Je an-
Inter actions</w>
Infec tious</w>
Inf anrix</w>
In sul
IX .</w>
IV ,</w>
I A</w>
HUMA LOG</w>
HIV ,</w>
H T
Guid elines</w>
G lob
G az
Fuz eon</w>
FO SA
F ra
F endrix</w>
F IN
F C
EU/1/98/0 70
EU/1/98/0 69
EU/1/08/4 65
EU/1/08/4 64
EU/0 /00
EU/0/00 /00
EU/0/00/00 0
EU/0/00/000 /
EU/0/00/000/ 000</w>
EE IG</w>
EC U</w>
E state</w>
E or
Dub lin.</w>
Disk us</w>
Direc tor</w>
Des pite</w>
Dan mark</w>
DK -2
D uration</w>
D odge</w>
D er
Cro hn
Com pared</w>
Ch ronic</w>
Ch em
CYP1A 2,</w>
CN S</w>
CELSEN TRI</w>
C aucas
C ancer</w>
Bi o
Bal tic</w>
B la
B ir
B O
Applic ations</w>
An d
Al tern
Al ert</w>
Adul t</w>
Acl asta</w>
AL TA</w>
A ri
A SE
9 8/</w>
8 8
66 76</w>
5 1
4- 20)</w>
4 8
4 %)</w>
2000 ,</w>
20 10</w>
2 20</w>
199 3</w>
15 ,</w>
1 10</w>
/00 4</w>
- and-
- 8
+37 0</w>
+35 1</w>
(glucos e)</w>
(C YP
(A4-0 16
(4 4-20)</w>
( in</w>
( 13
' S
' (
° C.</w>
yoursel f.</w>
yl valosin</w>
year ?</w>
y ing,</w>
x en
x 1</w>
wron g
work place</w>
work load</w>
wor se,</w>
wom an,</w>
wip ed</w>
wh is
weigh ing</w>
wa ys.</w>
w ed
w as
w ants</w>
viro logic</w>
vehic les.</w>
ve j</w>
ve :</w>
valu ed</w>
vacc ine
v al</w>
ur y.</w>
ur ban</w>
up dat
unfortun ate</w>
under goes</w>
um )</w>
ultim ately</w>
typ ical</w>
tw el
tri um
tremor ,</w>
treat y</w>
tr ust</w>
to ol</w>
tiv e?</w>
ti riz
ti redness</w>
thin ks</w>
then ?</w>
themsel ves,</w>
that ?</w>
that !</w>
th o</w>
th igh</w>
test s.</w>
ten ing</w>
ten d</w>
ten .</w>
temperat ure.</w>
tax es</w>
tan ks</w>
tam per
tak en.</w>
tak e:</w>
t ory</w>
t ended</w>
t emp
syring e.</w>
susp ended</w>
sur face,</w>
supervis ion.</w>
sum mit
sulf on
sulf ate</w>
sugges tive</w>
substitu tions</w>
substit ute</w>
stop per.</w>
stop ped,</w>
ster oid</w>
star ts</w>
stand s</w>
st age.</w>
spo on
spec ially</w>
sp orts</w>
sp ok
smok ing,</w>
sk i</w>
si ve,</w>
short ness</w>
she ep
sha do
sentenc ed</w>
selec tion</w>
secre t</w>
scho ols</w>
sch eric
scheric hia</w>
sa y:</w>
s overe
s h</w>
s es
s .
rul ed</w>
ru e</w>
ros is.</w>
rol ling</w>
ro cur
risk /</w>
ris en</w>
rim on
righ t.</w>
ri go
rex ia,</w>
review ed</w>
rever sal</w>
respectivel y</w>
requ is
rep ly</w>
remov ed.</w>
regul ator</w>
refe rences</w>
recept ors,</w>
rec ently,</w>
re form</w>
ra p</w>
r ural</w>
r ate,</w>
ques tion.</w>
quar ters</w>
qualific ation</w>
prov oc
propos al,</w>
pro toc
prison er</w>
princip al</w>
preserv ed</w>
pres sion,</w>
pre lim
prelim inary</w>
potenti al.</w>
post- operative</w>
plasma ,</w>
philos oph
phen o
pheno thiaz
pertus sis</w>
per c
penetr ate</w>
pen s.</w>
pe di
partner ship</w>
particip ants</w>
par alysis</w>
pack ,</w>
pa in)</w>
p s,</w>
p im
p are</w>
p ancyt
oz yme</w>
over dose,</w>
ous ness</w>
other s,</w>
ot ene</w>
ot e
os .</w>
ord in
ophob ia,</w>
open ing.</w>
ong side</w>
on s,</w>
omal tase</w>
ol ive</w>
ol an</w>
of ten,</w>
ob lastic</w>
o ks</w>
o /E
o/E sbo</w>
noti fy</w>
noti fication</w>
no body</w>
nil otinib</w>
nic a</w>
new ly</w>
neutropen ic</w>
neum ococcal</w>
ne .</w>
myel o
mur de
mul tin
mou th.</w>
monit or
molecu le</w>
min or
microgram s,</w>
metabol ism.</w>
metabol ism,</w>
menstr ual</w>
medi um-
meas ure.</w>
me al.</w>
materi als.</w>
mand ate</w>
m- cresol,</w>
m its</w>
lo bin
lipo protein</w>
lim it.</w>
li t</w>
le ment</w>
lat ent</w>
lan -
lan- Meier</w>
la ugh
l us
l s,</w>
l ing
l /</w>
kin es
kilome tres</w>
k i</w>
juven ile</w>
j e</w>
iv ox
it ec
issu es,</w>
is omer
is omaltase</w>
introduc ing</w>
interpre tation</w>
inter ruption</w>
integr ated</w>
institu tions.</w>
inj ury,</w>
inhibitor s)</w>
info @gsk
info @
inf l
incin eration</w>
in et
in correct</w>
improv ement.</w>
imp ose</w>
im ported</w>
im migrants</w>
ile z</w>
il leg
if f</w>
hydrox y-
hot el</w>
hon our
hon ia,</w>
holid ay</w>
ho c</w>
hecta res</w>
he /</w>
hand led</w>
haem arthro
h a</w>
gon ad
gent le
g ut</w>
g as
ful .</w>
fu vir
four th</w>
forc es</w>
foc used</w>
flu or
fl ame</w>
figh ting</w>
feed ing
fat al.</w>
fail ed</w>
facil itate</w>
f ound
f eder
f ain
eye :</w>
exp an
exerc ising</w>
excre tion.</w>
excep tions</w>
exce eds</w>
ex por
es is,</w>
eri us</w>
erc ept</w>
er !</w>
epide mi
envel oped</w>
enti rely</w>
entec avir</w>
end or
enc ies,</w>
en thusi
en suring</w>
en e,</w>
eme a.
el ig
el der
ec ological</w>
e rec
e om
e br
dy nam
du oden
drow sin
dri ven</w>
dos es)</w>
don ors</w>
don or</w>
docum ents.</w>
do z
dis ability</w>
direc tive,</w>
dip ivox
di vis
di etary</w>
descri be</w>
def ine</w>
dec line</w>
dec l
de tention</w>
de pri
de part
danger ous.</w>
danger ous,</w>
d one,</w>
d ab
cytar abine</w>
cyan ide</w>
cy ste
crush ed,</w>
crim e</w>
coun ts,</w>
corticosteroid s.</w>
cop e</w>
conver ting</w>
consti pation,</w>
consider ing</w>
conjunc tival</w>
conges tion</w>
conflic t</w>
condem ned</w>
concern .</w>
con sen
con clusion</w>
con clude</w>
complic ations.</w>
comple ment
com pl
com e,</w>
com a,</w>
co ast</w>
clud ing</w>
clos por
clon ing</w>
clo thing</w>
cle ared</w>
cigarett es</w>
cigare tte</w>
chole st
chemo therapy,</w>
chang ed.</w>
chang ed,</w>
ch annel</w>
cell ular</w>
cel ebr
ce tiriz
cat abolism</w>
cartridg es.</w>
careful ly,</w>
car bon
c ub
c ov
c ock
c ile</w>
bub bles</w>
bott les</w>
bott le,</w>
blister s)</w>
bli stered</w>
bis phosphon
bet ter.</w>
bel ong</w>
be ing,</w>
be gun</w>
be d.</w>
bar bar
ban k
b ol
b id
autom atically</w>
au gh
attribut able</w>
ator s.</w>
ati o</w>
ast e</w>
as yl
as be
arri ve</w>
arr hyth
ar om
ar d.</w>
ar d,</w>
ar abine</w>
applic ation,</w>
appl y.</w>
aph an
aphan e)</w>
ap t
anxi ety</w>
anti -</w>
anaem ia,</w>
an alyse</w>
an alogue</w>
an 's</w>
amin ogly
am es</w>
alopec ia,</w>
all s</w>
alfa-2 b,</w>
alendron ate</w>
ak ed</w>
air .</w>
afra id</w>
aff in</w>
adver tis
adren aline</w>
administe red,</w>
ad ded.</w>
accompan ying</w>
aber ration</w>
X eom
X IV
Wh ite,</w>
Wh at
War farin</w>
W TO</w>
W E
Vimp at</w>
Vectibi x</w>
VIRACE PT</w>
V ari
V II
V E</w>
Ur ine</w>
US D</w>
Tηλ .:</w>
Tob acco</w>
Th us</w>
TRAVAT AN</w>
TE L
T ylvalosin</w>
T un
T W
Synag is</w>
Sum m
Sub sequ
Strasbour g</w>
So vi
Simul taneous</w>
Sil apo</w>
Sign s</w>
Shel f-life</w>
Secret ariat</w>
SU R
S or
S mo
S CH
Ro tigotine</w>
Ripraz o</w>
Resist ance</w>
Regul ations</w>
Re y
Ras ilez</w>
Pl us</w>
Phot osensi
Pharmac odynamic</w>
P ac
Other wise</w>
O EC
Netherland s.</w>
NE VER</w>
N ap
Mon o
MAG ON</w>
M el
M ann
Los artan</w>
Lond on.</w>
Ljub lj
Labor atory</w>
L et.</w>
L ane</w>
Kap lan-Meier</w>
K u
Ital ia</w>
Islam ic</w>
Ira q</w>
Ir an</w>
Inf usion</w>
Induct Os</w>
Im mun
IN C
I MP
Hung ary</w>
Hamp shire</w>
HIV .</w>
HA AR
H av
H ER
H E
H ).</w>
Gre en</w>
GANFOR T</w>
G ra
For m</w>
Fin n
Fig ure</w>
Fe L
FOR STE
FIR MAGON</w>
F- 69800</w>
F ron
F a
Ex per
Emsel ex</w>
Effec tive</w>
Effec t</w>
EMEA /
E ye</w>
E scherichia</w>
E ry
DuoTra v</w>
Doc um
Dec re
D ou
D MAR
Cyan ok
Ce pl
Cardi ac</w>
CYST AG
CYP2C 19,</w>
CRI XIV
CM V</w>
C op
C min</w>
C le
C el
Bet ween</w>
B l
Authorisation (s)</w>
Austri an</w>
Associ ation</w>
An nex
Al c
Afric an</w>
Afgh an
Ac tivel
Absol ute</w>
AUC 0
AU C)</w>
ABILIF Y</w>
A tt
A erius</w>
A V
9 5/</w>
7 9
5. 3).</w>
5- fold</w>
5 ;</w>
5 6%</w>
5 '-
42 6/</w>
4. 8.</w>
4- 91</w>
39 %</w>
37 .
3 18</w>
27 .
200 7,</w>
200 4.</w>
2 %,</w>
198 5</w>
18 4
15 1</w>
1 35
1 2.</w>
1 ):</w>
1 %).</w>
0. 9</w>
- year-old</w>
) )</w>
(E PAR
(D V
(A C
( ‘</w>
( shock)</w>
( The</w>
( 3)</w>
( "
én é
é e</w>
ä gen</w>
{ fa
{ Name</w>
z ones</w>
z an
yn ast
yl ase</w>
y me
work ?</w>
wor d
women 's</w>
wo ol</w>
who le,</w>
what so
wh o,</w>
well- known</w>
vol can
vol ati
vi d
ven lafaxine</w>
vari ations</w>
vari ation</w>
v oid</w>
v o</w>
ut e.</w>
ure th
uni que</w>
un de
um s</w>
ulcer ation</w>
typ ically</w>
tw enty</w>
tub ing</w>
tu ri
trou ble</w>
tridg es</w>
tri b
transp lan
trans mit
tra ordinary</w>
tonn es,</w>
tob acc
to day.</w>
tion s?</w>
th y</w>
ter ing</w>
ten ce</w>
tain ed.</w>
tac hy
t es</w>
t es
t !</w>
system atically</w>
survi ved</w>
summar ises</w>
sulph ur</w>
suggest ing</w>
sug ar,</w>
successful ,</w>
success fully</w>
success es</w>
subjec ted</w>
sub set</w>
sub mission</w>
stret ch</w>
strateg y</w>
str ate
stimul ate</w>
stead y-
stand ard
st s.</w>
specif i
spec ul
sp ite</w>
sol e</w>
smug gl
sm all,</w>
sk a</w>
situ ations.</w>
sit y,</w>
sit agliptin</w>
sing -
sing- remitting</w>
simul taneous</w>
sil ic
signific antly.</w>
si t</w>
si a</w>
serot on
sen se.</w>
selec tive,</w>
se ment</w>
se at</w>
scr utin
scienti fic
scap ego
sal ine</w>
saf ety,</w>
saf e.</w>
sa ve</w>
sa id
s ’.</w>
s mil
run ny</w>
rod ents</w>
rocur onium</w>
road s</w>
ro oms</w>
ris k,</w>
ris es</w>
rheum atic</w>
reti re
resul t?</w>
resolv ed.</w>
renc y,</w>
reli eve</w>
relap ses</w>
rel ax
rel atives</w>
rel ate</w>
regi str
refuge es</w>
recru ited</w>
receiv es</w>
re sto
re serve</w>
re pit
re fin
rati oph
rat s.</w>
random iz
ran ulocyt
radiolab elling</w>
ques tions.</w>
pyl ori</w>
pu ts</w>
protein s,</w>
prop ag
pronounc ed</w>
prof its</w>
prob able</w>
pro thrombin</w>
pric es.</w>
preserv ative</w>
present ations</w>
pregnanc y,</w>
prefer red</w>
pre mis
pre mi
post- menopausal</w>
possib il
por no
poor ly</w>
polys accharide</w>
play ed</w>
pl enty</w>
pioglitaz one.</w>
pig ment
phosphat ase</w>
pharmac ovigil
per version</w>
per s</w>
pen d</w>
pe ti
patient- years</w>
patient s:</w>
path way</w>
patch es.</w>
pass age</w>
part -
par oxetine</w>
pa ying</w>
p. m.</w>
p- value</w>
p uri
ox ide,</w>
otox icity</w>
ot rop
os pit
opro liferative</w>
oph ren
oph aryng
op lan
op hy
om y
om .</w>
ol s,</w>
ol ds</w>
ograph ical</w>
oedema .</w>
ob serve</w>
ob acter</w>
o fi
ofi -av
noe a,</w>
no t?</w>
neutro phil
neutr al</w>
nerv ousness,</w>
nation ally</w>
n el.</w>
mur der</w>
mouth piece</w>
modi fications</w>
moder n</w>
mo tion</w>
milli on,</w>
mg ).</w>
metabolit e,</w>
met am
ment s?</w>
mechan ical</w>
mat ter.</w>
mat rix</w>
market ?</w>
mark edly</w>
mar ri
man age</w>
malignanc ies</w>
maculo papular</w>
lymph oblastic</w>
long- acting</w>
lo ts</w>
ligh t-
les ion</w>
leg s,</w>
le ts</w>
laun ched</w>
la y</w>
kid napp
kg )</w>
k g.</w>
k et</w>
iz ophren
ity :</w>
iti c</w>
it ted</w>
it oring</w>
it ol</w>
is er</w>
ir s</w>
ir ac
involv ed,</w>
intro duce</w>
intran asal</w>
inter n
inten sive</w>
instruc tions.</w>
insom nia,</w>
initi ate</w>
initi ally</w>
ing ent</w>
infus ion
induc es</w>
induc ers</w>
individu ally</w>
indic ator.</w>
incontin ence,</w>
in tra-
in tra
in k
in ase</w>
in ?</w>
impl ants</w>
impl anted</w>
im it
ill -
ic obacter</w>
ia c</w>
i po
hypoglycaem ic</w>
hypo x
hyper uric
hyper glycaemia</w>
hospit al,</w>
hom e.</w>
highligh ted</w>
hepat omegal
hepar in)</w>
har vest
gr ant</w>
gonad otroph
glucocortic oid
gluc agon</w>
gener ate</w>
gen icity</w>
gen der,</w>
ful fi
fulfi l</w>
frag ile</w>
form ,</w>
fluoro quinol
flu ids</w>
fish ,</w>
fil tr
fif th</w>
fiel d.</w>
fibr in
fem al
fe ed.</w>
far m</w>
famil y,</w>
fail ure
fac ts</w>
f at,</w>
f adin</w>
ext ?</w>
expres s</w>
experienc es</w>
exha ust
example :</w>
ex trav
ever -
et c
estim ates</w>
equip ment,</w>
epistax is,</w>
envis aged</w>
ent re
ent ered</w>
enox apar
enoxapar in</w>
encour aging</w>
enc y?</w>
enc ed</w>
enc e?</w>
en heimer</w>
en closed</w>
emerg e.</w>
emb er,</w>
el et
el ess</w>
eff ort</w>
eczem a</w>
ear th</w>
e osinophil
e ing</w>
e .,</w>
dysp honia,</w>
drowsin ess,</w>
dri ver
dra wn</w>
dos es,</w>
dom inal</w>
doctor ’s</w>
do wn,</w>
disturb ance</w>
dist al</w>
disinfec t
dis proportion
direc tor</w>
direc tions</w>
diffe renc
diff use</w>
di phther
develop s</w>
determin ation</w>
der weg</w>
dep th</w>
dementi a.</w>
deliv er</w>
dehydr ation,</w>
defin itive</w>
deep ly</w>
decis ion-
de pend</w>
das atinib</w>
damag ed,</w>
da .</w>
d ing
cyc lic</w>
cover age</w>
countr y
coord inated</w>
contr act
consult ant</w>
consist ency</w>
consecu tive</w>
concre te</w>
con form
compu ter
compromis ed</w>
compon ents.</w>
complet e,</w>
commod ity.</w>
collec t</w>
col labor
co hes
clon ed</w>
clin ic</w>
cl es,</w>
ck enheimer</w>
circ ulation</w>
chos en</w>
cholin ergic</w>
che ap</w>
challeng es</w>
challeng e</w>
ch ocol
ch es,</w>
cetiriz ine</w>
cent ury</w>
cau tion.</w>
cat aly
carb am
car ro
cad mium</w>
c ot
but t
burn ing,</w>
bur ning</w>
bur g</w>
bri ef
breast feeding</w>
bre ad</w>
brad y
bra in,</w>
bor ne</w>
body weight</w>
blood -
bloc ked</w>
bl ame</w>
benef ici
below ).</w>
belong ing</w>
be ver
bar ome
b ought</w>
b last</w>
b h
b and
aut um
au x
au g
attit ude</w>
ativ ity</w>
ativ es,</w>
atislav a</w>
at eral</w>
at ed
at al</w>
assemb ly</w>
as part
argum ent</w>
arch itec
ar derweg</w>
apt ani
aptani b</w>
approach .</w>
ap repit
ap one</w>
antigen )</w>
antid ote</w>
antibio tics,</w>
antibio tic</w>
anti- cancer</w>
ant acids</w>
and el
anaes the
am ectin</w>
alis ation.</w>
al li
ak e,</w>
aircr af
agre ements</w>
agend a.</w>
ag ranulocyt
ag e?</w>
aer oplan
ade .</w>
add -on</w>
adap ted</w>
ad .</w>
acces sible</w>
acc ession</w>
abov e.</w>
abnorm al
ab out.</w>
a /</w>
a '</w>
XX X/</w>
XX /</w>
X ol
Wa arderweg</w>
W est</w>
W al
V ildagliptin</w>
V TE</w>
Up on</w>
Union 's</w>
UK .</w>
Transfer ring</w>
Te k
Tas ign
TORI SE
TN F
T est
T am
T Y
T V</w>
T RO
Swed en,</w>
Sw ine</w>
Summ aries</w>
Str .</w>
Sta ff</w>
Sovi et</w>
Smo king</w>
Scal e</w>
STR UC
SINGUL AIR</w>
SI FRO
S us
S ik
S HAR
SHAR P</w>
Recon cile</w>
Re productive</w>
RE F
R .</w>
Pro pos
Pol y
Pol and</w>
Place bo
Photosensi tivity</w>
Ph D</w>
PR CA</w>
P ir
P en.</w>
Or fadin</w>
Op tim
OVI ST</w>
OP TR
OP AT
O ste
O l
O B
Nor way,</w>
Nor vir</w>
No thing</w>
Ne is
N y
N ot
N orm
N as
My el
Mus lim
Multi ple</w>
Mon itoring</w>
Me eting</w>
M é
M ol
M it
M id
M ex
Ly on</w>
Lo oking</w>
Lithu ania</w>
Lis bon</w>
Latvi j
Latvi a,</w>
L ist</w>
L iber
L da</w>
K on
K a
K )</w>
Investig ations</w>
Infec tions</w>
Infec tion</w>
Indi a</w>
In vir
In c
Immuno deficiency</w>
Hep at
Hel icobacter</w>
He art</w>
HPV- 16</w>
H ospit
H as</w>
H -
Gre ek</w>
Govern ment</w>
Glob al</w>
Gli olan</w>
GI ST</w>
G y
G row
G ly
G enzyme</w>
G B
Frequ encies</w>
Fer n
FeL V</w>
Farmac ê
FIN -0
F- 9
F ed
Exta via</w>
Espo o/Esbo</w>
Epi vir</w>
Ef ex
EU/1/98/070 /00
EU/1/98/069 /00
E ur
E lev
E ckenheimer</w>
E ating</w>
E X</w>
E ID
Dis card</w>
Di ffe
Di arrhoe
DO SA
D ynast
D riving</w>
D r
D id</w>
D am
Cor por
Commun ity,</w>
Ch er
Ch echn
Care ful</w>
Cardi ovascular</w>
Car tridges</w>
CYSTAG ON</w>
CYP3A 4,</w>
CV MP
C ros
C ri
C oc
C as
C D</w>
Brit ain</w>
Beta fer
Belgi an</w>
Bel ar
Barcel ona</w>
B ou
B ond
B le
B is
B V</w>
B H</w>
B C</w>
B )</w>
As k</w>
Applic ation</w>
An t
An alysis</w>
Afghan ist
Ab dominal</w>
9 4</w>
8 5
8 0%</w>
7 9</w>
60 318</w>
6. 1.</w>
6 00
50 .</w>
5 30</w>
5 /2001)</w>
4 7%</w>
4 6
4 -0
38 6/</w>
3 /98)</w>
200 2,</w>
20 /</w>
198 7,</w>
16 %</w>
12 8</w>
11. 1%</w>
10 1</w>
10 )</w>
1, 7
1 /98)</w>
0. 9
0. 6</w>
0. 5
0 /</w>
/200 1):</w>
/00 5</w>
/ dexamethasone</w>
-- -</w>
- one</w>
- off</w>
+ 386</w>
(S een</w>
(F R)</w>
(F HV</w>
(EPAR ).</w>
(A4 -
(90 5</w>
( to</w>
( r
( itchy</w>
( alu)</w>
( Pro
( International</w>
( 23</w>
' ?</w>
' (a</w>
" )</w>
í ne
{ INVENTED</w>
zo ster</w>
ys is,</w>
yoursel ves</w>
year s),</w>
yc in</w>
y et,</w>
xen ophob
writ ing
wo od
win d
widespre ad</w>
wh om?</w>
web sites</w>
we ver</w>
we igh</w>
we al
w rec
w ine-
w ild
vis ually</w>
ves sel</w>
ventric ular</w>
ven ess</w>
var ying</w>
val dec
v or
ut ropin</w>
uron tin</w>
ur ity.</w>
univer sity</w>
understo od.</w>
un t</w>
ulcer ative</w>
u tic
u te
u pri
twel ve</w>
tur na</w>
tun a</w>
tu al</w>
tro metam
tri al.</w>
transfer ases</w>
train ing.</w>
trac es</w>
tr y,</w>
tr act.</w>
tor s.</w>
ton ,</w>
tom or
tissu es.</w>
tion !</w>
ti red</w>
ti ght</w>
ter rib
ter med</w>
ten laan</w>
ten ecte
ten der
technolog y.</w>
techn ically</w>
te ar</w>
tal ked</w>
tack le</w>
t ach
sw ine</w>
sw allow</w>
support .</w>
suppor t,</w>
supervis ory</w>
sum mit</w>
sulphonyl urea</w>
suggest ed</w>
suffici ent.</w>
sucr ase-
sucrase- isomaltase</w>
struc tures</w>
stre et</w>
stre am
strain s)
str ug
stop ped.</w>
ste el</w>
star ted.</w>
st one</w>
st atic</w>
st as
st a
squeez e</w>
spread ing</w>
sovere ign
some where</w>
solv ents</w>
solid ar
sk in).</w>
sk i
simple x</w>
sign at
sid ase</w>
si ght</w>
short com
sh ift</w>
sex ually</w>
sevo flurane</w>
session s</w>
servic es.</w>
ser s</w>
ser ia</w>
se ats</w>
se arch</w>
sch izophren
sal iv
sa id,</w>
s wa
s ought</w>
rob ial</w>
ro r</w>
ro ot</w>
risk s,</w>
rin se</w>
righ t,</w>
ribavir in,</w>
ri a,</w>
rh initis,</w>
restructur ing</w>
restric t</w>
res us
res tim
require d,</w>
renc y.</w>
ren ic
remin ded</w>
remembe red</w>
relap sing-remitting</w>
rel ations</w>
rejec t</w>
rein forced</w>
regul ation,</w>
referendu m</w>
recy cle
recor ds</w>
recept or.</w>
rec tal</w>
rec ord
rec i
reason s,</w>
reason able</w>
re tin</w>
re start</w>
re sign
re flu
random ised,</w>
ra il</w>
ra ,</w>
r s,</w>
r an</w>
r ad
r ,</w>
provi der</w>
projec ts.</w>
profil es</w>
product ),</w>
produc ed.</w>
proceed ings</w>
procedu res.</w>
pro phylactic</w>
pro benecid</w>
preven tive</w>
present ation</w>
predic ted</w>
predic table</w>
pre val
pre v
pr ud
power ful</w>
poul try</w>
posi tion.</w>
porno graph
popul ations.</w>
poli tically</w>
po x</w>
po wered</w>
plasma .</w>
plasma -derived</w>
pl en
pl ant
pil ot</w>
phosph ok
pheny to
phas e.</w>
pharmac euticals</w>
ph ar
pestic ide</w>
pers on,</w>
perfor at
pathogen s</w>
pat tern
particip ate</w>
parti ally</w>
parliam entary</w>
par alys
pap il
pal e</w>
packag ing,</w>
pa st.</w>
pa st,</w>
p t</w>
over .</w>
ov ascul
our ,</w>
oul d,</w>
otrop ic</w>
ot or</w>
orm on</w>
or listat</w>
or g</w>
or ation</w>
or -
omet er</w>
om munic
olog ist</w>
ol u
ok ed</w>
og lobin
oestro gen</w>
ocy te</w>
occ u
observ ations</w>
o j
o fo
o V
non e
none thel
nom inal</w>
no tably</w>
no des</w>
nitro gen</w>
newly- diagnosed</w>
new -
nephro tic</w>
neon ates</w>
necess itate</w>
ne y</w>
ne ts</w>
nat ure.</w>
na ive</w>
myel oma</w>
my opathy,</w>
my cophenolate</w>
mur ine</w>
muc ous</w>
mu st,</w>
mother s.</w>
month ly</w>
monteluk ast</w>
mone y.</w>
mo dul
miner als</w>
min )</w>
mil l
mil d,</w>
micron ucle
meth ane</w>
met for
met als</w>
mention ed.</w>
medium- sized</w>
medic ations</w>
mechan ism
mean ?</w>
me at,</w>
mar ine</w>
mand atory</w>
manag ement,</w>
mal es</w>
mag az
ma iz
m ap
lys is</w>
lu x
lopin avir/</w>
long .</w>
liv es,</w>
lit ropin</w>
list s</w>
list en</w>
lip id</w>
li p</w>
leveti racetam</w>
leth arg
less en</w>
lear ning</w>
lear n</w>
lead er</w>
le aving</w>
lact at
lab els</w>
kin d.</w>
kidne ys.</w>
ke ts</w>
jus tic
ja un
j ug
ity )</w>
it rac
ir regular
iod ine</w>
intrathec al</w>
interest ,</w>
insul in-
institu tional</w>
institu tion
inotrache itis</w>
injection -site</w>
inhibit ing</w>
independ ence</w>
incid ent</w>
inactiv e.</w>
in toxic
in stead
in dop
in d
in appropriate</w>
import ant
im pos
if ene</w>
if en
id s.</w>
ici ous</w>
ic um</w>
ic he
i res</w>
i re
i qu
hyper stimulation</w>
hon ey</w>
hom ocy
ho od.</w>
his tid
him .</w>
hepatic ,</w>
hepati tis,</w>
hel ped</w>
hel p.</w>
heart be
head s</w>
he ar</w>
hand le</w>
ha ve,</w>
ha m,</w>
h r</w>
h ome
h iv
h ang
grow th.</w>
gre en
gras tim
gr icul
go l</w>
gener ic</w>
gener alised</w>
g ul
g old</w>
g le</w>
g ases</w>
func tions</w>
fract ure.</w>
forme d,</w>
form at</w>
follow- up
fol litropin</w>
fol i
foet us.</w>
foc enter
focenter @msd.</w>
fo ref
fluctu ations</w>
fit ted</w>
fish .</w>
firm ly</w>
fil grastim
fibr in</w>
fe ver
fe et</w>
farm s</w>
f an
extrav as
explan ation</w>
expl ain</w>
expect ancy</w>
exerc ise,</w>
exclus ively</w>
exacerb ations</w>
ev ent.</w>
et oric
estonia@gsk .com</w>
er min</w>
ep ith
entre pre
enthusi as
encour aged</w>
en rich
en fuvir
en ?</w>
ell ite</w>
elimin ation.</w>
ec k
ec it
e udra
e po
dur e</w>
dur able</w>
drug s,</w>
drop s,</w>
dro ps</w>
drin k
don ated</w>
document ed</w>
do or
do .</w>
diure tic
distur b</w>
distribu tion,</w>
disorder s),</w>
diseas es)</w>
discontinu ed.</w>
disc overed</w>
disappear s.</w>
dis cour
dis advant
direc tives</w>
di vision</w>
devic es</w>
des loratadine</w>
des ire</w>
depend s</w>
del i
decreas ed,</w>
decis ions.</w>
dec i
deb t</w>
death s.</w>
death ,</w>
de fe
de dicated</w>
dam age,</w>
dab ig
d rough
d on</w>
d l,</w>
d is</w>
d es.</w>
cul tures</w>
cros sing</w>
critic ism</w>
cris is,</w>
cris es</w>
cr amps</w>
cr amp
counter -
correspon d</w>
correc ted</w>
correc t.</w>
convul sions,</w>
cont ent,</w>
cont acts</w>
consum ers,</w>
consider s</w>
conduc ted.</w>
con strain
con az
compens ated</w>
com pres
colum n</w>
co ol
clo su
clar ified.</w>
cl ub
cirrh osis,</w>
ci um</w>
child hood</w>
cere brovascular</w>
cef triax
cat ches</w>
cast ing</w>
car d.</w>
calori e</w>
calici virus</w>
calici virosis</w>
bur g.</w>
bu prenorphine</w>
brea the</w>
bor tezomib</w>
bor row
bo ost
blister .</w>
ble phar
blad der,</w>
bio -
bi om
ber g</w>
beauti ful</w>
basel ine.</w>
barrel s</w>
ban ning</w>
bab y,</w>
bab ies</w>
bab ies.</w>
b arg
az osin</w>
author ization</w>
atten tion,</w>
attemp ting</w>
attack ed</w>
attach es</w>
att ach</w>
atic ,</w>
at rial</w>
at om</w>
asyl um</w>
asy mptom
aspergill osis</w>
as su
arm s.</w>
arm ed</w>
arc inogen
arbit r
ar otene</w>
antimic robial</w>
anti body.</w>
and s,</w>
and in
anal ges
an omal
an e,</w>
amin e.</w>
allevi ate</w>
allerg ies.</w>
all y
alis kiren</w>
alcohol ic</w>
al ists</w>
al a</w>
air port</w>
agit ation,</w>
aggres sion,</w>
afung in</w>
adv ances</w>
adop t</w>
adj unc
acknowledg ed</w>
acid s,</w>
acid .</w>
ach ,</w>
accoun t.</w>
able ?</w>
ab rup
ab road
a use,</w>
a id,</w>
a e,</w>
a !</w>
Z O
Z I
YYYY }</w>
Y ou
Y MD
YMD D</w>
Wh y,</w>
W aste</w>
V il
V I</w>
Univer sity.</w>
UK ,</w>
Tél :</w>
Tw enty</w>
Trit azide</w>
Trans fer</w>
To o</w>
Therap eutic</w>
Th us,</w>
Tel misartan</w>
Tek turna</w>
TI N
T echnolog
Sub st
Stra uss</w>
Str ada</w>
Statis tics</w>
St and
St al
Slovak ia</w>
Slovak ia,</w>
Si rolimus</w>
Sc andin
San der
SUBSTANCE (S)</w>
SS RI
SE )</w>
S S)</w>
Rh inotracheitis</w>
Repe atedly</w>
Rec ormon</w>
RI X</w>
R it
Psych iatric</w>
Produ tos</w>
Pro gres
Prim e</w>
Potassi um</w>
Pati ents)</w>
Pan retin</w>
PHAR MA</w>
P sori
P et
P V</w>
P T
P B</w>
Or ,</w>
OptiClik .</w>
O si
O bes
O D
Nob ody</w>
Neo Recormon</w>
Neis seria</w>
Ne urontin</w>
Na use
NU MB
N plate</w>
N ig
My ozyme</w>
Minist er</w>
Mar tin</w>
Malign ant</w>
MA C
M arch
M acu
M S,</w>
Lu ver
Ljublj ana</w>
Le ave</w>
Latvij ā</w>
Land straße</w>
L et
L ast</w>
K m</w>
K en
Jour nal</w>
J er
Isra el</w>
Interne t.</w>
Inte gr
Individu al</w>
In focenter@msd.</w>
In de
IN STRUC
I l
Hyper icum</w>
Hou tenlaan</w>
Hol land</w>
Ho wever</w>
Her pes</w>
Haemophil us</w>
HM E</w>
H ard</w>
Grow th</w>
Ga ul
GM BH</w>
GI ST
G am
G ad
Frankfur t</w>
Finn ish</w>
F le
F l
Ex amples</w>
Eston ia,</w>
Engl and</w>
En ter
En sure</w>
En brel
EC ALTA</w>
E s
E mp
E duc
Dynast at</w>
DO HME</w>
D ox
D P
Cop alia</w>
Chole stag
Chechn y
Characteris tic,</w>
Cepl ene</w>
Cat al
CYP2C 9</w>
CR F</w>
CO MM
CIAL IS</w>
C reat
C ard</w>
C A
C /
Brussel s,</w>
B ol
B enz
Am ne
Ad en
AUTHORISA TION
AR S</w>
AB ,</w>
A gener
8 /2001)</w>
8 %)</w>
7 %),</w>
6 67</w>
6 ),</w>
50 1</w>
5. 2</w>
5. 0</w>
5 8%</w>
5 /97)</w>
45 61</w>
40 1</w>
40 ,</w>
4 4%</w>
35 8-
34 1/</w>
34 -
3. 3</w>
3 00
3 /
3 ),</w>
26 12</w>
200 1,</w>
2. 5
199 5.</w>
18 2</w>
13 81</w>
12 3</w>
12 %</w>
10 4.9</w>
10 2</w>
1. 3</w>
1, 0
1 1-
1 1%</w>
02 9</w>
0. 02
0 2</w>
-f at</w>
- day</w>
- containing</w>
+ 39</w>
(S D)</w>
(M M
(E C)</w>
(CN S)</w>
(A5-0 20
(0) 8</w>
( up</w>
( total</w>
( these</w>
( p=
( from</w>
( first</w>
( 7.5</w>
( 5.
( 1)</w>
' that</w>
' s.</w>
” ,</w>
–  
í n</w>
ä n
´ s</w>
} ></w>
z ation</w>
you th</w>
y st
y ing.</w>
work s.</w>
work ing.</w>
work ers,</w>
work er</w>
wor rying</w>
wn ing</w>
will ing
wh en,</w>
web site.</w>
wat ching</w>
war d
w alk
vo ters</w>
vir ap
virap ine</w>
vill age</w>
view ed</w>
vie w.</w>
vi able</w>
vehic les,</w>
vascul itis</w>
valu es,</w>
v ägen</w>
v ax</w>
v acu
us sions</w>
us eful
ur ac
under go</w>
un tary</w>
un g</w>
un certain</w>
ufact uring</w>
ud ge</w>
u ste
ty ?</w>
tw o.</w>
trou gh</w>
triglycer ides,</w>
tremor s,</w>
treat ment:</w>
treat ed.</w>
transport ation</w>
train s</w>
tr ack
tonn e</w>
tion '</w>
time ?</w>
time -
tigec ycline</w>
tic ular</w>
ti pran
ti es?</w>
thromb ocy
this :</w>
the red</w>
tex tile</w>
test ing.</w>
ter m.</w>
tend er</w>
ten ed</w>
teleph one</w>
te eth</w>
tachy cardi
tac rolim
t s)</w>
t i</w>
t g
t '</w>
system atic</w>
syn erg
symb ol
swit ching</w>
suspec t</w>
survi ve</w>
supervis ed</w>
sup pos
suff ers</w>
suff er
succ ess.</w>
substanti ally</w>
sub sc
strong er</w>
stre ets</w>
strate gies</w>
str ö
str ingent</w>
sti tial</w>
stem s</w>
standardis ation</w>
stak e
st orm
st ell
st age,</w>
st a</w>
sper m</w>
special ists</w>
spe ech
sp ar
some body</w>
sol ve</w>
sol d.</w>
sodi um
sk elet
sion )</w>
sinus itis,</w>
simil ar
sign al</w>
si ties</w>
shop s</w>
sh ir
seve re
ser t</w>
selec t</w>
secre tion.</w>
se vent
se mi
se arch
se !</w>
scienti sts</w>
sc op
satis factor
san ofi-av
saf ety.</w>
sa me.</w>
sa id.</w>
s aving</w>
s ',</w>
rimon ab
rigo rous</w>
rhyth m</w>
ret ina</w>
respec t.</w>
residu al</w>
res ource</w>
res ist</w>
renew able</w>
regim en
refriger ator</w>
reflec ted</w>
redden ing</w>
recru it
recon struction</w>
recept ors.</w>
rec overed</w>
realis tic</w>
re strain
re perc
re mot
ram s</w>
radi o</w>
ra in</w>
ra f</w>
ra .</w>
r ing.</w>
question na
qu ote</w>
qu es</w>
purpos es,</w>
purch as
public ations</w>
public .</w>
psori asis</w>
proper ty</w>
proper ly,</w>
prop yl
progres s.</w>
program me
proce ed</w>
pro test
pro drug</w>
prior ities</w>
preven tion,</w>
pressu re
prescrib ing</w>
pran dial</w>
poly ox
poly mer
pim ec
pi g</w>
phosph ate,</w>
perpe tr
perman ently</w>
perid one</w>
per cep
peac eful</w>
par affin</w>
p ure</w>
p toc
p ly</w>
p ic</w>
p )</w>
ov ul
outcom es.</w>
ot rig
ori ent
